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Abstract 
Cancer is a leading cause of death in the modern world. Chronic inflammation facilitates 
tumourigenesis and cancer progression by providing an environment conducive to cancer. 
Dysregulation of the immune response, and particularly inflammation, is an important part of this 
process. 
Garlic (Allium sativum) has been used for centuries as both a prophylactic and therapeutic medicinal 
agent, more recent epidemiological and experimental evidence shows that garlic has both cancer-
preventative and immune system-enhancing effects. While garlic contains many bioactive 
compounds, garlic organosulfur compounds (OSCs) have been most widely studied for their anti-
cancer properties. In this study, we hypothesize that garlic OSCs modulate the inflammatory immune 
response by downregulating pro-inflammatory while stimulating anti-inflammatory responses, 
preventing the formation of a cancer-friendly chronic inflammatory environment. To test this 
hypothesis we established and optimised an in vitro inflammatory model using lipopolysaccharide-
stimulated RAW264.7 murine macrophages.  
Expression analysis of selected inflammatory genes was performed by qPCR on RNA harvested 4 h and 
8 h post treatment, while protein expression was analysed by ELISA using cell culture supernatant 
samples harvested 8 h and 24 h post treatment. These experiments were complemented by gene and 
protein arrays. Results showed that allicin had a more pronounced upregulatory effect on LPS-induced 
gene expression 4 h post-LPS treatment. In contrast, Z-ajoene generally had mild downregulatory 
effects on the expression of LPS-induced genes. Conversely, Z-ajoene had pronounced 
downregulatory effects on LPS-induced inflammatory proteins after 24 h, while allicin showed mild 
up- or downregulatory effects. Overall, we found that allicin induced an initial pro-inflammatory gene 
response, while Z-ajoene induced a longer-lasting anti-inflammatory response at a protein level. 
Finally, as many of the inflammatory genes investigated are regulated by the transcription factor 
STAT3, we investigated the effects of allicin and Z-ajoene on STAT3 phosphorylation and hence 
activation. Western blot analyses showed that allicin increased LPS-induced STAT3 phosphorylation 
(2-8 h), while Z-ajoene was found to decrease the phosphorylation of STAT3 after 4 h. These effects 
on STAT3 phosphorylation are in agreement with the early pro-inflammatory effect of allicin and the 
later anti-inflammatory effect of Z-ajoene on LPS-induced gene and protein expression.  Further, using 
Western blotting we showed that E/Z-ajoene directly interacts with and reversibly alkylates STAT3 via 
a thiol-disulfide reaction with a cysteine thiolate on STAT3.  
We propose that the covalent modification of STAT3 by E/Z-ajoene may provide the chemical basis for 
the observed decrease in STAT3 phosphorylation. This is the first time that a garlic OSC has been 
shown to modulate the immune system by directly interacting with STAT3. Our findings therefore 
support the use of dietary garlic containing Z-ajoene and allicin as an immunomodulatory agent which 
may have implications in the prevention of inflammatory diseases. 
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 Literature Review 
 Cancer 
Cancer is a collective term for diseases characterised by groups of cells with abnormal or uncontrolled 
growth, called tumours. Tumourigenesis is a multistep process which involves the sequential 
acquisition of genetic and epigenetic mutations in cells which may confer a proliferative advantage to 
these cells.  In the past 15 years, researchers have identified  a number of acquired biological 
capabilities inherent in cancer, which have been termed  the “Hallmarks of Cancer” 1,2. These 
capabilities are described as the ability to sustain proliferative signalling; evade growth suppressors; 
avoid immune destruction; enable replicative immortality; activate tumour invasion and metastasis; 
induce angiogenesis; resist cell death; and modify cellular metabolism2. Two characteristics 
recognised  to facilitate or enable the acquisition and maintenance of the aforementioned hallmarks 
include genomic instability (and mutability) and tumour-promoting inflammation 2.  
Significantly, cancer is a leading cause of death worldwide, with approximately 7.6 million deaths 
occurring in the year 2008, and 13.1 million cancer-related deaths projected for the year 20303. 
Despite medical advances in early cancer detection methods and the development of new anti-cancer 
drugs, limited access to healthcare and the high cost of cancer treatments obstructs early cancer 
diagnosis and effective treatment in low income groups3,4. This explains why 70% of world cancer 
deaths occur in low- and middle-income countries3,4. In recent years there has been a growing 
awareness that cancer prevention is of utmost importance5,6: it has been described by the World 
Health Organisation (WHO) as the “most cost-effective and long-term strategy for the control of 
cancer”4, as many cancers are preventable with environmental or exogenous causative agents playing 
a role 4,6. Some exogenous factors include tobacco and alcohol use; a lack of exercise; an unhealthy 
diet; obesity; chemical carcinogens; radiation; and bacterial and viral infections4,6.  
 Inflammation and cancer 
The causative agents or risk factors in cancer are often associated with changes to the immune system. 
The mammalian immune system consists of two components: the innate and adaptive immune 
responses7–9. The innate immune response is the first line of defence against microbial invasion and 
immediately recognises and counters infections while the slower, but more specific, adaptive 
response is mounted. The cellular components of the innate immune response comprise 
macrophages, dendritic cells, mast cells, neutrophils, eosinophils, and natural killer cells which can 
directly activate effector mechanisms of innate immunity. These include phagocytosis and activation 
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of pro-inflammatory pathways that induce the expression of a set of endogenous signals in the form 
of inflammatory cytokines and chemokines. These signals control the recruitment of leukocytes to the 
sites of infection and regulate the activation of appropriate effector mechanisms, for example by 
controlling differentiation of T lymphocytes into effector cells of a particular type. The acute 
inflammatory response and innate immune cells then secrete factors and activate multiple signalling 
pathways which promote wound healing7–9.  
 
Acute inflammation is short-lived and forms an essential part of the innate immune response. 
However, chronic inflammation (due to persistent infection or long-term exposure to chemical 
irritants) leads to  dysregulation of the inflammatory response and results in immunosuppression10,11. 
Research suggests that chronic or tumour-associated inflammation may facilitate the acquisition of 
some cancer hallmark capabilities2,12,13. This is because chronic inflammation leads to a cancer-friendly 
environment through sustained exposure of cells to growth and pro-angiogenic factors; anti-apoptotic 
regulators; extracellular matrix-remodelling enzymes; and damaging antimicrobial factors including 
defensins and reactive oxygen and nitrogen species (ROS and RNS)2,12,13. This leads to a pro-
proliferative, pro-angiogenic, anti-apoptotic, potentially DNA-damaging and immune surveillance-
compromised environment conducive to tumourigenesis2,12,13. Inflammation has thus been described 
as a double-edged sword in neoplasia: as an acute response to insult it can initiate the immune 
response and promote anti-tumour immunity, but under sustained chronic conditions it may facilitate 
immunosuppression and provide an environment conducive to tumour initiation, promotion and 
progression14. This has led to tumours being described as “wounds that do not heal”15. 
 
The presence of inflammatory immune cells, particularly tumour-associated macrophages (TAMs) and 
myeloid-derived suppressor cells (MDSCs) (a heterogeneous population of myeloid progenitor cells 
and immature innate immune cells) is closely associated with malignancy and all stages of 
tumourigenesis and tumour progression16,17. Indeed, there is a strong correlation between TAM and 
MDSC density within a tumour and poor patient prognosis 16,17. While TAMs appear to have a symbiotic 
relationship with cancer cells16, under certain conditions these cells can also display tumouricidal 
activities18.   
 
The paradoxical nature of the immune response extends to the effector molecules/proteins which 
include inflammatory cytokines, chemokines and enzymes. These effector proteins are largely 
produced by innate immune cells to induce inflammation and recruit immune cells7–9. While the 
classification of cytokines and chemokines as either pro- or anti-inflammatory mediators has been 
criticised for being overly simplistic19, it is still of value to consider their predominant activity. Typical 
3 
 
cytokines generally considered to exert pro-inflammatory effects include interleukin-1β (IL1B), 
interleukin-6 (IL6), interleukin-12 (IL12), interleukin-18 (IL18), interleukin-23 (IL23), interleukin-27 
(IL27) tumour necrosis factor (TNF) and interferon-γ (IFNG)19–22 *. On the other hand, interleukin-4 
(IL4), interleukin-10 (IL10), interleukin-13 (IL13) and tumour growth factor-β (TGFB) are generally 
considered to exert anti-inflammatory effects19,23. Chemokines are chemoattractant cytokines that 
facilitate chemotaxis of immune cells that express complementary receptors24. In this way, 
chemokines secreted in the inflammatory or tumour microenvironment selectively regulate the 
recruitment of immune cells to the site of injury9. Significantly, TAMs have been shown to have 
constitutive and elevated expression levels of many chemokines including chemokine C-C motif ligand 
2 (CCL2), chemokine C-C motif ligand 5 (CCL5), chemokine C-X-C motif ligand 9 (CXCL9), chemokine C-
X-C motif ligand 10 (CXCL10), chemokine C-X-C motif ligand 12 (CXCL12) and chemokine C-X-C motif 
ligand 16 (CXCL16), as well as chemokine receptors which facilitate their recruitment to tumour sites25. 
Important inflammatory enzymes include the cyclooxygenase (COX) enzymes which convert 
arachidonic acid into prostaglandins (hormone-like lipid signalling molecules), which regulate a variety 
of functions including vascular permeability, epithelial-barrier function and inflammation26,27. Another 
enzyme involved in the inflammatory response is the inducible nitric oxide synthase 2 (NOS2) which 
produces nitric oxide (NO); a reactive nitrogen species (RNS) involved in inflammatory signalling28,29. 
The expression and secretion of these inflammatory effector molecules or proteins is regulated by 
diverse cell signalling networks which are activated in response to cellular or exogenous stresses8.  
1.2.1. The role of NF-κB and STAT3 in tumourigenesis and cancer progression 
Transcription factors nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and signal 
transducer and activator of transcription 3 (STAT3) are central regulators of the immune response and 
have been shown to facilitate tumourigenesis and cancer progression30–32. NF-κB and STAT3 have been 
shown to regulate the expression of cytokines and chemokines as well as genes involved in cell 
survival, growth, angiogenesis and tissue remodelling30. Indeed, these transcription factors are often 
both constitutively active in cancer cells, and recent evidence suggests that they cooperate to promote 
tumourigenesis and cancer progression12,33–36. NF-κB and STAT3 likely facilitate tumourigenesis and 
cancer progression through their gene products which can re-activate inflammatory signalling 
pathways, resulting in feedback signalling loops that maintain a chronic inflammatory (and thus 
tumour-promoting) environment30,31,37–39. 
Since its discovery as an immunoglobulin gene DNA-binding factor in 198640, NF-κB has received much 
attention from cancer researchers. It has since been recognised as a master regulator of cellular 
development and the stress-induced immune response41. NF-κB is a heterodimeric protein consisting 
of different combinations of the five members of the REL-homology domain family of proteins: RELA 
*According to “The Guidelines for Human Nomenclature”166, human genes and proteins are represented by symbols 
written in uppercase Latin letters and Arabic numerals. Genes are distinguished from proteins by the use of italics. For 
further information see Section 2.6 
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(also known as p65), RELB, c-REL, p50 and p5242. In the cell, cytoplasmic NF-κB heterodimers remain 
inactive while complexed with inhibitory NF-κB (IκB) proteins30. NF-κB signalling is induced by the 
engagement of pattern recognition receptors (e.g. toll-like receptors (TLRs)), cytokine receptors or 
antigen receptors which activate signalling pathways and thereby mediate phosphorylation and 
consequent activation of IκB kinases (IKKα or IKKβ). IKKα or IKKβ phosphorylate IκB proteins, which 
induces ubiquitin-mediated degradation of IκB and allows NF-κB heterodimers to translocate into the 
nucleus and facilitate gene transcription. NF-κB gene transcription is further regulated by NF-κB post-
translational modifications (such as acetylation and S-glutathionylation) and through interactions with 
transcription factors or co-factors30. Some NF-κB target genes include cytokines such as IL1B, IL6, IL12 
subunit β (IL12B), IL10 and IL27; chemokines including CCL2, CCL3, CCL4, CCL5, CCL20, CXCL1, CXCL2, 
CXCL3 and CXCL10; TNF superfamily ligands (TNFSF) including TNF (also known as TNFSF2) and TNF-
related apoptosis inducing ligand (TRAIL, also known as TNFSF10); growth or differentiation factors 
including colony stimulating factor 2 (CSF2) and colony stimulating factor 3 (CSF3); and inflammatory 
enzymes COX2 and NOS2 (reviewed by Pahl (1999)43). 
As previously mentioned, NF-κB plays a central role in tumourigenesis where it is often constitutively 
active in cells in the chronic inflammatory environment32,38,44. In an established tumour, however, NF-
κB activation and function is often inhibited in TAMs while remaining active in tumour cells25. This 
suggests that during tumourigenesis, prolonged activation of NF-κB in both pre-malignant and 
immune cells can facilitate tumour initiation and promotion, while in the tumour microenvironment 
constitutively active NF-κB in tumour cells and compromised NF-κB activation in TAMs maintains 
inflammatory conditions but compromises immune surveillance. NF-κB activation, therefore, has 
complex context-dependent effects in the tumour microenvironment, especially with regards to the 
tumourigenic stage and cell type. 
STAT3 is another transcription factor involved in immune system regulation and implicated in cancer45. 
It is a member of the evolutionarily-conserved signal transducer and activator of transcription (STAT) 
protein family that regulates diverse cellular functions including cell growth, proliferation, 
differentiation and survival46. STAT3 is activated in response to a variety of factors including intrinsic 
cytokines and growth factors (often NF-κB target gene products such as IL6 and IL10) and extrinsic 
chemical carcinogens, pathogens and UV radiation31. These factors regulate STAT3 activation by 
inducing receptor and non-receptor tyrosine kinase-mediated phosphorylation of STAT3 at Tyr705 
(reviewed by Aggarwal et al. (2009)47). STAT3 Tyr705 phosphorylation induces homo- or heterodimer 
(with STAT1) formation and subsequent nuclear translocation, where STAT3 regulates the 
transcription of multiple gene targets involved in the immune response47. Target genes include 
inflammatory cytokines, such as IL6, IL10, IL11, IL17, IL23; chemokines including CXCL1248; pro-
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proliferative growth factors and cell cycle proteins including vascular endothelial growth factor (VEGF) 
49 and cyclin D1/D250; and anti-apoptotic mediators such as B-cell lymphoma-2 (BCL2) 49.  
Interestingly, differences in the duration of STAT3 activation have profound effects on the 
inflammatory response51,52. A transient peak in STAT3 activation (generally induced by IL6-family 
cytokines) results in a pro-inflammatory immune response, while sustained STAT3 activation (induced 
by IL10-family cytokines) induces the expression of anti-inflammatory and immunosuppressive 
genes51,52. Like NF-κB, STAT3 gene targets can either promote or repress tumourigenesis. The IL6-
induced pro-inflammatory STAT3 signalling, for example, has been shown to protect against 
tumourigenesis by promoting the acute inflammatory response and hence immunosurveillance, but 
dysregulation of this pathway can result in excessive inflammation and the formation of a chronic 
inflammatory and tumour-promoting microenvironment53. The IL10-induced anti-inflammatory and 
immunosuppressive response, on the other hand, plays an important role in resolving inflammation 
by dampening the immune response in order to promote wound healing and restore normal tissue 
function23,54–56. In addition, IL10-mediated STAT3 signalling protects against inappropriate immune 
responses which can result in autoimmune diseases23,54–56. Colitis, for example, can result from an 
overactive immune response mounted against commensal gut microflora57. These IL10/STAT3-
mediated immunosuppressive and wound-healing mechanisms, however, can also be co-opted in a 
tumour to promote excessive cell proliferation and safeguard premalignant cells from apoptosis and 
immune surveillance31,58,59.  
While NF-κB and STAT3 are both fast-acting transcription factors which respond to intrinsic and 
extrinsic cell stress signals to initiate the transcription of important immune-regulating genes, they 
are clearly regulated by distinct signalling mechanisms30. It is important to note that as STAT3 and NF-
κB activator mutations are rare, constitutive activation of NF-κB and STAT3 during chronic 
inflammation and in the tumour microenvironment is generally mediated by dysregulation of 
upstream signalling proteins or through cytokine activation of signalling pathways30,60. Significantly, 
NF-κB transcriptional activity can indirectly activate STAT3 by inducing the transcription of STAT3 
signalling molecules, and vice versa30. In addition, NF-κB and STAT3 have been shown to directly 
interact and this interaction can regulate the expression of NF-κB target genes33–35,61,62. This NF-κB-
STAT3 complex preferentially transcribes genes with binding sites for both NF-κB and STAT3 over 
genes with only NF-κB binding sites35. This complex web of regulation has significant implications in 
chronic inflammatory conditions and in the tumour microenvironment where both transcription 
factors are active, as their interaction has been shown to enhance the transcription of tumour-
promoting genes, while suppressing NF-κB-mediated transcription of immunostimulatory and 
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tumour-suppressing genes 33,35,63. STAT3 and NF-κB are therefore attractive therapeutic targets for 
inflammatory diseases as well as cancer.  
Therapeutic attempts to prevent cancer via NF-κB or STAT3 inhibition have had mixed outcomes in 
animal models of tumourigenesis. In some cases, inhibition of NF-κB 64,65 or STAT3 49,53,66–70 signalling 
can prevent tumour formation, induce apoptosis in cancer cells and thereby decrease tumour size. 
Inhibition of either NF-κB71,72 or STAT323,55,73 signalling, however, has also been shown to promote 
inflammation, tumourigenesis and tumour progression. Grivennikov and Karin (2010) suggest that the 
different outcomes observed from the use of NF-κB or STAT3 inhibitors are a result of differential 
responses from immune cells and epithelial cells30. It is thus important to consider all cell types present 
in the inflammatory or tumour microenvironment when developing drugs to target these important 
transcription factors with a view to prevent or treat cancer. An alternative strategy to directly 
targeting NF-κB or STAT3 pathways is to target inflammatory cytokines, enzymes and mediators which 
facilitate the activation and maintenance of NF-κB and STAT3 signalling. Examples of these kind of 
drugs include non-steroidal anti-inflammatory drugs (NSAIDs) (e.g. aspirin) 74,75 and cytokine and 
chemokine inhibitors76,77. Further, drugs which inhibit NF-κB and STAT3 interaction could prevent the 
preferential transcription of many tumour-promoting gene products with NF-κB and STAT3 binding 
sites, without compromising the acute inflammatory immune response30. 
1.2.2. Use of NSAIDs in cancer prevention  
NSAIDs, such as aspirin (acetylsalicylic acid) and ibuprofen, are anti-inflammatory, anti-analgesic and 
anti-pyretic drugs used to treat rheumatoid diseases as well as general pain and inflammation74. 
Further, many of these drugs have shown a protective effect against cancer development as well as 
cancer progression by downregulating the inflammatory response and preventing the formation and 
maintenance of a chronic inflammatory and tumour-promoting microenvironment (reviewed by 
Ulrich et al. (2006)74). Regular, long-term (>5 years) intake of aspirin has been shown to protect against 
tumourigenesis, progression and metastasis of gastrointestinal tract cancers, most significantly 
colorectal cancer78.  
NSAIDs act through inhibition of COX enzyme activity74. As previously mentioned, COX enzymes 
convert arachidonic acid into prostaglandins which regulate a variety of functions including platelet 
aggregation (blood-clotting), inflammation, vascular permeability, mucus production and control of 
mucosal pH27. These functions are essential for maintaining the integrity of the gastrointestinal tract 
mucosa, which protects the body against stresses present in the lumen of the digestive tract such as 
gastric acid, changes in osmolarity, cytotoxic substances and pathogens (reviewed by Wallace 
(2008)27). Unsurprisingly, the long term use of COX enzyme-inhibiting NSAIDs has been shown to 
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increase the risk of gastrointestinal bleeding79, ulcers80, and liver damage81. Due to these unwanted 
side-effects, the long-term use of NSAIDs in cancer prevention has limited therapeutic application. 
These findings  have led to a shift towards the use of natural anti-inflammatory compounds, often 
present in the diet, to aid in the prevention and control of cancer82.  
1.2.3. Immunomodulatory and anti-inflammatory properties of natural 
dietary compounds  
A number of natural compounds derived from dietary sources have been shown to have anti-
inflammatory and chemopreventative activities similar to those seen for NSAIDs74,82. Interestingly, 
comparisons of various epidemiological studies report that the duration and continuity of NSAID use 
is more significant than the dosage with regards to cancer prevention75. The benefits of natural dietary 
anti-inflammatory and chemopreventative compounds are that they are non-toxic, inexpensive, and 
can be consumed on a daily basis with little or no side effects. Natural compounds therefore provide 
a sustainable, cost-effective and healthy alternative to NSAIDs for cancer prevention. Figure 1.1 shows 
the source and chemical structure of a number of naturally occurring dietary anti-inflammatory 
compounds82.  
While the prophylactic and/or therapeutic effects of the individual compounds listed in Figure 1.182 
are too numerous to discuss here, many of these compounds have been shown to downregulate the 
expression of inflammatory cytokines including IL1B, IL6, IL12 and TNF and the inflammatory enzymes; 
COX2 and NOS282. These compounds likely act by modulating proteins or enzymes from diverse 
inflammatory signalling pathways including NF-κB, c-Jun N-terminal kinase (JNK), STAT3, 
phosphoinositide 3-kinase/protein kinase B (PI3K/PKB) and mitogen-activated protein kinases (MAPK) 
(reviewed by Pan et al. (2009)82). While it does not appear in Figure 1.1, dietary garlic has been used 
for thousands of years to treat and prevent infections, heart disease and cancer83.  
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Figure 1.1: Sources and chemical structures of some natural anti-inflammatory and immunomodulating 
compounds. Reproduced with permission  from Pan et al, (2009)82 © American Chemical Society, 2009. 
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 Medicinal use of garlic 
Garlic (Allium sativum) has been used for over 3000 years for both culinary and medicinal purposes83. 
The Papyrus Ebers, which dates back to 1500BC,  and is the oldest extant medical text, advocates garlic 
for the treatment of asthma, headaches, tumours and infections83. Today’s research has shown garlic 
to display anti-inflammatory84–86, antibacterial87–89, antifungal90,91, antiviral92, antithrombotic93, lipid-
lowering94 and anti-oxidant95 properties. In addition, garlic has been shown to elicit both cancer 
preventative and therapeutic effects96–99.  
1.3.1. Epidemiological evidence for garlic consumption protecting against 
cancer 
Modern epidemiological studies have shown an inverse relationship between dietary garlic 
consumption and cancer incidence, especially cancers of the gastrointestinal tract100–103. One of the 
first studies to address the relationship between garlic consumption and gastric cancer was a 
population-based study in China that showed a 40% decrease in gastric cancer risk in individuals with 
a diet rich in Allium vegetables (the Allium genus includes onions, garlic, chives, scallions, shallots 
leeks)103. Meta-analyses of the available epidemiological literature have supported this early finding, 
showing an inverse relationship between garlic or Allium consumption and the incidence of gastric 
cancer104–106. In contrast, another meta-analysis study conducted by Kim and Kwon (2009) found no 
credible evidence in support of a relationship between garlic intake and reduced risk of cancers107. 
More controversial, however, is the protective effect of garlic or Allium vegetable consumption against 
colorectal cancer. While earlier meta-analyses conducted by Fleischauer and Arab (2001)106 and Ngo 
et al. (2007)108 showed protective effects of garlic or Allium vegetable consumption against colorectal 
cancer, more recent meta-analyses conducted by Hu et al. (2014)109 and Zhu et al. (2014)110 have 
suggested that garlic consumption does not protect against colorectal cancer.  
 Chemical structures of naturally occurring garlic organosulfur 
compounds 
Garlic contains many bioactive compounds which are reported to have beneficial health effects 
including lectins111, steroid saponins90, flavonoids 112, organoselenium compounds, and organosulfur 
compounds (OSCs) 96,113. Of these, garlic OSCs have been the most widely studied for their role as anti-
cancer agents (reviewed by Amagase (2006)).  Figure 1.2 shows the chemical structures of a number 
of predominant garlic OSCs. 
The major sulfur-containing compound found in intact garlic cloves is alliin, which upon crushing, 
cutting or grinding comes into contact with the cell vacuole enzyme alliinase114. Alliinase converts alliin 
10 
 
into pyruvic acid, ammonia and sulfenic acid. The sulfenic acid is a reactive intermediate which can 
readily dimerise through hydrolysis into diallyl thiosulfinate (allicin) (Figure 1.3A)114. Allicin, which 
gives garlic its typical pungent smell and strong garlic taste, is a highly reactive compound with potent 
anti-microbial activity. The production of allicin therefore protects the plant from pathogenic invasion 
and discourages pests from eating it115. Being unstable, allicin rapidly degrades into a number of oil- 
and water-soluble polysulfides (Figure 1.2), primarily via two types of chemical reactions, β-
elimination and S-thiolation (Figure 1.3) 116.  
 
Figure 1.2: The predominant secondary products of allicin degradation in crushed garlic. (1) diallyl sulfide 
(DAS), (2)  allyl methyl sulfide (AMS), (3)  allyl methyl disulfide (AMDS), (4) dimethyl disulfide (DMDS), (5) diallyl 
disulfide (DADS), (6) diallyl trisulfide (DATS), (7) allyl methyl trisulfide (AMTS), (8) dimethyl trisulfide (DMTS), (9) 
S-allyl cysteine (SAC), (10) S-allyl mercaptocysteine (SAMC), (11) 2-vinyl-2,4-dihydro-1,3-dithiin, (12) 3-vinyl-3,4-
dihydro-1,2-dithiin, (13) E/Z-4,5,9-trithiadodeca-1,6,11-triene 9-oxide (E/Z-ajoene). Note that compounds 9 and 
10 are the only water soluble compounds. Reproduced with permission from Schäfer and Kaschula (2014)117. 
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The secondary garlic OSCs derived from allicin include dithiins, ajoenes and allyl sulfides (e.g. diallyl 
sulfide (DAS), diallyl disulfide (DADS) and diallyl trisulfide (DATS)) 118. Figure 1.3B-E show the formation 
of some of the bioactive allicin rearrangement products as elucidated by Block et al. (1984, 1986)93,116. 
Dithiins are proposed to be formed from the dimerisation of two thioacroleins, which are formed 
through β-elimination of allicin (Figure 1.3B). The E/Z-isomers of ajoene are formed when two 
molecules of allicin combine to form a sulfonium ion, which can then undergo β-elimination followed 
by -addition of 2-propenesulfenic acid to yield a mixture of E- and Z-isomers of ajoene93 (Figure 1.3C). 
DADS can be formed through an S-thiolation reaction between allyl mercaptan (AM) and allicin (Figure 
1.3D), while DATS is proposed to be formed via hydrolysis of the sulfonium ion followed by addition 
of AM coupled with the expulsion of 2-propenesulfenic acid (Figure 1.3E). All of these interconversion 
reactions are proposed to occur naturally in damaged garlic cells. Therefore the exact chemical 
composition of a garlic preparation varies widely depending on the mode and age of the preparation. 
Fresh preparations contain higher concentrations of allicin, whereas aged preparations contain higher 
concentrations of the second generation compounds DADS, DATS and E/Z-ajoene. 
Studies investigating the metabolism of allicin from human breath, plasma and gastric fluid samples 
show that allicin is also a highly reactive and metabolically unstable compound when consumed119,120. 
Sample analysis has revealed that allicin is never detected; however the products of allicin degradation 
are detected, including DADS, DATS, allyl methyl sulfide (AMS) and allyl methyl disulfide (AMDS) 119,120. 
The presence of these products indicates that allicin S-thiolation and β-elimination reactions occur 
within the body. There are many potential thiol nucleophiles in living systems which could be the 
target of allicin S-thiolation. These include susceptible cysteine thiols in proteins which could 
potentially become alkylated through S-thiolation by allicin121. Significantly, Miron et al. (2000) 
showed that allicin not only interacts with thiol-containing molecules in the cell, but that it can easily 
permeate membrane lipid bilayers without causing membrane fusion, aggregation or leakage. This 
suggests that allicin may rapidly exert its therapeutic effects within the intracellular environment by 
S-thiolating thiol-containing proteins and molecules122.   
The second-generation allyl sulfides formed from allicin degradation are more stable than allicin and 
are reported to be found in blood and breath samples after garlic ingestion119. These compounds 
appear to remain in circulation in the body for longer periods than allicin although it is likely that they 
succumb to the same fate as they are also excellent thiolating agents119. Therefore, although the 
chemical composition of consumed garlic varies in the exact distribution of organosulfur compounds, 
they are likely to act via a similar mechanism i.e. via protein thiolation.  
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Figure 1.3: The formation of allicin and some bioactive allicin rearrangement products by β-elimination and S-
thiolation reactions in crushed garlic cloves. A. The formation of allicin from alliin is catalysed by the enzyme 
alliinase B. Dithiins are formed from the allicin β-elimination product thioacrolein. C. E/Z-ajoenes are formed 
from addition of two allicin molecules to generate the sulfonium ion, which undergoes β-elimination and 
subsequent -addition of 2-propenesulfenic acid. D. Diallyl disulfide is formed via S-thiolation of allicin by allyl 
mercaptan. E. Diallyl trisulfide is formed by hydrolysis of the sulfonium ion in (C) and subsequent S-thiolation by 
allyl mercaptan. These mechanisms of chemical interconversion were elucidated by Block et al. (1984, 
1986)93,116. 
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 Garlic organosulfur compound chemistry and metabolism 
Garlic OSCs are reported to be active both as cancer preventative and therapeutic agents123–129. On a 
therapeutic level, garlic compounds have been shown to inhibit proliferation and induce apoptosis in 
cancer cells, both in culture and in animal models123–127 (Supplementary Table B1, Appendix B). In 
addition, garlic has been shown to protect against free radical (ROS and RNS) damage by upregulating 
the expression of anti-oxidant enzymes (Supplementary Table B2, Appendix B). In cancer prevention, 
garlic compounds have been shown to be active anti-mutagenic agents capable of inhibiting induction 
of cancer through chemical carcinogens128,129. While this very likely contributes to the cancer 
preventative potential of garlic, it may also be attributed to their underlying effects on the immune 
system85,130–132. Research groups to date have used several different experimental approaches and 
various garlic preparations – including garlic powder extract, garlic oil and purified garlic OSCs – to 
study the effect of garlic on numerous aspects of the immune system88,97,132,133. The variability in 
experimental design, especially regarding the chemical composition of different garlic extracts, has 
made comparison between studies challenging (reviewed by (Schäfer and Kaschula (2014)117). The 
principle components of different garlic extracts as well as methods of preparation have been 
summarised by Trio et al., (2014)134. Generally, garlic essential oils are reported to contain high 
quantities of the allyl sulfides (DADS, DATS and allyl methyl trisulfide (AMTS)); garlic powder is 
reported to contain alliin and allyl sulfides (DADS and DATS); aged garlic extract (AGE) is reported to 
contain high concentrations of the water soluble S-allyl cysteine (SAC) and S-allyl mercaptocysteine 
(SAMC) compounds; while freshly crushed garlic contains allicin, allyl sulfides, ajoenes and dithiins134. 
Some important papers which report on the effect of garlic compounds and preparations on 
inflammatory cytokines and chemokines; inflammatory enzymes; and signalling pathways and 
transcription factors are summarised in Tables 1.1-1.3, respectively, and are described in detail in the 
following section.  
  
14 
 
 Evidence for the effects of garlic on inflammatory cytokine and 
chemokine expression 
Table 1.1 summarises the literature reporting the effects of garlic extract or garlic OSC treatment on 
the induced expression of a number of pro- and anti-inflammatory cytokines and chemokines.  
Table 1.1: A summary of the literature reporting the effects of garlic OSC and garlic extract on induced 
expression of inflammatory cytokines and chemokines. All abbreviations and symbols used in this table can be found 
in the list of Abbreviations and Symbols. 
 
Functional 
Componen
t 
Concentration Experimental System Reported effect Ref 
Alliin 0.05-3 μg/ml LPS-induced PBMCs (in vitro) Increased IL1B and TNF expression. 
Decreased IL6 expression. 
135 
Garlic 
extract 
0.1-10 μg/ml PMA-, ionomycin- or LPS-
stimulated whole blood PBMCs (in 
vitro) 
Increased IL10 expression. Decreased 
IL1A, IL2, IL6, CXCL8 (IL8), IL12, TNF, 
IFNG expression. 
84 
Garlic 
extract 
20 mg/kg per 
day x 14 days 
Leishmania major-infected BALB/c 
mice (in vivo) 
Increased IL2 and IFNG. Decreased IL4 
expression. 
136 
Allicin 5-80 μM TNF-stimulated HT-29 and Caco-2 
adenocarcinoma cells (in vitro) 
Decreased IL1B, CXCL8 (IL8), CXCL9 and 
CXCL10.  
137 
Garlic 
extract 
10-1000 μg/ml Placenta and pre-eclampsic 
placenta explants (in vitro) 
Decreased IL6 (normal placental 
explants) and TNF (pre-eclampsic 
placental explants). 
Increased IL10 (for 10 μg/ml) in normal 
placental explants. 
Decreased IL10 (for 1000 μg) in normal 
and pre-eclampsic placental explants. 
86 
Alliin 0.1 mM LPS-induced 3T3-L1 cells (in vitro) Decreased IL6 expression.  
138 
DATS 100-200 μM LPS-stimulated RAW264.7 
macrophages (in vitro) 
Decreased IL6, IL10, IL12, CXCL1, CCL2 
& TNF expression.  
139 
Allicin 1-100ng/ml Thioglycollate-induced murine 
peritoneal macrophages (in vitro) 
Increased IL1, IL6 and TNF expression. 
132 
DAS, DADS, 
AMS 
1-10 μM, 0.1-
0.5 μM, 2-20 
μM 
LPS-stimulated RAW264.7 
macrophages (in vitro) 
DAS: Decreased IL1B, IL6, IL10, TNF 
expression.  
DADS: Decreased IL10, TNF and 
increased IL1B and lL6 expression.  
AMS: Decreased TNF and increased 
IL10 expression. 
140 
DADS 100 μM TNF-stimulated MDA-MB-231 
breast cancer cells (in vitro) 
Decreased CCL2 expression. 
141 
DAS 15 μM TNF- or histamine-stimulated A7r5 
aortic smooth rat muscle cells (in 
vitro) 
Decreased IL1B and TNF expression.  
142 
E/Z-ajoene 20 μM LPS-stimulated RAW264.7 
macrophages (in vitro) 
Decreased IL1B, IL6 and TNF 
expression. 
143 
GPE, DADS 10-100 mg/L, 1-
100 μmol/L 
LPS-induced human whole blood 
(in vitro) 
Decreased IL1B and TNF expression. 
85 
GPE 1 g-3 g Healthy human volunteers (in vivo) Increased IL12 expression and no 
change in IL8 and TNF expression in 
urine samples. 
144 
AGE 1-3 doses of 20 
mg/kg every 
2nd day 
BALB/c mice with allergic airway 
inflammation (in vivo) 
Increased IFNG expression and 
decreased airway inflammation. 145 
DAS 150 mg/kg x 6 
days 
Gentamicin-induced nephrotoxicity 
in Wistar rats (in vivo) 
Decreased expression of TNF.  
95 
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Much of the literature suggests that treatment with garlic OSCs or garlic extract decreases the 
inflammation-induced expression of IL1B, IL6 and TNF (Table 1.1). The downregulatory effect of garlic 
treatment was also seen for IL12, but these results are less reliable as only 2 out of 3 studies are in 
agreement. The expression of IL12 in LPS-stimulated PBMCs84 and RAW264.7 macrophages139 was 
found to be reduced by both garlic extract and DATS treatment, respectively. In contrast, an increase 
in IL12 was seen in urine collected from healthy human volunteers administered with 1-3 g of garlic 
powder extract (GPE)144. This suggests that garlic may elevate IL12 expression in the absence of 
inflammation, but decreases IL12 expression by monocytes and macrophages during the inflammatory 
response.  
The effect of garlic treatment on IL10 expression appears to differ between studies. Hodge et al. (2002) 
showed that treatment of LPS-stimulated whole blood peripheral blood mononuclear cells (PBMCs) 
with ≥ 1 μg/ml garlic extract resulted in a significant increase in IL10 production84. Similarly, Chang et 
al. (2005) showed that IL10 expression in LPS-stimulated RAW264.7 macrophages was increased by 
AMS but decreased by DAS and DADS treatment. Interestingly, a study conducted by Makris et al. 
(2005) looked at the expression of cytokines in explants of placentas with or without pre-eclampsia (a 
hypertensive disorder in pregnant women which can develop into eclampsia, which is life-threatening 
to the mother and infant) and found that treatment  with lower concentrations of garlic extract (10 
μg/ml) increased IL10 expression, while higher concentrations of garlic extract (1000 μg/ml garlic 
extract) decreased IL10 expression. This discrepancy is likely a result of garlic compound toxicity at 
higher concentrations.  
Interferon-γ (IFNG) expression was shown to be increased following treatment with both fresh or aged 
garlic extract in two independent studies looking at inflammation in BALB/c mice136,145. Conversely,  
Hodge et al. (2002) showed that the expression of IFNG in phorbol myristate (PMA)- or ionomycin-
stimulated T-cells was significantly decreased following treatment with 1-10 μg/ml garlic extract84.  
While there are few studies reporting the effects of garlic treatment on the expression of chemokines, 
all studies included in Table 1.1 show a downregulatory effect on the expression of all reported 
chemokines including CCL2139,141, CXCL1139, CXCL8 (also known as IL8)84,137, CXCL9 137 and CXCL10137.  
Taken together, the majority of papers reviewed show a consistent downregulatory effect for garlic 
treatment on the expression of IL1B (5 out of 7 studies) 85,137,140,142,143, IL6 (7 out of 8 studies) 84,86,135,138–
140,143 and TNF (8 out of 11 studies) 84–86,95,139,140,142,143. There is less evidence for the downregulatory 
effect of garlic treatment on IL12 (2 out of 3 studies) 84,139 and the upregulatory effect on IFNG (2 out 
of 3 studies)136,145. Finally, the modulation of IL10 expression by garlic treatment appears to be 
16 
 
dependent on the garlic OSC and the concentration used, although it may also be due to toxicity of 
the garlic OSC at the high concentrations used. 
 Evidence for the effects of garlic on inflammatory enzymes  
Cyclooxygenase-2 (COX2) and NOS2 enzymes are involved in generating inflammation-promoting 
prostaglandins (especially prostaglandin E2 (PGE2))26 and NO28, a signalling molecule important in 
inflammation. There is significant evidence to suggest that garlic OSCs inhibit inflammation by 
downregulating the expression of COX2 and NOS2 enzymes (Table 1.2).  
Table 1.2: A summary of the literature reporting the effects of garlic OSCs or garlic extract on inflammatory 
enzymes.  All abbreviations and symbols used in this table can be found in the list of Abbreviations and Symbols. 
Functional 
Componen
t 
Concentration Experimental System Reported effect Ref 
Allicin; E/Z-
ajoene,  
1-100 μM;  
0.1-20 μM 
LPS-stimulated RAW264.7 
macrophages (in vitro) 
Decreased NOS2 expression and NO 
accumulation. 
146 
E/Z-ajoene 10 μM LPS-stimulated RAW264.7 
macrophages (in vitro) 
Increased COX2 expression, but inhibited 
enzyme activity and release of PGE2. 
147 
DAS, DADS, 
AMS 
1-10 μM, 0.1-0.5 
μM, 2-20 μM 
LPS-stimulated RAW264.7 
macrophages (in vitro) 
DAS: decreased COX2 and PGE2. 
DAS, DADS, AMS: decreased NO 
accumulation. 
DAS, DADS: decreased NOS2 expression. 
148 
DAS, DADS, 
AMS 
1-10 μM, 0.1-0.5 
μM, 2-20 μM 
LPS-stimulated RAW264.7 
macrophages (in vitro) 
Decreased PGE2 and NO levels. 
 
140 
E/Z-ajoene 20 μM LPS-stimulated RAW264.7 
macrophages (in vitro) 
Decreased COX2 and NOS2 expression and 
decreased NO and PGE2 production.  
143 
DADS 100 mg/kg Ethanol-induced gastric 
ulceration in Sprague-
Dawley rats (in vivo) 
Decreased NOS2 expression. 149 
DADS 
DATS 
200-400 μM 
100-200 μM 
LPS-stimulated RAW264.7 
macrophages (in vitro) 
DADS and DATS inhibited expression of 
COX2, NOS2. 
DATS inhibited production of PGE2 and NO. 
139 
Allicin 1-100 ng/ml Thioglycollate-induced 
murine peritoneal 
macrophages (in vitro) 
Increased NO expression. 132 
 
Table 1.2 shows that the inflammatory enzymes COX2 and NOS2 and their products PGE2 and NO 
were generally downregulated by garlic OSC treatment. The expression of NOS2 was decreased by 
garlic OSC treatment in all studies reporting the effect of garlic OSC treatment on NOS295,139,146,148,149, 
while NO expression was decreased in 5 out of 6 studies139,140,143,146,148. COX2 expression was decreased 
in 3 of 4 studies139,143,147,148 while PGE2 was decreased in all 5 studies139,140,143,147,148 reporting the effects 
of garlic OSC treatment. Dirsch and Vollmar (2001) treated cells with 1 μg/ml LPS (which simulates a 
bacterial infection) and 10 μM E/Z-ajoene and found an increase in LPS-induced COX2 expression, but 
showed a decrease in PGE2 (the major product of COX2 conversion of arachidonic acid into 
prostaglandins) and thus showed a decrease in COX2 enzyme activity147. Conversely, Lee et al. (2012) 
also stimulated RAW264.7 macrophages with 1 μg/ml LPS but used a higher concentration of E/Z-
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ajoene (20 μM) and found a decrease in LPS-induced COX2 expression as well as a decrease in COX2-
dependent PGE2 production143. Therefore, while lower concentrations of E/Z-ajoene increase LPS-
induced COX2 expression (as compared to a decrease in expression seen for higher doses), E/Z-ajoene 
treatment inhibited the COX2 enzyme directly thereby resulting in a decrease in PGE2 production.  
According to the literature, garlic OSC treatment appears to reduce the inflammation-induced 
expression of pro-inflammatory enzymes NOS2 and COX2 with a concomitant decrease in the 
production of the pro-inflammatory signalling molecules PGE2 and NO. 
 Evidence for the effects of garlic on inflammatory signalling 
pathways  
As discussed in Section 1.2.1, the transcription factors NF-κB and STAT3 play important roles in 
mediating immune responses and have been implicated in tumourigenesis and cancer progression. 
NF-κB gene targets include inflammatory cytokines and chemokines; inflammatory enzymes; growth 
factors and anti-apoptotic mediators. Similarly STAT3, while regulating the expression of inflammatory 
mediators, is also involved in downregulating the inflammatory responses via IL10-STAT3 pathway 
signalling. IL10-STAT3 pathway is, however, also involved in immunosuppression, which can promote 
tumourigenesis and cancer progression. A review of the literature indicates that garlic OSCs affect 
many proteins involved in inflammatory signalling and immune regulatory pathways. Table 1.3 
summarises the literature reporting the effects of garlic OSCs on a number of different signalling 
pathways activated during the immune response. 
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Table 1.3: A summary of the literature reporting the effects of garlic OSC and garlic extract on inflammatory 
signalling pathways and transcription factors. All abbreviations and symbols used in this table can be found in 
the list of Abbreviations and Symbols. 
Functional 
Componen
t 
Concentration Experimental System Reported effect Ref 
Allicin 5-80 μM TNF-stimulated HT-29 and 
Caco-2 colorectal 
adenocarcinoma cells (in 
vitro) 
Suppressed degradation of IκB. 137 
DADS, AM 1-100 μM TNF-stimulated HUVECs  
(in vitro) 
No effect on TNF-induced NF-κB activation 
or NF-κB-regulated E-selectin. 
130 
Alliin 0.1 mM LPS-induced 3T3-L1 
adipocytes (in vitro) 
Decreased ERK phosphorylation. 138 
E/Z-ajoene 5-40 μM Human promyeloleukemic 
cells (in vitro) 
Apoptosis induced by stimulated NF-κB 
activation. 
99 
GPE, DADS 10-100 mg/L, 
1-100 μmol/L 
LPS-induced human whole 
blood (in vitro) 
Decreased NF-κB activity. 85 
DATS 20-40 μM IL6-stimulated DU145 and 
LNCaP prostate cancer cells 
(in vitro) 
Decreased IL6-induced STAT3 
phosphorylation and nuclear translocation.  
150 
DATS 100-200 μM LPS-stimulated RAW264.7 
macrophages (in vitro) 
Downregulated NF-κB & MAPK signalling. 
Prevented PKB and TAK1 phosphorylation. 
139 
DATS 40 mg/kg x 5 
days per week 
Immunohistochemistry of 
orthotopically implanted PC-
3 prostate cancer-cell 
tumours in nude BALB/c 
mice (in vivo) 
Inhibited activation of PKB and NF-κB 
pathways, and downregulated associated 
gene expression.  
124 
DAS 15 μM TNF- or histamine-
stimulated A7r5 aortic 
smooth rat muscle cells (in 
vitro) 
Inhibited PI3K/PKB, AP1 and NF-κB 
signalling. Prevented NF-κB p65 nuclear 
accumulation.  
142 
 
Five out of seven studies reporting effects of garlic treatment on NF-κB show a downregulatory effect 
on NF-κB activation and/or nuclear accumulation85,124,137,139,142. In contrast, Dirsch et al. (2004) showed 
no effect of DADS or AM treatment on TNF-induced NF-κB activation in human umbilical vein 
endothelial cells (HUVECs)130, while the same research group showed that E/Z-ajoene treatment 
induced apoptosis in human promyeloleukemic cells via NF-κB activation99. The downregulation of NF-
κB signalling may be a result of inhibition of PI3K/PKB activation via DAS or DATS treatment, as 
reported in 3 studies124,139,142. Ho et al. (2014) reported that DAS decreased the LPS-induced 
phosphorylation of PKB as well as activated kinase-1 (TAK1); the latter forms part of the MAPK 
signalling pathway142. In addition, Quintero-Fabián et al. (2013) saw a decrease in the phosphorylation 
of extracellular signal-regulated kinases (ERKs) (also involved in the MAPK pathway) in LPS-induced 
3T3-L1 adipocytes following treatment with alliin138. There is only one study in which an effect on 
STAT3 has been reported. Here, DATS was found to  decrease Tyr705 phosphorylation and nuclear 
translocation of the STAT3 transcription factor in IL6-stimulated prostate cancer cells 150.  
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In summary, the literature appears to support the general downregulation by garlic OSCs of multiple 
NF-κB pathway signalling proteins and inhibition of NF-κB activation. There is a single study reporting 
an inhibitory effect of DATS treatment on STAT3 activation in cancer cells150, but no literature reports 
on the effect of garlic OSC treatment on STAT3 activation in immune cells. 
 Possible chemical biology behind the biological activity of garlic 
OSCs  
In cells, the antioxidant molecule GSH can form mixed disulfide bonds with redox-sensitive (low acid-
dissociation constant (pKa)) cysteine thiols on proteins via a process called S-glutathionylation (Figure 
1.4A) 151,152. The addition of GSH to cysteines via S-glutathionylation is a post-translational 
modification of proteins which can protect against ROS-mediated damage, regulate protein function 
or enzyme activity and can play a role in cell signalling (reviewed by Dalle-Donne et al. (2007) and Klatt 
and Lamas (2000)151,152).  
Currently there are about 150 prokaryote and eukaryote proteins known to be S-glutathionylated153. 
Among these are apoptotic mediators (e.g. caspase-3154 and Fas155), cytoskeletal proteins  (β-tubulin156 
and actin157) and signalling proteins and transcription factors (e.g. NF-κB subunits158,159, IκB kinase 
(IKK)160, and STAT3161). A more comprehensive list of S-glutathionylation protein targets can be seen 
in the review by Pastore and Piemonte (2012). As cysteine thiols in proteins are evolutionarily 
conserved, and are important in protein folding (and thus conformation) and activity, the reversible 
modification of cysteine thiols in proteins by S-glutathionylation has important implications in cell 
signalling (reviewed by Klatt and Lamas (2000)). For example, S-glutathionylation of the transcription 
factors NF-κB p50 158, NF-κB RELA (p65)159 and STAT3161 have been shown to affect DNA binding and 
hence transcriptional activity of these proteins. S-glutathionylation is thus functionally analogous to 
protein phosphorylation, which is a well-known post-translational modification that regulates protein 
conformation and activity. 
S-glutathionylation is considered a mechanism through which the intracellular redox state of cells is 
transduced into a functional response152. Significantly, S-glutathionylation reactions are redox 
sensitive: changes in the ratio of reduced GSH and oxidised GSH (GSSG) (GSH as a mixed disulfide) and 
changes in the levels of ROS and RNS can dictate whether cysteine thiolates form mixed-disulfide 
bonds with GSH or are oxidised into sulfenates or S-nitrothiols by ROS and RNS, respectively. S-
glutathionylation and antioxidant thiol-transferase enzymes can reduce sulfenates and S-nitrothiols in 
proteins back into cysteine thiols and thereby restore protein function. Under conditions of oxidative 
stress however, when there is an increase in GSSG relative to GSH, these sulfenates and S-nitrothiols 
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can be irreversibly oxidised by ROS and RNS resulting in permanent loss of protein activity and even 
cell death152.   
 
Figure 1.4: S-thiolation of protein cysteine thiols by glutathione, E/Z-ajoene and allicin. A. A cysteine thiol of a 
protein is S-glutathionylated by reduced glutathione.  A cysteine thiol of a protein is S-thiolated or alkylated by 
B. E/Z-ajoene and C. allicin. 
 
Garlic OSCs have been proposed to exert biological effects similar to S-glutathionylation through S-
thiolation/disulfide exchange with cysteine thiols on proteins163, as illustrated in Figure 1.4. It is thus 
likely that proteins susceptible to S-glutathionylation are also susceptible to S-thiolation/disulfide-
exchange with garlic OSCs. In support of this, a number of in vitro studies demonstrate that garlic OSCs 
can alkylate and inhibit the activity of thiol-containing enzymes. Allicin, for example, has been shown 
to alkylate and inactivate papain and alcohol dehydrogenase in a cell-free system164. Another study 
demonstrated that E/Z-ajoene inhibits glutathione reductase enzyme activity by alkylating an active 
site cysteine (Cys58)165. In addition, Hosono et al. (2005) demonstrated that DATS alkylates two β-
tubulin cysteines (Cys12β and Cys354β) and this inhibits tubulin polymerisation and induces apoptosis 
in cultured human colon cancer HCT-1 and DLD-1 cells127.  
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As many proteins involved in inflammatory signalling pathways are known to be targets of S-
glutathionylation158–161, garlic OSCs may modulate immune function by targeting (and alkylating) these 
proteins.  
 Significance 
Based on the evidence in Tables 1.1-1.3, it is clear that garlic OSCs affect a number of cellular processes 
involved in the immune response. The variability in experimental design, however, has made 
comparisons between these studies challenging. For example, some studies used pure garlic OSCs 
while others used garlic extracts with unknown or unspecified chemical composition. The 
concentrations of garlic OSCs or garlic extracts used greatly varied across studies, and many studies 
did not first determine compound toxicity in the chosen cell line or model. In addition, the studies 
used many different cell types (e.g. cancerous, epithelial or myeloid cells) which may respond 
differently to garlic OSC or garlic extract treatment. For these reasons, it is unclear which garlic OSCs 
elicit the immunomodulating effects of garlic, whether the concentrations used are biologically 
relevant, and whether the same effects seen on cancer and normal epithelial cells apply to immune 
cells.  With this in mind, we developed an in vitro model to ascertain the effects of sub-toxic doses of 
pure garlic OSCs on immune system function and signalling in cultured macrophages.   
1.10.1. Hypothesis 
We hypothesise that garlic OSCs counterbalance the establishment of a chronic inflammatory 
microenvironment, which is critical to the initiation, promotion and progression of many cancers. In 
this way garlic OSCs may aid in cancer prevention. Garlic OSCs may act on a chemical level by S-
thiolating redox susceptible cysteine residues in proteins, which inhibit enzyme activity or modulate 
cell signalling pathway. Further, as S-thiolation is similar to the well-known post-translational 
modification S-glutathionylation, we hypothesise that the targets of S-glutathionylation are targets of 
garlic OSCs. 
1.10.2. Aim 
To determine whether pure garlic OSCs are able to modulate the inflammatory response in vitro. 
1.10.3. Objectives 
Using pure synthesised garlic OSCSs we will determine compound toxicity using cell viability assays in 
cultured RAW264.7 murine macrophages. In order to determine the effects of garlic-OSC treatment 
on LPS-induced inflammation, we will establish a well-defined in vitro inflammatory model that 
simulates regular dietary consumption of garlic. Once this has been achieved we will assess the effects 
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of garlic OSC treatment on the induced inflammatory response in these cells using quantitative real-
time PCR (qPCR) gene expression and enzyme-linked immunosorbent assay (ELISA) protein expression 
analysis. If we find that the selected garlic OSCs modulate the inflammatory response, we will look at 
associated transcription factors or signalling proteins to see if garlic OSCs directly affect protein 
function through mixed-disulfide bond formation. These experiments will serve as the basis for the in 
vitro proof-of-concept required for an ethics application for future in vivo experiments to determine 
the effects of garlic OSC gavage on induced gastrointestinal- and colorectal inflammation in BALB/c 
mice. 
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 Materials and Methods 
All solutions used are described in detail in Appendix A. 
 Cell culture 
2.1.1. Cell lines and cell culture media 
Abelson murine leukaemia virus-transformed murine macrophages (RAW264.7) (TIB-71TM, ATCC®) 
were cultured in Dulbecco’s-modified Eagle Medium (DMEM, Lonza, BioWhittaker®) supplemented 
with 10% foetal bovine serum (FBS Superior Cat. No. S0615, Biochrom AG), 1% PEN-STREP (Lonza, 
BioWhittaker®, 100U/ml penicillin and 100 μg/ml streptomycin), also referred to as “complete 
medium”. The cells were grown in a humidified atmosphere (5% CO2) at 37◦C. Media was changed 
every 2-3 days and cells were routinely checked for mycoplasma contamination. 
2.1.2. Cell plating and splitting 
Cell lines were cultured in 25 cm2 or 50 cm2 culture flasks (Corning®, Sigma-Aldrich) and were split 
when 80% confluent. Medium was removed and cells were incubated with 5 ml lidocaine- 
ethylenediaminetetraacetic acid (EDTA) (Appendix A) for 2 min at 37°C. Lidocaine-EDTA suspended 
cells were transferred into 15 ml tubes and centrifuged at 1500 xg for 3 min. The supernatant was 
removed and the cells were resuspended in complete medium, transferred to a fresh culture flask and 
incubated at 37◦C (5% CO2). Thereafter, the medium was changed every 2-3 days. Cells were cultured 
for up to 10 passages after which they were discarded and a new frozen cell stock was thawed and 
cultured. Preliminary experiments were conducted which confirmed that there was no detectible 
difference in cell morphology and LPS-induced cytokine expression following cell splitting with 
lidocaine-EDTA or using a cell scraper (data not shown).  
2.1.3. Cell counting  
For counting purposes, 10 μl of the resuspended cells (Section 2.1.2) was added to 90 μl Trypan blue 
(Celtic Molecular Diagnostics (Pty) Ltd), of which 10 μl was pipetted onto a haemocytometer slide 
(Neubauer) covered by a coverslip. The number of cells was determined using the method described 
in the Neubauer manual. To determine the volume of cells needed, the following formula was used: 
Volume (ml) =
Number of cells required 
Number of live cells (per ml)
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 Garlic organosulfur compounds 
Chemically pure DATS (98%) supplied in acetone was purchased from the Cayman Chemical Company, 
while technical grade (80%) DADS in oil form was purchased from Sigma-Aldrich and purified by 
distillation (performed in the Chemistry Department at the University of Cape Town) prior to use.  
Both allicin and E- and Z-ajoene were synthesised by Daniel Kuzsa, in the Chemistry Department at the 
University of Cape Town (UCT) according to the previously published method described by Block et al. 
(1986)116. Allicin was prepared via the oxidation of DADS in peracetic acid and purified at 4°C by flash 
silica gel chromatography.   
 
 
Figure 2.1: Characterisation of allicin by 1H nuclear magnetic resonance spectroscopy.1H NMR H (400MHz, 
CDCl3) 3.83 (1H, S-CH2-C, dd, J 14.1, J 7.2) 3.85 (1H, S-CH2-C, dd, J 14.1, J 7.2) 3.91 (1H, SO-CH2-C, dd, J 13.2, J 7.0) 
4.01 (1H, SO-CH2-C, dd, J 13.2, J 7.0) 5.26 (1H, S-CH2-CH=CH2, d, J = 10), 5.36 (1H, S-CH2-CH=CH2, d, J = 10), 5.48 
(1H, CH2=CH-CH2-SO, d, J = 16), 5.50 (1H, CH2=CH-CH2-SO, d, J = 16), 5.95-6.02 (2H, CH2-CH-CH2, ddt, J = 16, J = 
10, J = 7.2) 
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Ajoene was synthesised from allicin by thermal rearrangement in refluxing acetone and the E- and Z-
geometric isomers were separated by slow silica gel chromatography. Compound purity was assessed 
by 1H nuclear magnetic resonance (NMR) spectroscopy and silica-gel thin layer chromatography (TLC) 
(Section 2.3).  
 
 
Figure 2.2: Characterisation of E-ajoene by 1H nuclear magnetic resonance spectroscopy. 1H NMR H (400MHz, 
CDCl3) 6.3 (1H, d, J 14.6, H-4); 5.9 – 5.7 (3H, m, H-8, H-2 and H-5); 5.4 (2H, m, H-9); 5.1 (2H, m, H-1); 3.6 - 3.3 (6H, 
m, H-7, H-6, H-3). 
Allicin, which is known to be unstable, was stored as a 1 mg/ml solution in water at -80°C. DADS, E- 
and Z-ajoene were stored as pure oil or diluted in dimethyl sulfoxide (DMSO, Sigma-Aldrich) and stored 
at -80ᵒC.  DATS was diluted in acetone and stored at -20°C. Regular TLC analysis (Section 2.3) of these 
compounds showed that allicin, DADS, DATS and E- and Z-ajoene were not prone to degradation when 
stored under these conditions. 
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 Figure 2.3: Characterisation of Z-ajoene by 1H nuclear magnetic resonance spectroscopy. 1H NMR H (400MHz, 
CDCl3) 6.56 (1H, d, J = 9.5, H-4); 5.97 – 5.70 (3H, m, H-8, H-2 and H-5); 5.4 (2H, m, H-9); 5.1 (2H, m, H-1); 3.7 - 3.4 
(6H, m, H-7, H-6, H-3).  
 Thin layer chromatography  
Silica-gel thin layer chromatography (TLC) was used to test for compound purity prior to the use of the 
garlic OSCs in experiments. While TLC can detect trace amounts of impurity, this method is limited to 
qualitative detection. As 1H NMR was used to characterise and demonstrate purity of the selected 
garlic OSCs, TLC was used to test for OSC degradation which may occur subsequently over time during 
storage.  This technique was used instead of 1H NMR as it is an easy and rapid technique sensitive 
enough to reveal trace amounts of impurities and hence degradation. In addition TLC could be 
performed in the laboratory at the UCT Medical School whereas 1H NMR would need to be performed 
at the UCT Chemistry Department. Silica-gel TLC allows for separation of compounds due to 
differences in attraction to the stationary phase (silica gel) and solvent, usually a mixture of ethyl 
acetate and hexanes. The garlic OSCs solubilised in water, acetone or DMSO were spotted 0.5 cm from 
the bottom of a TLC Silica gel 60 F254 aluminium plate (Merck) using a Hirschmann micropipette 
(Sigma-Aldrich) and left to dry. The TLC plate was then placed in a sealed development tank containing 
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a mixture of ethyl acetate (EtOAc) and hexanes (20% EtOAc and 80% hexanes was used for allicin; 80% 
EtOAc and 20% hexanes was used for E- and Z-ajoene; and 50% EtOAc to 50% hexanes was used for 
DADS and DATS). After the EtOAc/hexane solvent mixture had migrated approximately 3cm, the 
solvent front was marked and the TLC plate was visualised under a 254 nm ultraviolet lamp. The ‘spots’ 
on the plate were circled using a pencil and the compound was considered pure if there was a single 
‘spot’ on the plate. The retardation factor (Rf) value was calculated by dividing the distance travelled 
by the compound or ‘spot’ by the distance travelled by the solvent. Rf values were then compared to 
previously determined Rf values for the pure compounds and purity could be confirmed if the Rf values 
were similar.  
 Cell viability assay (MTT assay) 
To determine cytotoxicity of the selected garlic compounds on RAW264.7 murine macrophages, 
thiazolyl blue tetrazolium bromide (MTT) colourimetric viability assays were performed. Actively-
metabolising cells convert the MTT reagent (yellow tetrazolium salt) into a purple formazan product. 
This reaction involves electron transfer from pyrimidine nucleotide co-factors NADH and NADPH to 
the MTT reagent which is in turn reduced to a purple formazan product. The crystalline formazan is 
solubilised and the absorbance is measured at 595 nm with a spectrophotometer. As the amount of 
formazan produced is directly proportional to the number of viable cells, this assay can be used to 
measure the cytotoxicity of various garlic OSCs on treated cells. 
Briefly, 96-well plates were seeded with 6000 cells per well, suspended in 90 μl of complete DMEM. 
After 24 h, cells were treated with 10 μl of the garlic OSC at a range of concentrations at 2-fold dilutions 
varying from 0-100 μM (and 0-100 mM for DADS). After a 24 h treatment period, the cells were treated 
with MTT reagent (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Cat. No. M2128, 
Sigma-Aldrich) at a final concentration of 0.5 mg/ml for 4 h. Thereafter, Solubilisation Reagent 
(Appendix A) was added to a final concentration of 5% and incubated at 37ᵒC for 24 h. Absorbance at 
595 nm was measured using a plate-reading spectrophotometer (VersaMax™ Tuneable Microplate 
Reader, Molecular Devices). The negative control for these experiments was cells treated with 0.1% 
of either DMSO (for DADS, E-ajoene and Z-ajoene), acetone (DATS) or water (Allicin), diluted in DMEM. 
Each data point had 8 technical repeats. As previous studies have shown that the MTT reagent can be 
reduced by redox-sensitive compounds, a preliminary experiment was performed to ascertain 
whether the garlic OSCs used in this study, namely DADS, DATS, E-ajoene, Z-ajoene or allicin were able 
to reduce MTT to formazan in a system without cells. None of these compounds were found to reduce 
MTT to formazan (data not shown).  
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The data was analysed using GraphPad Prism 5.00 (GraphPad Software, http://www.graphpad.com) 
and fitted using a non-linear regression with a sigmoidal dose-response curve (variable slope). The 
average IC50, defined as the concentration of the compound found to inhibit cell viability by 50% after 
24 h, was obtained from 4 independent experiments. 
 In vitro inflammatory model  
Briefly, 400 000 cells per well were plated in 6-well plates, allowed to settle/adhere overnight. 
Thereafter, cells were pre-treated with ½ IC50 concentrations of the chosen garlic OSC. In order to 
simulate regular dietary consumption, cells were given a second dose after 24 h. In conjunction with 
the second dose, cells were stimulated with 10 ng/ml LPS (E. coli serotype O55:B5, Cat. No. L4005, 
Sigma-Aldrich) (unless otherwise indicated). Total RNA was extracted from cells 4 h and 8 h post LPS 
addition (or as indicated) for qPCR analysis for selected cytokines and inflammatory mediators. 
Additionally, supernatants and cell lysates were collected 8 h and 24 h post LPS addition or as indicated 
and analysed by sandwich ELISA and Western blot, respectively, for secretion of selected cytokines 
and inflammatory mediators.  
Table 2.1: A summary of the experimental design for the in vitro inflammatory model with two independent 
treatment variables and four treatment groups. 
Variables Untreated LPS-treated 
Untreated Group A  Group B 
Garlic OSC-treated Group C Group D 
 
Table 2.1 summarises the experimental design with two independent variables, LPS treatment and 
garlic OSC treatment, and four treatment groups. Group A (untreated cells) served as a control for 
Group B (LPS-treated cells) and Group C (garlic OSC-treated cells), while Group B and Group C served 
as controls for Group D (garlic OSC- and LPS-treated cells).  
Note that a minimum of three independent experiments (biological repeats) were performed with 
treatment groups run in triplicate (technical repeats) in each individual experiment.  
 Gene and protein nomenclature 
In this thesis standardised abbreviations (referred to as symbols) have been used to refer to genes 
and proteins. According to the Human Gene Nomenclature Committee, human genes and proteins 
are represented by symbols written in uppercase Latin letters and Arabic numerals, and genes are 
distinguished from proteins by the use of italics166. Human interleukin-1β, for example is written as 
IL1B (gene) or IL1B (protein). In contrast, mouse gene symbols start with a capital letter, followed by 
29 
 
lowercase letters and are also italicised167. Mouse protein symbols are written in the same format as 
human proteins167. Mouse interleukin-1β is written as Il1b (gene) and IL1B (protein). Within the 
literature review, human gene and protein symbols have been used for consistency. As the 
experimental work for this thesis was conducted using the murine macrophage cell line RAW264.7, 
symbols used in the rest of this thesis refer to the mouse, unless otherwise indicated. When gene and 
protein expression of selected cytokines and inflammatory mediators were referred to together, both 
abbreviations were used i.e. Il1b/IL1B. 
  Gene expression analysis 
mRNA was extracted from treated cells as described in Section 2.5, treated with DNase I to remove 
DNA contaminants, and reverse transcribed into complementary DNA (cDNA). cDNA was used to 
determine relative gene expression of selected cytokines and inflammatory mediators after LPS-
stimulation using qPCR. 
2.7.1. RNA extraction 
Prior to RNA extraction, all surfaces and pipettes were cleaned with RNase ZapTM (Sigma-Aldrich) in 
order to remove RNase contaminants. The pipettes were then treated with 10 % bleach and placed 
under an ultraviolet lamp to degrade any contaminating DNA. Media was removed and adherent cells 
were washed with 1 ml PBS. 500 μl PBS was added to each well in the 6-well plate, and adherent cells 
were removed by scraping with a sterile cell scraper (Corning®, Sigma-Aldrich) and transferred into a 
2 ml microcentrifuge tube. Cells were pelleted by centrifugation (250xg for 5 min), the supernatant 
was removed and RNA was extracted using the GeneJETTM RNA Purification kit (Thermo Scientific) 
according to manufacturer’s instructions. Briefly, the cell pellet was resuspended in Lysis Buffer 
supplemented with 40 mM dithiothreitol (DTT, Sigma) and vortexed for 10 s. To ensure complete cell 
homogenisation, cell lysates were passed through a blunt 21-gauge needle fitted to an RNase-free 
syringe, after which 360 μl of 96 % ethanol was added to each sample cell lysate. The GeneJETTM RNA 
Purification Column was loaded with 700 μl of lysate and centrifuged at 12000 xg for 1 min. The flow-
through was discarded and loading was repeated until all lysate was loaded onto the column. The 
column was then transferred to a new 2 ml collection tube and washed 3x (with 700 μl of Wash Buffer 
1, 600 μl Wash Buffer 2 and finally 250 μl of Wash Buffer 2) and centrifuged at 12000 xg for 1 min 
between each wash step. The column was then inserted into a 1.5 ml microcentrifuge tube and 100 
μl of nuclease-free water (Thermo Scientific) was added to the column, followed by a 1 min 
centrifugation at 12000 xg. The flow-through containing the extracted RNA was collected and the 
concentration was measured using a Thermo Scientific NanoDrop 2000 Spectrophotometer. RNA 
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purity was checked by ensuring that sample ratios of absorbance 260/280 and 260/230 were above 
1.8 and 2, respectively. 
2.7.2. DNase I treatment 
In order to remove genomic DNA from extracted RNA samples, samples were treated with DNase I 
endonuclease (Thermo Scientific). Briefly, 1 μg of RNA was combined with 1 μl of 10x Reaction Buffer 
containing Mg2+ and 1U of DNase I. The sample volume was then made up to 10 μl with nuclease-free 
water (Thermo Scientific). When higher concentrations of RNA were required, the reaction was scaled 
up. Samples were then incubated at 37°C for 30 min. After which, samples were either cleaned by 
ethanol precipitation (Section 2.7.3) or – if the RNA was intended for use with the RT2 Profiler PCR 
Array Plates (Qiagen) (Section 2.8) – samples were repurified using GeneJETTM RNA Purification 
Columns as previously described (Section 2.7.1) with the exception that the Lysis Buffer was not 
supplemented with DTT and samples were not homogenised through a needle.  
2.7.3. Ethanol precipitation of RNA oligonucleotides 
Ethanol precipitation was performed in order to remove DNase I endonuclease from RNA samples. 
RNA samples in 2 ml microcentrifuge tubes were made up to 400 μl with nuclease-free water (Thermo 
Scientific) after which 50 μl of 3 M sodium acetate and 1.5 ml of 96% ethanol was added. Samples 
were then vortexed for 10 s and stored at -80ᵒC overnight. Thereafter, samples were centrifuged at 
13000 xg for 20 min at 4ᵒC. Supernatants were removed and 200 μl of cold 96% ethanol (stored at -
20ᵒC) was added to each tube. The ethanol was poured off,  samples were left to dry for 20 min after 
which 10 μl of nuclease-free water was added to the pellet and the RNA was resuspended by pipetting. 
RNA concentration and purity was then measured using a Thermo Scientific NanoDrop 2000 
Spectrophotometer. Only RNA samples with ratios of absorbance for 260/280 and 260/230 that were 
above 1.8 and 2, respectively, were used for reverse transcription. 
2.7.4. RNA integrity analysis 
Representative RNA samples were sent to the Centre for Proteomic and Genomic Research (CPGR) to 
be analysed on an Agilent 2100 Bioanalyzer (Agilent Technologies) for RNA quality and integrity. The 
Agilent 2100 Bioanalyzer software assigns an RNA Integrity Number (RIN) based on the measured 
electrophoretic trace of the entire RNA sample. RINs between 7 and 10 indicate mRNA of acceptable 
quality for reverse-transcription PCR and downstream qPCR analysis. All samples sent for RNA integrity 
analysis returned RIN values of ≥8, indicating that the RNA extraction and sample processing methods 
used return high quality RNA and that samples are not prone to RNA degradation. 
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2.7.5. Reverse transcription of RNA 
DNase I-treated RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
(Applied BiosystemsTM), according to manufacturer’s instructions. A 2x Reverse Transcription master 
mix was prepared containing 2 μl of 10x RT Buffer, 0.8 μl of 100 mM dNTP mix, 2 μl of 10x RT Random 
Primers, 1 μl of MultiScribeTM Reverse Transcriptase (50 U/μl) and 4.2 μl of nuclease-free water.  For 
each reaction, 1 μg of total RNA was made up to a 10 μl volume with nuclease-free water in 8-well 
PCR stripettes. 10 μl of 2x Reverse Transcription master mix was added to 10 μl of RNA sample and 
mixed by pipetting. The PCR stripettes were sealed and briefly centrifuged in a desktop centrifuge and 
placed on ice. The following program was set up on the Applied Biosystems Gene Amp® PCR system 
2700 thermal cycler set for a 20 μl reaction volume: 25ᵒC for 10 min (annealing step), 37ᵒC for 120 min 
(elongation step) and 85ᵒC for 5 min (denaturation step). Samples were stored at -20ᵒC until further 
use. For large experiments, the reverse transcription reaction was scaled up accordingly. 
2.7.6. Quantitative real-time PCR (qPCR) 
The Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
guidelines describe the minimum information required to allow for peer-review of qPCR 
experiments168. These reporting guidelines encourage better experimental practice by improving the 
accuracy, repeatability and reliability of qPCR experiments. A MIQE checklist can be found in Appendix 
C. This checklist was used for all qPCR experiments performed. 
2.7.6.1. Primer oligonucleotide design  
qPCR experiments were performed for the following genes; cyclooxygenase-2 (Cox2) (official gene 
name Prostaglandin-endoperoxide synthase 2 (Ptgs2)), Il1b, Il6, Il10, Il12b, Nos2, Tnf, and 
Trail/Tnfsf10. Primer sequences for selected genes were either designed using Primer3Plus free online 
software169 or obtained from the Real Time Primer DataBase (RTPrimerDB)170, with the exception of 
primers for Il12b, which were purchased from Qiagen (Cat. No. 330001 PPM03020E). Primer suitability 
was analysed using OligoAnalyzer 3.1 software (Integrated DNA Technologies, Inc) for oligonucleotide 
melting temperature (Tm) (Supplementary Table C2, Appendix C) possible hairpin loop structures (max 
Tm recorded in Supplementary Table C2, Appendix C) and homodimers and heterodimers. Default 
parameters were used with the exception of the Mg2+ concentration, which was set at 3 mM. The 
spontaneity of the formation of homodimers and heterodimers is measured as Gibbs Free energy 
(delta G) (kcal/mole); the smaller the delta G value, the more spontaneous the formation of the 
structure. In order to control for highly spontaneous homodimers and heterodimers, a cut off of the 
difference between the delta G value for the oligonucleotide binding to its perfect complement 
(Maximum Delta G) and the most spontaneous homodimer or heterodimer was chosen to be less than 
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-30 kcal/mol. In other words, the spontaneity of the oligonucleotide binding to its perfect complement 
was always -30 kcal/mol more spontaneous than any other structure (Supplementary Table C2, 
Appendix C). Further, all primers were tested for alignment with NCBI sequences using NCBI Primer 
BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast/)against Mus musculus with default settings. 
Accession numbers of matching sequences were recorded in Supplementary Table C2, Appendix C. 
Primers which met the aforementioned standards, were synthesised in the UCT Molecular and Cellular 
Biology DNA Synthesis Laboratory using an Applied Biosystems 394 DNA Synthesizer. 
Table 2.2: Primer oligonucleotides used for qPCR analysis of relative gene expression. Further information 
regarding primer amplification efficiency; amplicon positions on coding sequences; primer melting 
temperatures; NCBI Blast results; transcript variants; and homo- and heterodimer formation can be found in 
Supplementary Table C2, Appendix C. 
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β-actin Actb NM_007393 11461 168 F AGAGGGAAATCGTGCGTGAC 20 138 
R CAATAGTGATGACCTGGCCGT 21 
β2-
microglobulin 
B2m NM_009735 12010 1192 F ATTCACCCCCACTGAGACTGA 21 86 
R CTCGATCCCAGTAGACGGTC 20 
Glyceraldehyde
-3-phosphate 
dehydrogenase 
Gapdh NM_008084 14433 N/A F CCAATGTGTCCGTCGTGGATCT 22 149 
R GTTGAAGTCGCAGGAGACAACC 22 
G
e
n
e
s 
o
f 
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te
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Prostaglandin-
endoperoxide 
synthase 2 
Ptgs2 
(also 
Cox2)* 
NM_011198 17709 N/A F CCAGCACTTCACCCATCAGTT 21 53 
R ACCCAGGTCCTCGCTTATGA 20 
Interleukin-1β Il1b NM_008361 16176 N/A F CAGGCAGGCAGTATCACTCA 20 350 
R AGGCCACAGGTATTTTGTCG 20 
Interleukin-6 Il6 NM_031168 16193 138 F GAGGATACCACTCCCAACAGACC 23 141 
R AAGTGCATCATCGTTGTTCATACA 24 
Interleukin-10 Il10 NM_010548 16153 140 F GGTTGCCAAGCCTTATCGGA 20 192 
R ACCTGCTCCACTGCCTTGCT 20 
Nitric oxide 
synthase 2 
Nos2 NM_010927 18126 151 F CAGCTGGGCTGTACAAACCTT 21 95 
R CATTGGAAGTGAAGCGTTTCG 21 
Tumour 
Necrosis Factor 
Tnf NM_013693 21926 3747 F CAAAATTCGAGTGACAAGCCTG 22 114 
R GAGATCCATGCCGTTGGC 18 
TNF 
superfamily 
member 10 
Tnfsf1
0 (also 
Trail)* 
NM_009425 22035 N/A F TCTTGAACAGACCCTGCTTG 20 179 
R CCGAGTGATCCCAGTAATGTG 21 
*While prostaglandin-endoperoxide synthase 2 (Ptgs2/PTGS2) is the official name, this gene/protein is widely referred to as cyxlooxygenase-
2 (Cox2/COX2) in the literature. For clarity we refer to this gene as Cox2/Ptgs2 and protein as COX2/PTGS2 from here onwards. While, TNF 
superfamily member 10 (Tnfsf10/TNFSF10) is the official name, this gene/protein is widely referred to as TNF-related apoptosis inducing 
ligand (Trail/TRAIL) in the literature. For clarity we refer to this gene as Trail/Tnfsf10 and protein as TRAIL/TNFSF10 from here onwards. 
When written out in full we refer to these genes or proteins as cyclooxygenase-2 and TNF-related apoptosis-inducing ligand. 
2.7.6.2. Confirmation of primer specificity: melt curves and gel electrophoresis 
Melt curve analysis was used to control for primer specificity and was checked for a single peak 
indicative of a single qPCR product (amplicon). Melt curve analysis makes use of SYBR Green I dye 
which is an asymmetrical cyanine dye that preferentially binds to double stranded DNA. (dsDNA) The 
DNA-dye complex absorbs light at 497 nm and emits light at 520 nm, and can thus be used to measure 
the quantity of DNA in qPCR. In order to determine whether there was a single amplicon product, a 
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melt curve analysis was performed, where the temperature of the sample is increased incrementally 
while the instrument continues to measure fluorescence (Supplementary Figure C1, Appendix C). As 
the dsDNA dissociates, so will the SYBR Green I dye resulting in a decrease in fluorescence. The change 
in slope of the fluorescence is plotted against the temperature to create a melt curve. A single peak 
on a melt curve indicates that all dsDNA dissociated at the same temperature, suggesting that there 
is a single amplicon. In order to verify the presence of a single product, qPCR samples and 5 μl 
O’GeneRuler 50 bp DNA Ladder (Thermo Scientific) were loaded onto a 3% agarose gel and subjected 
to gel electrophoresis in 1x TBE (Appendix A) for 2 h at 100V  to separate products by size 
(Supplementary Figure C1, Appendix C). 
2.7.6.3. qPCR reagents and reaction conditions 
qPCR experiments were carried out using the SensiMixTM SYBR®-No-ROX Kit (BioLine). A master mix 
for each gene target was prepared for the required number of reactions. A 1x master mix contained 5 
μl of 2x SensiMix™ SYBR® No-ROX (final concentration of 3 mM MgCl2), 1 μl of 10 μM forward primer 
(final concentration 1 μM), 1 μl of 10 μM reverse primer (final concentration 1 μM) and 2 μl of 
nuclease-free water. Using a multichannel pipette, 9 μl of the master mix was loaded per well into 
either a 96-well or 384-well white polypropylene LightCycler® 480 Multiwell plate (Roche), followed 
by 1 μl cDNA (prepared as described in Section 2.7.5) to make a final reaction volume of 10 μl. The 
plate was sealed with Optical Adhesive Film (Roche) and centrifuged for 3 min at room temperature 
in an Eppendorf® 5810R centrifuge to remove air bubbles. Each sample for each gene target was 
performed in duplicate including negative controls; the no-template control and no-reverse 
transcription control were included to control for DNA contamination. The samples were considered 
free of DNA contamination if the difference between the negative control quantification cycle (Cq) 
and the lowest concentration unknown sample (that would have the highest Cq value of the unknown 
samples) was > 5 Cqs. In addition, a 10-fold serial dilution of cDNA, pooled from all samples within a 
given experiment, was included in each experiment from which primer target and run-specific 
amplification efficiency was calculated (Section 2.7.6.5). The qPCR reaction conditions for the Roche 
LightCycler 480II are detailed in Table 2.3. 
Table 2.3: Quantitative real time PCR thermal cycling conditions. 
Cycles Temperature (ᵒC) Time  Notes 
1 95 10 min Polymerase activation 
45 95 30 s Denaturation 
64* (see Section 2.7.6.4) 30 s Annealing 
72 90 s Extension & Fluorescence 
Acquisition 
1 Range set Melt curve analysis 
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2.7.6.4. Optimisation of qPCR annealing temperature 
In order to determine the ideal conditions for qPCR using the primers listed in Table 2.2, a temperature 
gradient qPCR was performed using a gradient qPCR machine, the CFX96 Touch™ Real-Time PCR 
System (Bio-Rad Laboratories, Inc). Reaction conditions used are described in Table 2.3, with the 
following annealing temperatures:  58, 59, 60, 61, 62, 63, 64 and 65ᵒC. The annealing temperature 
which on average yields the lowest Cq values for the targets tested is the optimal temperature. In this 
case the optimum annealing temperature was 64ᵒC (Supplementary Figure C3, Appendix C) and thus 
the annealing temperature for all subsequent qPCR experiments was set to 64ᵒC. Note as this 
experiment used a different qPCR machine, compatible white polypropylene Hard-Shell® 96-Well PCR 
Plates (Bio-Rad Laboratories, Inc) were used for this experiment only.  
2.7.6.5. PCR efficiency correction 
Conversion of Cq values to normalised relative quantities (NRQ) is required in order to determine 
relative gene expression. Relative quantification of gene expression was achieved by normalising the 
expression of a gene of interest to the expression of stable reference genes using qBase plus software 
(Biogazelle). qBase plus software utilises a modified version of the PCR efficiency-corrected method171, 
which makes use of a serial dilution curve to calculate the amplification efficiency of the primer 
oligonucleotides. The qBase plus method as described by Hellemans et al. (2007)172 allows for PCR 
efficiency-correction as well as normalisation to multiple reference genes. Amplification efficiencies 
from a representative experiment for primer oligonucleotides are included in Supplementary Table C2 
(Appendix C).  
2.7.6.6. Reference gene stability and selection using geNorm geometric 
normalisation factor  
The conventional use of a single reference gene for normalisation in relative qPCR experiments can 
result in inaccurate interpretation of relative gene expression data173. This is especially true when a 
reference gene is not stably expressed in tissues, cell lines or across experimental conditions173. It is 
therefore important to assess the stability of reference genes prior to normalisation. It has also been 
shown that normalising a gene of interest to a normalisation factor (calculated as the geometric mean 
of multiple stably-expressed reference genes) provides more accurate and reliable results173. In order 
to determine reference gene stability and the minimum number of reference genes required for 
accurate normalisation, three reference genes - β-actin (Actb), glyceraldehyde -3 phosphate 
dehydrogenase (Gapdh), and β2-microglobulin (B2m) - were analysed using qBase plus software 
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(Biogazelle) (see Hellemans et al. (2007) and Vandesompele et al. (2002)172,173 for details on formulae) 
(Table 2.4). All three reference genes analysed had acceptable geometric normalisation factor 
(geNorm M) (<0.5) and coefficient of variation (CV) (<0.2) values. While Gapdh and B2m were the 
two most stable of these genes, the amplification efficiency determined for B2m (Supplementary 
Table C2, Appendix C) did not fall within the acceptable 90–110% range. Actb and Gapdh were 
therefore chosen to determine the normalisation factor for all future experiments.  
Table 2.4: Reference gene stability and selection. Potential reference genes β-actin (Actb), β-microglobulin 
(B2m) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) were assayed for stability across treatment 
conditions.  The geNorm M (geometric normalisation factor) and CV (coefficient of variation) values were 
determined by the qBase plus software (Biogazelle) geNorm function. Acceptable values are geNorm M and CV 
values below 0.5 and 0.2, respectively.   
Reference gene geNorm M CV 
Actb 0.358 0.159 
B2m 0.341 0.135 
Gapdh 0.311 0.114 
 
 RT2 Profiler PCR Arrays 
Murine Inflammatory Response and Autoimmunity RT² Profiler PCR Arrays (Cat. No. PAMM-077Z, 
Qiagen) were performed to determine the effect of selected garlic OSCs on LPS-induced inflammatory 
gene expression for 84 different genes. Samples were processed and analysed for RNA integrity as 
described under Sections 2.7.1, 2.7.2 and 2.7.4. A pooled sample, consisting of three technical repeats, 
was used for each treatment group.  
2.8.1.  Reverse transcription  
Total RNA was reverse transcribed into cDNA using the RT2 First Strand Kit (Qiagen) according to 
manufacturer’s instructions. Briefly, 500ng of RNA was added to 2 μl Genomic DNA Elimination Buffer, 
made up to 10 μl with RNase-free water and mixed by pipetting. Samples were incubated at 42ᵒC for 
5 min and then transferred to ice. A 10x reverse transcription mix was made for four reactions 
containing 16 μl of 5x Buffer BC3, 4 μl Control P2, 8 μl RE3 Reverse Transcriptase Mix and 12 μl RNase-
free water. 10 μl of the reverse transcription mix was added to each sample and mixed by pipetting. 
Samples were then incubated at 42°C for 15 min and the reaction was stopped by incubating at 95ᵒC 
for 5 min. Samples were then made up to 111 μl by adding 91 μl of RNase-free water and stored at -
20ᵒC. 
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2.8.2. Quantitative real-time PCR (qPCR)  
A PCR components mixture was made for each sample containing 650 μl 2x RT2 SYBR Green 
Mastermix, 102 μl cDNA and 548 μl of RNase-free water. The PCR components mixture for each 
sample was then transferred into a 50 ml reagent reservoir (Axygen®, Corning, Sigma-Aldrich) and 10 
μl was loaded onto the Roche Lightcycler compatible 384-well RT² Profiler PCR Array plates. The 
provided 384EZLoad covers were used to guide pipetting of samples into the correct wells. The plate 
was then sealed using the Optical Adhesive Film and centrifuged at 1000 xg for 1 min at room 
temperature in an Eppendorf® 5810R centrifuge. qPCR was performed using the Roche LightCycler 
480II and cycling conditions are detailed in Table 2.5. Cq values were exported to Microsoft Excel and 
analysed using qBase plus software with the assumption that the oligonucleotide primer efficiencies 
were 100%. Results are shown as the average of two independent experiments.   
Table 2.5: RT2 Profiler PCR Array thermal cycling conditions 
Cycles Temperature (ᵒC) Time  Notes 
1 95 10 min Polymerase activation 
45 95 15 s Denaturation 
60 1 min Annealing, elongation and 
fluorescence acquisition 
1 Range set Melt curve analysis 
 
 
   
 Protein expression analysis 
2.9.1. Enzyme-Linked Immunosorbent Assay 
Cell culture supernatants from cells treated as described in Section 2.5 were assayed for 
concentrations of the following cytokines: IL1B, IL6, IL10, TNF and IL12B using sandwich ELISAs (BD 
OptEIATM, BD Biosciences). A murine TRAIL (TNFSF10) ELISA kit was purchased from Komabiotech. 
2.9.1.1. Sample preparation 
RAW 264.7 murine macrophages were treated as described in Section 2.5 and cell culture 
supernatants were collected 24 h after addition of LPS. The supernatants were centrifuged at 350 xg 
for 5 min at 4°C to remove floating cells and debris after which the supernatants were transferred into 
new microcentrifuge tubes and either used immediately for ELISA analysis or stored at -80ᵒC until use. 
2.9.1.2.  Protocol 
A 96-well high-binding polystyrene ELISA plate (Microlon®, Greiner Bio-One) was coated with 100 μl 
of capture antibody (1:250) diluted in 1x PBS. The plate was covered with a lid, placed in a sealed 
humidified container and stored at 4ᵒC overnight. (Note that for all subsequent incubation steps, the 
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plate was covered with a lid and incubated at room temperature inside a humidified container to 
minimise evaporation.) The following day, the wells were aspirated and washed 3x with ELISA Wash 
Buffer 1 (Appendix A). The wells were blocked with 200 μl of Assay Diluent (BD OptEIATM, BD 
Biosciences) for 1 h. The plate was washed 3x with ELISA Wash Buffer 2 (Appendix A). Standards were 
prepared as 2-fold serial dilutions in Assay Diluent (BD OptEIATM, BD Biosciences) with the following 
highest concentrations: 1000 pg/ml for IL6, TNF, Il12B and 2000 pg/ml for IL1B and IL10. Blank Assay 
Diluent served as the zero standard (0 pg/ml). Wells were loaded with 100 μl of standard or sample in 
duplicate and incubated for 2 h. The plate was then washed 5x with ELISA Wash Buffer 1, after which 
100 μl of the working detector (detection antibody at kit–specified concentration and streptavidin-
horseradish peroxidase (HRP) (1:250) diluted in Assay Diluent) was added to each well and incubated 
for 1 h. The plate was then washed 7x with ELISA Wash Buffer 1, 100 μl of Substrate Solution (BD 
PharmigenTM TMB Substrate Reagent Set, BD Biosciences) was added to each well and the plate was 
then incubated in the dark for 30 min. The enzyme reaction was stopped using 100 μl of 1 M H2SO4. 
The plate was briefly heated with a flame to remove any air bubbles and absorbance was measured 
using a plate-reading spectrophotometer (VersaMax™ Tuneable Microplate Reader, Molecular 
Devices) at 450 nm (within 30 min after stopping the reaction). Protein concentration of samples was 
determined by plotting the concentration of the standards against the corresponding OD reading to 
generate a standard curve.  
2.9.2. SDS-PAGE and Western blot analysis 
2.9.2.1. Preparation of cell lysates and determination of protein concentration 
Cell lysates were collected from adherent cells by adding 200 μl Cell Lysis Buffer (1x Cell Culture Lysis 
5x Reagent (Promega) supplemented with 1x HaltTM Protease Inhibitor Cocktail (100x) (Thermo 
Scientific)) and scraping with the back of a pipette tip. Cell lysates were transferred into 
microcentrifuge tubes and incubated on ice for 5 min, centrifuged at 13 000 xg for 5 min and the 
supernatants were collected and stored at -20°C until further use. Protein concentration was 
determined using the PierceTM BCA Assay Kit (Pierce Biotechnologies) according to manufacturer’s 
instructions.  
2.9.2.2. SDS-Polyacrylamide Gel Electrophoresis (PAGE) 
10 μg total protein per sample was mixed with 2 μl of 5x Non-Reducing Lane Marker (Thermo 
Scientific) containing 0.1 M DTT and incubated at 95ᵒC for 5 min in order to linearise proteins. Samples 
were then loaded onto 1.5 mm thick 10% sodium dodecyl sulphate (SDS)-polyacrylamide gels 
(Appendix A) along with 5 μl of PageRulerTM Plus Prestained Protein Ladder (Thermo Scientific). SDS-
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polyacrylamide gel electrophoresis (PAGE) gels were electrophoresed in 1x SDS-PAGE Running Buffer 
(Appendix A) in a Mini PROTEAN IITM system (BioRad) at 100 V for approximately 90 min. 
2.9.2.3. Western blotting 
SDS-PAGE separated proteins were then transferred onto a nitrocellulose membrane (HybondTM, 
Amersham) in 1x SDS-PAGE Transfer Buffer (Appendix A) at 100 V for 1 h. Equal loading and protein 
transfer was confirmed by Ponceau staining (Appendix A) of the nitrocellulose membranes. 
Nitrocellulose membranes were then blocked at room temperature for 1 h on a rocking platform 
shaker with 5% w/v bovine serum albumin (BSA, Sigma-Aldrich) in TBS (Appendix A) with 0.1% Tween 
in TBS (TBST) for phospho-STAT3, otherwise in 5% w/v non-fat powdered milk in PBS (Appendix A) 
with 0.1% Tween (PBST) .  
Table 2.6: Primary antibodies used in Western blotting.  
Primary Antibody Target 
MW 
(kDa) 
Organism 
raised in 
Monoclonal/ 
Polyclonal  
Dilution 
used 
Source Cat. No. 
Dansyl N/A* Rabbit monoclonal 1:7500 Life 
Technologies 
A-6398 
COX-2 (C-20) 70-72 Goat polyclonal 1:1000 Santa Cruz 
Biotechnology 
sc-1746 
GAPDH(FL-335) 37 Rabbit polyclonal 1:1000 Santa Cruz 
Biotechnology 
sc-25778 
Phospho-STAT3 
(Tyr705)(D3A7) 
80 Rabbit monoclonal 1:2000 Cell Signalling 
Technology® 
9145 
STAT3 (124H6) 80 Mouse monoclonal 1:1000 Cell Signalling 
Technology® 
9139 
* The dansyl antibody was used to detect dansylated proteins and therefore the MW of interest was that of the protein of interest. 
 
After membrane blocking, the primary antibody at the concentration listed in Table 2.6 was added to 
10 ml of the appropriate blocking solution and the membranes were incubated at 4°C on a rocking 
platform shaker overnight. The membrane was then washed 3x in 10 ml TBST or PBST, after which a 
secondary HRP-conjugated antibody against the organism the antibody was raised in was added in 5% 
w/v BSA-TBST or 5% w/v milk-PBST and incubated at room temperature for 1 h. The blot was washed 
3x in 10 ml TBST or PBST, thereafter 1 ml of LumiGlo® Chemiluminescent substrate (KPL) was pipetted 
onto the membrane and chemiluminescence was visualised using the VisionWorks LS BiospectrumTM 
500 Imaging system (UVP). In order to probe the membrane for another protein, the blot was stripped 
in 1 M glycine pH2.2 for 10 min and washed 1x in PBST. Blocking was repeated using 5% non-fat milk 
PBST for 1 h prior to the addition of the primary antibody and the procedure was repeated as 
described above. Relative quantification of protein bands was performed using the UVP densitometry 
tool.  
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 Proteome ProfilerTM Mouse Cytokine Array 
A Proteome ProfilerTM mouse cytokine Array (Cat. No. ARY006, R&D Systems) for 40 mouse cytokines 
and chemokines was performed to obtain a more comprehensive overview of the effects of selected 
garlic OSCs on LPS-induced cytokine expression. This array consists of four nitrocellulose membranes 
spotted with 40 different anti-cytokine antibodies. Incubation of these membranes with cell culture 
supernatants, followed by addition of Streptavidin-HRP and chemiluminescent detection reagents 
allows for relative quantitation of cytokine concentration. Briefly, nitrocellulose membranes were 
blocked with 2 ml of Array Buffer 6 in the provided 4-Well Multidish for 1 h on a rocking platform 
shaker. Samples were prepared by adding 500 μl of cell culture supernatant to 500 μl of Array Buffer 
4 and 500 μl of Array Buffer 6. Reconstituted Detection Antibody Cocktail (15 μl) was then added and 
samples were mixed and incubated at room temperature for 1 h. After membrane blocking, Array 
Buffer 6 was aspirated and the prepared sample/antibody mixtures were added to the membranes 
and incubated at 4°C on a rocking platform shaker overnight. The following day, membranes were 
washed 3x with 20 ml 1x Wash Buffer for 10 min. Streptavidin-HRP diluted (1:2000) in 2 ml Array Buffer 
6 was then added to the membranes and incubated for 30 min on a rocking platform shaker. After 
which, membranes were washed 3x with 20 ml 1x Wash Buffer for 10 min and placed onto acetate 
sheets. Chemi Reagent Mix (1 ml) was pipetted onto the membrane and chemiluminescence was 
visualised using the VisionWorks LS BiospectrumTM 500 Imaging system (UVP).  Relative protein 
quantification was performed using the UVP densitometry tool.  
 Protein alkylation by dansylated-ajoene  
In order to determine whether garlic OSCs undergo a thiol-disulfide exchange reaction with the 
transcription factor STAT3, E/Z-ajoene labelled with a dansyl functional group (synthesised by 
Jonathon Cotton, Department of Chemistry, UCT) (Figure 2.4)  was incubated with recombinant STAT3 
protein and run on an SDS-PAGE gel either under non-reducing or reducing conditions (100 mM DTT).  
 
 
 
Figure 2.4: Chemical structure of the dansylated-E/Z-ajoene. The dansyl functional group is highlighted in blue. 
Briefly, 25 μM of dansyl-labelled E/Z-ajoene was incubated with 0.5 μM of recombinant human STAT3 
protein (Cat. No. SRP2062, Sigma-Aldrich), made up to 5 μl in PBS, for 2 min at room temperature. 
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Either 1 μl of 5x Non-Reducing Lane Marker (Thermo Scientific) or 1 μl of 5x Reducing Lane Marker (5x 
Non-Reducing Lane Marker, containing 100 mM DTT), was added to the sample and samples were 
incubated at 95°C for 5 min. Samples were loaded and run on an SDS-PAGE gel (Section 2.9.2.2) and 
then transferred to a nitrocellulose membrane (Section 2.9.2.2). Nitrocellulose membranes were 
probed with the dansyl antibody, and reprobed with the STAT3 antibody (see Table 2.6). Co-
localization of the STAT3 and dansyl residue under non-reducing conditions indicates that a thiol-
disulfide reaction took place between the dansyl-labelled E/Z-ajoene and STAT3. 
 Statistical analysis 
One-way analysis of variance (ANOVA) significance testing along with Tukey’s Hypothesis testing was 
performed to compare differences in gene and protein expression of the 4 treatment groups namely; 
untreated, LPS-treated, garlic treated and garlic treatment in conjunction with LPS-stimulation. Prior 
to one-way ANOVA testing, the D'Agostino & Pearson omnibus normality test and Levene’s test were 
performed to determine whether the data violated the normality and homogeneity of variance 
assumptions, respectively. A violation of homogeneity of variance can, however, be ignored if the 
sample sizes in each group are equal174. Further, as many cytokines are only expressed by 
macrophages upon exposure to an inflammatory stimulus such as LPS, the untreated group and the 
garlic OSC -treated group often displayed very small variance (the expression was often zero or close 
to zero). Therefore the homogeneity of variance assumption was sometimes violated due to more 
variance in the LPS-treated groups compared to the control groups. For this reason, if the groups were 
normally distributed, the data were considered to be parametric and one-way ANOVA significance 
testing was performed.  
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 Results 
 MTT colorimetric cell viability assays  
In order to determine the concentration at which the selected garlic OSCs show sub-toxic effects on 
the murine macrophage cell line RAW264.7, thiazolyl blue tetrazolium bromide (MTT) colorimetric 
viability assays were performed. This assay is based on the reduction of yellow tetrazolium salt (MTT) 
to purple formazan crystals by metabolically active cells. We determined percentage cell viability by 
measuring relative absorbance at 595 nm and this was plotted against the log concentration of the 
garlic OSC to generate a dose-response curve (Table 3.1) using GraphPad Prism 5.00 (GraphPad 
Software, http://www.graphpad.com) dose-response curve fitting to a non-linear response. The IC50 
value is defined as the concentration of the compound found to inhibit cell viability by 50% after a 24 
h incubation period. Since we wanted to study the effects of the garlic OSCs on immune modulation, 
we wanted to select a dose that did not elicit any cytotoxic effects to the macrophages. We therefore 
selected half the IC50 value (a value in the sub-toxic concentration range of the compound determined 
to be ≥ 90 % cell viability) for the garlic OSCs, for all subsequent gene and protein expression 
experiments. 
 Establishing an in vitro inflammatory model   
In order to determine the effects of the selected garlic OSCs on the inflammatory immune response, 
an in vitro inflammatory model was developed. The murine macrophage cell line RAW264.7 was 
chosen with the idea of ultimately determining the effects of garlic OSC gavage on induced 
gastrointestinal and colorectal inflammation in BALB/c mice (an in vivo inflammatory model).  The 
experimental work from this thesis will serve as the basis for the in vitro proof-of-concept required for 
an ethics application for future in vivo experiments. It must be noted that although LPS-induced 
inflammation in macrophages is a common model for acute bacterial infection, cancer-friendly chronic 
inflammation cannot be studied at an in vitro level using cultured macrophages as these cells become 
unresponsive to inflammatory stimuli following prolonged exposure175.   
In this in vitro model, we stimulated an inflammatory response in murine RAW264.7 macrophages 
using lipopolysaccharide (LPS), before assessing the effects of garlic OSC treatment on said 
inflammatory response. To simulate regular dietary consumption of garlic, cells were given two ½ IC50-
concentration doses of the individual garlic OSCs, 24 h apart. Twenty-four hours after the first dose of 
the garlic OSC was given, cells were treated with a second dose of the garlic OSC in conjunction with 
LPS. However, in order to establish this in vitro model, it was important for us to first optimise the 
conditions for LPS treatment.   
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Table 3.1 Chemical structures and representative IC50 dose-response curves of selected garlic OSCs. Log 
concentration is plotted against percentage cell viability determined using MTT colorimetric assays for the 
RAW264.7 murine macrophage cell line. Average IC50 values were calculated from 4 independent experiments 
and half IC50 values were chosen as a sub-toxic concentration for all subsequent cell culture experiments.  
*An IC50 dose-response curve could not be determined for DADS even at millimolar (mM) concentrations. The DADS graph 
is therefore depicted as the absorbance at 595nm plotted against log concentration. 
 
Compound Chemical Structure Sigmoidal Dose-Response Curve Mean IC50 ± 
SD (μM) 
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4.39 ± 1.31 2.20 
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3.2.1. Optimizing LPS concentration and stimulation time 
Cells of the innate immune system recognise pathogen-associated molecular patterns (PAMPs) from 
foreign microorganisms to which they mount an immune response176. The bacterial endotoxin LPS is 
a PAMP found in the outer membrane of gram-negative bacteria176. While LPS stimulation of cultured 
macrophages is a common in vitro assay used to study the inflammatory response, the concentration 
used for a particular experiment can vary from 1 ng/ml up to 10 μg/ml146,177–179. The chosen dosage 
depends on the biological origin of the LPS, the cell line used, the stimulation time and the desired 
level of inflammatory response. In this study we used LPS from E. coli serotype O55:B5 (Cat. No. L4005, 
Sigma-Aldrich) and initially determined the optimum concentration and stimulation time for the in 
vitro inflammatory model.  
3.2.1.1. Determining the optimal concentration of LPS 
Gene expression of the cytokines Il1b, Il6, Il10 and Tnf was measured by qPCR analysis after a 4 h-
stimulation period with either 0, 1, 10, 100 or 1000 ng/ml LPS (Figure 3.1 A). A review of the literature 
suggested that a 4 h LPS-stimulation time was most appropriate for the analysis of the gene expression 
of multiple cytokines and chemokines177,180,181. After 4 h, 1000 ng/ml LPS induced the highest gene 
expression of Il6 and Il10, while LPS-induced expression of Il1b and Tnf peaked at 100 ng/ml (Figure 
3.1A). Furthermore, while 1 ng/ml LPS was sufficient to induce increased gene expression for Il1b, Il6 
and Tnf after 4 h, this concentration did not induce Il10 gene expression at the same timepoint. As we 
wanted an LPS concentration high enough to detect inflammatory gene and protein expression, but 
low enough to determine whether treatment with garlic OSCs modulated the inflammatory response, 
a concentration of 10 ng/ml LPS was chosen for all further experiments.  
3.2.1.2. Determining optimal timepoints for gene and protein expression analysis 
Cytokines, chemokines and inflammatory mediators are expressed at different times during the 
inflammatory response182,183. We performed preliminary experiments to determine the best 
timepoints at which to harvest RNA and cell culture supernatants for gene and protein expression 
analysis of selected cytokines, respectively. Murine RAW264.7 macrophages were treated with 10 
ng/ml LPS and RNA and cell culture supernatants were collected 0, 2, 4, 6, 8, 12 and 24 h after addition 
of LPS. Figure 3.1B shows the gene and protein expression profiles for the aforementioned cytokines 
at these timepoints. Gene expression peaked between 2 and 8 h for all cytokines tested, while protein 
expression generally peaked between 6 and 12 h.  
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Figure 3.1: Dose- and time-dependent gene and protein expression of interleukin-1β, interleukin-6, 
interleukin-10 and tumour necrosis factor in response to LPS. A. LPS-induced gene expression of selected 
cytokines was measured by qPCR after 4 h incubation with 0, 1, 10, 100 and 1000 ng/ml LPS. Mean fold change 
in gene expression (± SEM) compared to the untreated control samples was determined for 3 samples per 
condition. B. Temporal gene- and protein-expression profiles of selected LPS-induced cytokines. Samples 
harvested 0, 2, 4, 6, 8, 12 and 24 h after LPS addition were analysed by qPCR and sandwich ELISA, respectively. 
While mean gene expression (lines) is presented relative to untreated controls, due to detectable background 
transcription, protein expression (bars) is presented as pg/ml as some cytokines are not expressed in the absence 
of an inflammatory stimulus. 
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It must be noted that in Figure 3.1B, the peak in IL1B protein expression (between 2 and 6 h) precedes 
the peak in gene expression (at 6 h). This may be explained by cleavage, activation and secretion of 
the inactive cytosolic pro-IL1B into mature IL1B which occurs in response to PAMP stimulation184. As 
we wanted to assess the effects of garlic OSC treatment on the LPS-induced expression of multiple 
cytokines, chemokines and inflammatory mediators, time points for sampling gene and protein 
expression levels were chosen to best represent the peaks in expression of the cytokines seen in the 
preliminary experiments (Figure 3.1A). Therefore, the timepoints 4 h and 8 h were chosen for all 
subsequent gene expression analyses while 8 h and 24 h were chosen for subsequent protein 
expression analyses. Figure 3.2 shows a workflow diagram summarising the methods used to obtain 
RNA and cell culture supernatant or cell lysate samples for all subsequent gene and protein expression 
analysis experiments.  
 
 
Figure 3.2: Workflow diagram for the in vitro inflammatory model in murine RAW264.7 macrophages. 
3.2.1.3. Selection of garlic organosulfur compounds  
The effects of the garlic OSCs allicin, DATS, E-ajoene, and Z-ajoene on LPS-induced gene expression of 
Il1b, Il6, Il10 and Tnf were determined in order to select the representative garlic OSCs for subsequent 
experiments. We excluded DADS because we could not obtain an IC50 value even at 100mM 
concentrations (Table 3.1). The MTT assay was working as the cells were able to reduce MTT reagent 
into formazan crystals and DADS compound purity was assessed by 1H NMR and TLC. Preliminary 
experiments showed that E-ajoene, Z-ajoene and DATS did not appear to affect the LPS-induced 
expression of Il6 (Figure 3.3B), Il10 (Figure 3.3C) and Tnf (Figure 3.3D) after 4 h. However, DATS and E-
ajoene treatment showed a downregulating trend on the LPS-induced expression of Il1b, while Z-
46 
 
ajoene treatment resulted in the largest decrease in LPS-induced Il1b expression (Figure 3.3A). Allicin 
treatment, on the other hand, upregulated the LPS-induced expression of all four cytokines tested 
(Figure 3.3). Therefore allicin (a major component of raw garlic) and DATS, E-ajoene, and Z-ajoene 
(major components of cooked garlic) appeared to elicit contrasting immune responses. Allicin is a 
highly unstable compound which is present in high concentrations in freshly crushed garlic 
preparations, while Z-ajoene is present in aged garlic preparations or cooked garlic preparations and 
is more representative of dietary garlic185. To best simulate the effect of dietary garlic on LPS-induced 
inflammation, we wanted to choose two compounds that represent raw and cooked garlic. As allicin 
is the major garlic OSC in raw garlic it was chosen for further experimentation. In addition, Z-ajoene 
was chosen to represent cooked garlic as it had the strongest effect on LPS-induced Il1b expression 
and we had a dansyl-tagged E/Z-ajoene which would be used for protein interaction studies 
Figure 3.3: The effect of garlic OSC treatment on LPS-induced gene expression of selected cytokines in murine 
RAW264.7 macrophages. qPCR gene expression analysis was performed on RNA extracted from cells pre-
treated with ½IC50 concentrations of either allicin, DATS, E-ajoene or Z-ajoene. After 24 h cells were stimulated 
with a second dose of the garlic OSC and stimulated with 10 ng/ml LPS for 4 h. Mean percentage gene expression 
of A. interleukin-1β, B. interleukin-6, C. interleukin-10 and D. tumour necrosis factor is shown relative to the LPS 
control (set to 100% expression). All data are presented as mean ± SEM of three samples per condition for a 
single experiment.  
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 Gene and protein expression of selected cytokines and 
inflammatory mediators  
In order to determine whether the garlic OSCs allicin and Z-ajoene affect LPS-induced inflammation, 
gene and protein expression analysis on selected cytokines and inflammatory mediators was 
performed. Experiments were performed as described in the Figure 3.2. Briefly, cells were stimulated 
with ½ IC50 concentrations of allicin or Z-ajoene; after 24 h a second dose was administered in 
conjunction with 10 ng/ml LPS.  
Total RNA was extracted 4 h and 8 h after addition of LPS (in conjunction with the second dose of the 
selected garlic OSC) and analysed by qPCR. Gene expression analysis was performed on the 
inflammatory cytokines Il1b, Il6, Il10, Il12b and Tnf; inflammatory enzymes Nos2 and Cox2/Ptgs2; and 
the pro-apoptotic ligand Trail/Tnfsf10.  
Protein expression of IL1B, IL6, IL10, IL12B, TNF and TRAIL/TNFSF10 was analysed by sandwich ELISA 
using cell culture supernatants collected 8 h and 24 h after addition of LPS (in conjunction with the 
second dose of the selected garlic OSC). COX2 protein expression was analysed by Western blotting 
using whole cell lysates.  
As many of the genes and proteins are only expressed upon exposure to an inflammatory stimulus, all 
figures show percentage gene or protein expression relative to the LPS-treated (positive control) 
samples (set to 100% expression).  
In general, the mRNA gene expression data are supported at the protein level (Figure 3.4-3.11) and 
LPS treatment either significantly upregulated or showed a strong increasing trend in the expression 
of the selected cytokines and inflammatory mediators. Treatment with the garlic OSCs alone did not 
significantly affect the gene or protein expression of any of the analysed cytokines or inflammatory 
mediators (Figures 3.4 - 3.11). Treatment with allicin or Z-ajoene, however, did affect LPS-induced 
expression and these effects were, in general, similar for both allicin and Z-ajoene (Figure 3.4-3.11 & 
summarised in Table 3.2). However, allicin mostly had a more potent immunomodulatory effect (Table 
3.2). 
Gene and/or protein expression of Il1b/IL1B, Il6/IL6 and Il12b/IL12B (Figure 3.4 - 3.6) were 
downregulated, while Il10/IL10, Cox2/COX2 and Trail/Tnfsf10 (Figure 3.7, Figure 3.9 & Figure 3.10) 
were upregulated by garlic OSC treatment. LPS-induced expression of Tnf/TNF and Nos2 was 
differentially affected by allicin and Z-ajoene (Figure 3.8).  
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Figure 3.4: The effect of selected garlic OSCs on LPS-induced interleukin-1β gene and protein expression in 
murine RAW264.7 macrophages. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-ajoene, 
followed by a second dose after 24 h in conjunction with 10 ng/ml LPS. Total RNA for qPCR gene expression 
analysis was extracted 4 h or 8 h after LPS stimulation, while cell culture supernatants for sandwich ELISA protein 
expression analysis were collected 8 h or 24 h after LPS stimulation.  A, B.  Allicin experiment. C, D.  Z-ajoene 
experiment. Percentage mean expression (±SEM), determined from three independent experiments, is shown 
relative to the LPS-control (set to 100% expression). One-way ANOVA significance testing followed by Tukey’s 
HSD test (* p<0.05; **, p<0.01; ***, p<0.001; ns, not significant) was performed to assess statistical relevance. 
Note that the differences in IL1B protein production in the untreated samples (panel B versus panel D) might be 
caused by interassay variability due to different batches of the ELISA kit used. 
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Figure 3.5: The effect of selected garlic OSCs on LPS-induced interleukin-6 gene and protein expression in 
murine RAW264.7 macrophages. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-ajoene, 
followed by a second dose after 24 h in conjunction with 10 ng/ml LPS. Total RNA for qPCR gene expression 
analysis was extracted 4 h or 8 h after LPS stimulation, while cell culture supernatants for sandwich ELISA protein 
expression analysis were collected 8 h or 24 h after LPS stimulation.  A, B.  Allicin experiment. C, D.  Z-ajoene 
experiment. Percentage mean expression (±SEM), determined from three independent experiments, is shown 
relative to the LPS-control (set to 100% expression). One-way ANOVA significance testing followed by Tukey’s 
HSD test (* p<0.05; **, p<0.01; ***, p<0.001; ns, not significant) was performed to assess statistical relevance. 
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Figure 3.6: The effect of selected garlic OSCs on LPS-induced interleukin-12 subunit-β gene and protein 
expression in murine RAW264.7 macrophages. Interleukin-12 subunit-β is a subunit of the interleukin-12 and 
interleukin-23 cytokines. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-ajoene, followed by a 
second dose after 24 h in conjunction with 10 ng/ml LPS. Total RNA for qPCR gene expression analysis was 
extracted 4 h or 8 h after LPS stimulation, while cell culture supernatants for sandwich ELISA protein expression 
analysis were collected 8 h or 24 h after LPS stimulation.  A, B.  Allicin experiment. C, D.  Z-ajoene experiment. 
Percentage mean expression (±SEM), determined from three independent experiments, is shown relative to 
the LPS-control (set to 100% expression). One-way ANOVA significance testing followed by Tukey’s HSD test (* 
p<0.05; **, p<0.01; ***, p<0.001; ns, not significant) was performed to assess statistical relevance. 
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Figure 3.7: The effect of selected garlic OSCs on LPS-induced interleukin-10 gene and protein expression in 
murine RAW264.7 macrophages. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-ajoene, followed 
by a second dose after 24 h in conjunction with 10 ng/ml LPS. Total RNA for qPCR gene expression analysis was 
extracted 4 h or 8 h after LPS stimulation, while cell culture supernatants for sandwich ELISA protein expression 
analysis were collected 8 h or 24 h after LPS stimulation.  A, B.  Allicin experiment. C, D.  Z-ajoene experiment. 
Percentage mean expression (±SEM), determined from three independent experiments, is shown relative to the 
LPS-control (set to 100% expression). One-way ANOVA significance testing followed by Tukey’s HSD test (* p<0.05; 
**, p<0.01; ***, p<0.001; ns, not significant) was performed to assess statistical relevance. 
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Figure 3.8: The effect of selected garlic OSCs on LPS-induced tumour necrosis factor gene and protein 
expression in murine RAW264.7 macrophages. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-
ajoene, followed by a second dose after 24 h in conjunction with 10 ng/ml LPS. Total RNA for qPCR gene 
expression analysis was extracted 4 h or 8 h after LPS stimulation, while cell culture supernatants for sandwich 
ELISA protein expression analysis were collected 8 h or 24 h after LPS stimulation.  A, B.  Allicin experiment. C, 
D.  Z-ajoene experiment. Percentage mean expression (±SEM), determined from three independent 
experiments, is shown relative to the LPS-control (set to 100% expression). One-way ANOVA significance testing 
followed by Tukey’s HSD test (* p<0.05; **, p<0.01; ***, p<0.001; ns, not significant) was performed to assess 
statistical relevance. 
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Figure 3.9: The effect of selected garlic OSCs on LPS-induced cyclooxygenase-2 gene and protein expression in 
murine RAW264.7 macrophages. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-ajoene, 
followed by a second dose after 24 h in conjunction with 10 ng/ml LPS. Total RNA for qPCR gene expression 
analysis was extracted 4 h or 8 h after LPS stimulation, while whole cell lysates for western blot analysis were 
collected 8 h or 24 h after LPS stimulation.  A, B.  Allicin experiment. C, D.  Z-ajoene experiment. Percentage 
mean gene expression (± SEM), determined from three independent gene expression experiments and two 
independent protein expression experiments, is shown relative to the LPS-control (set to 100% expression). 
Protein expression was determined by densitometric analysis normalised to GAPDH expression. One-way 
ANOVA significance testing followed by Tukey’s HSD test (*, p<0.05; **, p<0.01; ***, p<0.001) was performed  
to assess statistical relevance.  
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Figure 3.10: The effect of selected garlic OSCs on LPS-induced TNF-related apoptosis-inducing ligand gene 
expression in murine RAW264.7 macrophages. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-
ajoene, followed by a second dose after 24 h in conjunction with 10 ng/ml LPS. Total RNA for qPCR gene 
expression analysis was extracted 4 h or 8 h after LPS stimulation. A. Allicin experiment. B.  Z-ajoene experiment. 
Percentage mean expression (±SEM), determined from three independent experiments, is shown relative to 
the LPS-control (set to 100% expression). One-way ANOVA significance testing followed by Tukey’s HSD test (* 
p<0.05; **, p<0.01; ***, p<0.001; ns, not significant) was performed to assess statistical relevance. 
 
 
 
 
 
 
 
 
 
Figure 3.11: The effect of selected garlic OSCs on LPS-induced nitric oxide synthase-2 gene expression in 
murine RAW264.7 macrophages. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-ajoene, 
followed by a second dose after 24 h in conjunction with 10 ng/ml LPS. Total RNA for qPCR gene expression 
analysis was extracted 4 h or 8 h after LPS stimulation. A.  Allicin experiment. B.  Z-ajoene experiment. 
Percentage mean expression (±SEM), determined from three independent experiments, is shown relative to 
the LPS-control (set to 100% expression). One-way ANOVA significance testing followed by Tukey’s HSD test (* 
p<0.05; **, p<0.01; ***, p<0.001; ns, not significant) was performed to assess statistical relevance. 
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Table 3.2: Summary of the effect of allicin and Z-ajoene treatment on LPS-induced gene and protein expression 
of selected cytokines and inflammatory mediators. Mean percentage gene or protein expression (±SEM) is 
shown relative to the LPS control. Significant changes in expression are shown in green for downregulation and 
red for upregulation. Values are reported to one decimal place. 
Cytokine/ 
Inflammatory 
mediator 
Protein 
Symbol 
Allicin experiments Z-ajoene experiments 
Mean % Gene 
Expression 
±SEM 
Mean % Protein 
Expression 
±SEM 
Mean % Gene 
Expression 
±SEM 
Mean % Protein 
Expression 
±SEM 
4 h 8 h 8 h  24 h 4 h 8 h 8 h  24 h 
Interleukin-1β IL1B 104.2 
± 7.4 
78.6 ± 8.6 98.8 
±7.4 
68.2 
± 8.8 
72.2 
± 6.5 
77.6 ± 6 76.5 
± 25.1 
39.0 
± 12.1 
Interleukin-6 IL6 167.1 ± 
7.3 
87.3 ± 7.8 106.4 ± 
2.3 
50.0 ± 
11.5 
107.0 ± 
7.7 
70.6 ± 
6.1 
78.6 ± 
14.9 
94.7 ± 
7.4 
Interleukin-12 subunit 
β 
IL12B 67.7 ± 6 76.5 ± 9.7 62.5 ± 
7.7 
66.4 ± 
22.5 
64.4 ± 
8.7 
76.2 ± 
12.2 
67.2 ± 
7.0 
116.4 ± 
26.0 
Interleukin-10 IL10 263.6 ± 
27.1 
287.3 ± 
24.9 
276.8 ± 
41.6 
225.5 ± 
30.3 
146.3 ± 
16.3 
109.5 ± 
6.4 
94.1 ± 
6.7 
117.5 ± 
14.5 
Tumour Necrosis Factor TNF 133.6 ± 
13.6 
142.5  ± 
22.9 
159.9  
± 11.9 
196.0  ± 
29.9 
83.0  ± 
5.8 
128.6  ± 
13.58 
87.8  ± 
5.6 
135.3  ± 
23.3 
Cyclooxygenase-2 COX2/ 
PTGS2 
162.6  ± 
9.6 
95.8  ± 
10.3 
171.8  ± 
17.0 
208.9  ± 
97.2 
122.7  ± 
8.5 
72.6  ± 
4.9 
300.3  ± 
6.3 
568.5  ± 
427.9 
TNF-Related Apoptosis 
Inducing Ligand 
TRAIL/ 
TNFSF10 
382.8  ± 
51.4 
426.9  ± 
49.0 
None detected* 136.2  ± 
16.1 
352.9  ± 
84.0 
None detected* 
Nitric Oxide Synthase 2 NOS2 111.9  ± 
8.7 
142.0  ± 
21.4 
Not analysed** 80.0  ± 
8.6 
93.8  ± 
7.3 
Not analysed** 
* Cell culture supernatants were analysed for TRAIL/TNFSF10, but no expression was detected. **Protein expression levels of NOS2 were 
not measured.  
3.3.1. Cytokines downregulated by garlic OSC treatment 
Interestingly, while allicin generally had a more potent effect on LPS-induced gene regulation (Table 
3.2), the effect on Il1b/IL1B downregulation was stronger for Z-ajoene treatment. Z-ajoene decreased 
LPS-induced IL1B protein to 39.0% expression after 24 h as opposed to 68.2% for allicin. This finding is 
supported by the preliminary gene expression data looking at the effect of garlic OSCs (allicin, DATS, 
E-ajoene and Z-ajoene) where Z-ajoene was found to have the strongest downregulating effect after 
4 h (Figure 3.3A). In contrast, the preliminary gene expression experiment (Figure 3.3A) shows a 
significant increase in LPS-induced Il1b following allicin treatment, while no change in expression was 
seen in Figure 3.4A. While these data are inconsistent, the gene expression analysis shown in Figure 
3.4A is more reliable as it is an average of three independent experiments, while the data from Figure 
3.3A is a single preliminary experiment.  
Of particular interest is the effect of allicin on Il6 gene expression. While both garlic OSCs had an 
overall-downregulating effect on Il6/IL6 expression, Il6 gene expression was shown to be significantly 
upregulated by allicin treatment to 167.1% after 4 h (Figure 3.5A, Table 3.2., see also Figure 3.3B). At 
8 h, however, allicin treatment significantly downregulated Il6 gene expression to 87.3%. Protein 
expression data show that after 8 h, allicin treatment results in no significant difference in expression 
levels of IL6, but after 24 h IL6 expression is halved relative to LPS alone (Table 3.2). Based on the 
preliminary temporal expression profile (Figure 3.1B), Il6 gene expression peaks at 8 h, while protein 
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expression peaks between 12 and 24 h. Allicin treatment, therefore, appears to cause a shift in the 
temporal LPS-induced Il6/IL6 expression profile towards earlier peaks in gene and protein expression.   
IL12B (MW: 40 kDa) is a subunit of the pro-inflammatory IL12 and IL23 cytokines186. Allicin and Z-
ajoene significantly decreased LPS-induced Il12b gene expression to approximately 65% after 4 h 
(Table 3.2). In addition, allicin treatment resulted in a significant decrease in IL12B protein expression 
after 8 h. Further Il12b/IL12B gene and protein expression at other timepoints, while not statistically 
significant, showed a decreasing trend in expression following garlic OSC treatment.  
3.3.2. Cytokines and inflammatory mediators upregulated by garlic OSC 
treatment 
LPS-induced Il10/IL10 gene and protein expression is greatly upregulated (>225.5% in expression 
compared to LPS treated cells) by allicin treatment at all timepoints (Figure 3.5A & B & Table 3.2). Z-
ajoene while significantly upregulating Il10 gene expression after 4 h (146.3%) only shows a weak-
increasing trend in protein expression after 24 h (Figure 3.5C & D & Table 3.2). It should be noted, 
however, that this significant increase in gene expression of Il10 seen for Z-ajoene treatment after 4 
h (Figure 3.5C) is not consistent with Figure 3.3C which shows no change in expression. Figure 3.3C, 
however, shows the results from a single experiment, whereas Figure 3.5C is an average of three 
independent experiments, and is thus more reliable. 
LPS-induced expression of the Cox2/COX2 enzyme was generally upregulated by garlic OSC treatment 
(Figure 3.9 & Table 3.2). Both allicin and Z-ajoene significantly upregulated LPS-induced Cox2 
expression after 4 h, but allicin had no effect and Z-ajoene significantly decreased Cox2 gene 
expression after 8 h. Western blot densitometry data showed an increasing trend in COX2 protein 
expression for both allicin and Z-ajoene treatment. While two independent experiments showed 
increases in LPS-induced COX2 protein expression when treated with allicin or Z-ajoene, when 
percentage expression values from these experiments were averaged, inter-experimental variability 
resulted in large SEM values. Statistically significant differences in COX2 protein expression could not 
be reached due to this inter-experiment variability, however, it does appear that both allicin and Z-
ajoene induce increased COX2 protein expression in LPS-treated macrophages. 
Both allicin and Z-ajoene treatment greatly increased (generally more than 300% expression) the LPS-
induced gene expression of Trail/Tnfsf10 (Figure 3.10 & Table 3.2). Cell culture supernatants were 
tested by sandwich ELISA for TRAIL/TNFSF10 protein expression, but as no protein was detected in 
any of these samples, no protein expression data is shown for TRAIL (TNFSF10).  
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3.3.3. Cytokines and inflammatory mediators affected differently by garlic 
OSCs 
Tnf/TNF gene and protein expression was significantly upregulated by allicin treatment for all 
timepoints measured (Figure 3.8A & B & Table 3.2., see also Figure 3.3D). Z-ajoene, on the other hand, 
downregulated LPS-induced TNF expression after 4 h for gene expression, but this was not seen after 
8 h or at the protein level after 8 h and 24 h (Figure 3.8C & D & Table 3.2). Further, Z-ajoene mediated 
downregulation of LPS-induced Tnf gene expression after 4 h of treatment was not seen in Figure 3.3D, 
which showed no change in expression. Z-ajoene treatment, however, showed upregulating trends on 
LPS-induced TNF gene- and protein expression after 8 h and 24 h respectively. Due to large SEM values 
(Table 3.2), however, it is likely that Z-ajoene has no effect on TNF expression at these timepoints. 
While allicin treatment slightly increased LPS-induced Nos2 gene expression, Z-ajoene showed a 
modest downregulation of LPS-induced Nos2 expression. These trends, however, were not statistically 
significant. Due to time constraints, NOS2 protein expression was not investigated. 
3.3.4. Selecting optimal timepoints for gene and protein array experiments 
As suggested by the preliminary experiments shown in Figure 3.1B, it is important to consider that 
cytokines and inflammatory mediators have different temporal expression profiles. The findings 
presented in Figures 3.4-3.11 show that allicin and Z-ajoene clearly modulate the expression of the 
selected cytokines and inflammatory mediators. We therefore decided to conduct gene and protein 
expression arrays which will provide a broader indication of the effects of allicin and Z-ajoene on LPS-
induced gene and protein expression. These arrays are, however, limited in that only a few samples 
can be analysed. We therefore had to choose the most appropriate timepoints at which to measure 
gene- and protein expression. In Table 3.2 it is apparent that both allicin and Z-ajoene generally elicited 
stronger effects on LPS-induced gene expression of the selected cytokines and inflammatory 
mediators after a 4 h treatment period as compared to 8 h. We therefore chose the 4 h timepoint for 
gene expression arrays.  
Similarly, the 24 h treatment period resulted in a greater number of significant differences in LPS-
induced protein expression for allicin-treated cells (Table 3.2). In contrast, Z-ajoene treatment only 
resulted in the significant increase of LPS-induced COX2 protein levels after 8 h and a significant 
decrease in LPS-induced IL1B protein levels after 24 h of treatment. As allicin treatment showed the 
strongest effect on LPS-induced expression of the selected cytokines and inflammatory mediators 
after 24 h of treatment, along with the fact that Z-ajoene treatment shows a similar upregulating trend 
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on LPS-induced COX2 protein expression after 24 h, the 24 h timepoint was chosen for subsequent 
protein array analyses.  
 RT2 Profiler PCR Array for Inflammatory Response and 
Autoimmunity 
Once the conditions, as described in Figure 3.2, and the optimal treatment timepoint (4 h for the gene 
expression analysis experiments) were established (Section 3.3.4), the effect of allicin and Z-ajoene-
treatment on LPS-induced inflammatory gene expression using RNA samples isolated 4 h after 
stimulation with 10 ng/ml LPS was analysed on the commercially available RT2 ProfilerTM PCR Array 
(Qiagen®). This array analyzed the expression of 84 genes known to be involved in the inflammatory 
response and autoimmune pathways.  
While this array provides a broad indication of the effects of the selected garlic OSCs on LPS-induced 
inflammatory gene expression, it is important to note that the array does not allow for technical 
repeats. Therefore, a single sample, pooled from 3 biological samples, was used per treatment 
condition.  
Results of allicin and Z-ajoene treatment on the expression of 84 genes with and without LPS-
stimulation are summarised in Figure 3.12 and Figure 3.14, respectively. The selection criterion for 
gene-responsiveness to a given treatment was a fold change ≥ 2 upon treatment with LPS and/or 
garlic OSCs. LPS-treated cells, garlic OSC-treated cells and garlic OSC- and LPS-treated cells were 
compared to untreated cells, while garlic OSC-LPS-treated cells were also compared to LPS treatment 
alone. Genes were excluded from the analysis if the average quantification cycle (Cq) was above the 
defined Cq cut-off of 35, which indicates that gene expression was very low and therefore unreliable. 
Changes in gene expression in Table 3.3 and Table 3.4 are displayed as fold up- or downregulation 
compared to untreated cells or LPS-treated cells. We chose to show fold regulation as opposed to fold 
change as the latter method can result in data which is skewed in favour of upregulation in expression. 
This is because a decrease in expression is represented by a number between 0 and 1, while an 
increase in expression is represented as a value greater than 1. Fold up or downregulation uses the 
reciprocal of the fold change values showing downregulation (i.e. between 0 and 1) in order to apply 
equal weight to increases and decreases in expression. A fold change of 0.75, for example, can be 
converted to fold down-regulation by taking the reciprocal of the fold change: 
1
0.75
 equals a fold down-
regulation of 1.33 (shown as -1.33). One drawback, however, is that large fold down-regulation values 
are seen when the gene expression is zero or very close to zero expression (Table 3.3 and Table 3.4). 
Similarly very large fold upregulation values can indicate that the reference sample had little or no 
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expression of the gene of interest. Those data must be treated with caution as the fold up- or 
downregulation values, while indicating that there is a large difference in expression between the 
sample of interest and the reference sample, may not be biologically relevant. 
3.4.1. Allicin treatment 
 Of the 84 genes analysed, ten were excluded for technical reasons, and 16 did not respond to any of 
the treatment conditions (Figure 3.12). As this thesis focuses on the immunomodulatory effects of 
garlic OSCs, the 20 genes responsive to both LPS treatment and allicin-LPS treatment (numbers shown 
in red, Figure 3.12) were selected for further analysis. Responsive genes were those that had a positive 
or negative fold change ≥ 2 compared to untreated cells for allicin-responsive and LPS-responsive 
genes, and LPS-treated cells for allicin-LPS-responsive genes. 
 
 
 
 
 
 
 
 
 
Figure 3.12: A Venn diagram summarising the results of the Inflammatory Response and Autoimmunity RT2 
Profiler PCR Array (Qiagen®) following treatment with LPS and/or allicin treatment of murine RAW264.7 
macrophages. The number of genes responsive to allicin treatment, LPS treatment and allicin-LPS treatment is 
shown. Responsive genes were those that had a positive or negative fold change ≥ 2 compared to untreated 
cells for allicin-responsive and LPS-responsive genes, and LPS-treated cells for allicin-LPS-responsive genes. 
Genes with an average quantification cycle (Cq) of ≥ 35 were excluded. Genes responsive to both LPS and allicin-
LPS treatment (red numbers) were chosen for further analysis. 
 
These genes were divided into 5 functional categories, namely chemokines, interleukins, receptors, 
TNF Ligand Superfamily and other genes (Figure 3.13) and are listed in detail in Table 3.3.  
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Figure 3.13: Gene groupings of the inflammatory genes responsive to both LPS treatment and allicin-LPS 
treatment in murine RAW264.7 macrophages. Genes identified from the RT2 Profiler PCR Array to have a ≥ 2 
fold up- or downregulation in expression for both LPS-treated cells and allicin-LPS-treated cells were selected 
for further analysis and categorised as either chemokines, interleukins, receptors, TNF ligand superfamily or 
other.  
 
3.4.1.1. Chemokines 
In Figure 3.13 and Table 3.3, the largest group of genes is the chemokines consisting of 4 C-C motif- 
and 5 C-X-C motif ligand chemokines. Interestingly, all C-X-C motif ligand family chemokines analysed 
in this array were affected by both LPS treatment as well as allicin-LPS treatment, with the exception 
of Cxcl1 and Cxcl5 which were excluded. Of the nine chemokines analyzed, LPS-induced Ccl8 and Ccl20 
gene expression was downregulated by allicin treatment, while LPS-induced Ccl5 (also known as 
regulated on activation, normal T cell expressed and secreted (Rantes)), Ccl11, Cxcl2, Cxcl3, Cxcl9, 
Cxcl10 and Cxcl11 expression was upregulated by allicin treatment (Table 3.3). In general it appears 
that allicin treatment enhances LPS-induced gene expression of chemokines after 4 h. 
3.4.1.2. Interleukins 
Of the interleukins, LPS-induced Il6 and Il10 gene expression was upregulated by allicin treatment, 
consistent with the 4 h treatment qPCR gene expression data from Figure 3.5A and Figure 3.7A, 
respectively. The expression of Il22, a member of the IL10 superfamily of interleukin cytokines, was 
downregulated by all treatment conditions (Table 3.3). LPS treatment resulted in a 2.8-fold decrease 
in Il22 expression, which was further decreased upon allicin treatment trending towards zero 
expression compared to untreated cells. 
  
Chemokines 
(9)
Interleukins 
(3)
Receptors (4)
TNF Ligand 
Superfamily 
(2)
Other (2)
61 
 
Table 3.3: Fold regulation of selected inflammatory genes responsive to both LPS treatment and allicin-LPS 
treatment. Fold up- (red) or downregulation (green) is shown relative to untreated cells. Fold-up or 
downregulation is also shown for allicin-LPS-treated cells compared to LPS-only treated cells (numbers in bold). 
Genes are grouped according to functional family as chemokines, interleukins, receptors, TNF ligand superfamily 
members and other.  
Gene name Gene Symbol 
Fold Up- or Downregulation 
Allicin vs. 
untreated 
LPS vs. 
untreated 
Allicin-LPS vs. 
untreated 
Allicin-LPS 
vs. LPS 
Chemokines 
Chemokine C-C motif Ligand 5 Ccl5 (also 
Rantes) 
3.7 802.6 1685.4 2.1 
Chemokine C-C motif Ligand 8 Ccl8 -115.1 2.6 -141.5 -370.6 
Chemokine C-C motif Ligand 11 Ccl11 2.7 -7.1 1.8 12.6 
Chemokine C-C motif Ligand 20 Ccl20 25.7 457.8 184.2 -2.5 
Chemokine C-X-C motif Ligand 2 Cxcl2 1.4 356.7 713.4 2.0 
Chemokine C-X-C motif Ligand 3 Cxcl3 -1.1 139.0 275.4 2.0 
Chemokine C-X-C motif Ligand 9 Cxcl9 -29.8 -8.3 24075.6 199602.1 
Chemokine C-X-C motif Ligand 10 Cxcl10  -1.1 203.4 426.2 2.1 
Chemokine C-X-C motif Ligand 11 Cxcl11 -1.1 830.9 2988.9 3.6 
Interleukins 
Interleukin-6 Il6 17.1 68728.2 158639.1 2.3 
Interleukin-10 Il10 -1.8 10.1 25.6 2.5 
Interleukin-22 Il22 -11639.6 -2.8 -14313.0 -5090.3 
Receptors 
Chemokine C-X-C motif receptor 
type 4 
Cxcr4 1.8 -16.5 -3.8 4.3 
Interleukin 10 receptor, subunit-
β 
Il10rb 1.2 -2.0 1.0 2.0 
Interleukin-23 receptor Il23r -9132.3 -172.6 29.1 5031.5 
Toll-like receptor 3 Tlr3 2.5 2.7 6.3 2.3 
TNF Ligand Superfamily  
Fas Ligand Fasl (also Tnfsf6) -4115.9 -6086.9 -2426.6 2.5 
TNF ligand superfamily member 
14  
Tnfsf14  3.7 -4.4 -1.7 2.6 
Other 
Cyclooxygenase-2  Cox2 (also 
Ptgs2) 
1.8 45.8 92.1 2.0 
E-selectin Sele 22.8 28.6 110.3 3.9 
 
3.4.1.3. Receptors 
Table 3.3 shows that LPS treatment and allicin-LPS treatment affected the expression of four receptors 
including chemokine C-X-C motif receptor-4 (Cxcr4), IL10 receptor subunit-β (Il10rb), IL23 receptor 
(Il23r) and Toll-like receptor 3 (Tlr3)(Table 3.3). LPS treatment caused the downregulation of Cxcr4, 
Il10rb and Il23r expression while increasing Tlr3 expression (Table 3.3). LPS treatment resulted in a 
16.5-fold decrease in Cxcr4 expression compared to untreated cells. Allicin treatment was able to 
buffer the LPS-induced downregulation of Cxcr4 to only a 3.8-fold decrease compared to untreated 
cells. Il10rb expression was downregulated 2-fold by LPS treatment, and allicin treatment was able to 
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completely abrogate this downregulation. Il23r was downregulated by both LPS-only treatment and 
allicin-only treatment, but LPS-induced downregulation was reversed by allicin-treatment in 
conjunction with LPS-treatment, resulting in a 29.1-fold increase in expression compared to untreated 
cells (a 5031.5-fold increase compared to LPS-treated cells). LPS and allicin treatment on their own 
therefore downregulated the expression of the Il23r, but the synergistic effect of both treatments 
resulted in a sizeable upregulation of expression. Tlr3 gene expression was increased in response to 
allicin treatment (2.5-fold) and LPS treatment (2.7-fold). Allicin treatment further increased the LPS-
induced upregulation of Tlr3, 2.3-fold compared to LPS-treated cells.  
3.4.1.4. TNF ligand superfamily 
LPS treatment reduced the expression of TNF ligand superfamily member 14 (Tnfsf14) and Fas ligand 
(Fasl/Tnfsf6), both members of the TNF ligand superfamily (Table 3.3). The downregulating effect of 
LPS on the expression of these pro-apoptotic ligands was lessened when cells were treated with allicin. 
Allicin-LPS treatment resulted in an approximately 2.5-fold increase in expression of both pro-
apoptotic ligands when compared to LPS-treated cells but did not reach the expression level of the 
untreated cells. Further, while allicin treatment alone greatly reduced Fasl/Tnfsf6 expression (tending 
towards zero expression), it resulted in a 3.7-fold increase in expression of Tnfsf14 as compared to 
untreated cells. 
3.4.1.5. Other 
Cycoloxygenase-2 (COX2), also known as prostaglandin-endoperoxide synthase 2 (PTGS2), is an 
enzyme involved in the production of prostaglandins. LPS-treatment resulted in a 46-fold increase in 
Cox2 expression and allicin treatment doubled this LPS-induced Cox2 expression (Table 3.3). These 
data are consistent with Figure 3.9A which shows that allicin treatment significantly increases the gene 
expression of LPS-induced Cox2 (p<0.001) after 4 h. 
The expression of E-selectin (Sele), an adhesion molecule involved in immune cell recruitment, was 
increased 22.8-fold by allicin treatment alone and 28.6-fold by LPS treatment as compared to 
untreated cells. Allicin treatment further increased the LPS-induced expression of Sele 3.9-fold.  
3.4.2. Z-ajoene treatment 
Of the 84 genes analysed, 18 were excluded and 22 did not respond to any of the treatment conditions 
(Figure 3.14). In general, Z-ajoene had a less pronounced effect on LPS-induced expression of the 
genes analysed, compared to allicin treatment (Figure 3.12). This is in agreement with the qPCR and 
ELISA data from Section 3.3, which also showed that allicin treatment had a more pronounced 
immunomodulatory effect than Z-ajoene.  
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Figure 3.14: A Venn diagram summarising the results of the Inflammatory Response and Autoimmunity RT2 
Profiler PCR Array following treatment with LPS and/or Z-ajoene treatment of murine 
RAW264.7macrophages. The number of genes responsive to Z-ajoene treatment, LPS treatment and Z-ajoene-
LPS treatment is shown. Responsive genes were those that had a positive or negative fold change ≥ 2 compared 
to untreated cells for Z-ajoene-responsive and LPS-responsive genes, and LPS-treated cells for Z-ajoene-LPS-
responsive genes. Genes with an average quantification cycle (Cq) of ≥35 were excluded. -Genes responsive to 
both LPS and Z-ajoene-LPS treatment (red numbers) were chosen for further analysis.  
Further, no genes were found to be responsive to all three treatments according to the 2-fold up- or 
downregulation cut-off (Figure 3.14). Of the eight genes regulated by both LPS treatment and Z-
ajoene-LPS treatment (red numbers in Figure 3.14), four chemokines, two receptors and two members 
of the TNF ligand superfamily were identified (summarised in Figure 3.15). 
 
 
 
 
 
 
 
 
Figure 3.15 Gene groupings of the inflammatory genes responsive to both LPS treatment and Z-ajoene-LPS 
treatment in murine RAW264.7 macrophages. Genes identified from the RT2 Profiler PCR Array to have a ≥ 2 
fold up- or downregulation in expression for both LPS-treated cells and Z-ajoene-LPS-treated cells were selected 
for further analysis and categorised as either chemokines, interleukins, receptors or TNF ligand superfamily 
members. 
Chemokines 
(4)
Receptors (1)
TNF ligand 
superfamily 
(2)
Interleukins 
(1)
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3.4.2.1. Chemokines 
LPS treatment upregulated all chemokines that met the inclusion criterion (Table 3.4). Z-ajoene 
treatment resulted in a 2.1-fold reduction of LPS-induced expression of Ccl7 and Ccl20 and a 3.1-fold 
reduction in Cxcl3 expression. LPS-induced Cxcl11 expression, however, was upregulated 2.7-fold by 
Z-ajoene treatment. In general, Z-ajoene appears to downregulate the gene expression of chemokines 
(Table 3.3), in contrast to allicin treatment where greater upregulation of inflammatory mediators was 
observed (Table 3.4). 
3.4.2.2. Interleukins 
LPS-induced a 15.8-fold increase in interleukin-1 receptor antagonist (Il1rn) expression, while Z-ajoene 
downregulated its LPS-induced expression 4.4-fold (Table 3.3). While Il1b expression was not affected 
by Z-ajoene-LPS treatment (determined by the cut off of a 2-fold change in expression compared to 
LPS treated cells), we looked at Il1b expression as qPCR and ELISA experiments showed significant 
downregulation of LPS-induced expression by Z-ajoene treatment (Figure 3.4C and D). Consistent with 
this data, Z-ajoene treatment reduced LPS-induced expression of Il1b 1.5-fold in the RT2 Profiler PCR 
array experiment (data not shown). 
Table 3.4: Fold regulation of selected inflammatory genes responsive to both LPS treatment and Z-ajoene-LPS 
treatment. Fold up- (red) or downregulation (green) is shown relative to untreated cells. Fold-up or 
downregulation is also shown for Z-ajoene-LPS-treated cells compared to LPS-treated cells (numbers in bold). 
Genes are grouped according to functional family as chemokines, interleukins, receptors and TNF ligand 
superfamily members. 
Gene name Gene Symbol 
Fold Up Or Downregulation 
Z-ajoene 
vs. 
untreated 
LPS vs. 
untreated 
Z-ajoene-LPS 
vs. untreated 
Z-ajoene-
LPS vs. LPS 
Chemokines 
Chemokine C-C motif ligand 
7 
Ccl7  1.0 6.6 3.1 -2.1 
Chemokine C-C motif ligand 
20 
Ccl20 1.0 64.0 31.1 -2.1 
Chemokine C-X-C motif 
ligand 3 
Cxcl3 1.0 4.1 1.3 -3.1 
Chemokine C-X-C motif 
ligand 11 
Cxcl11 1.0 2.0 5.3 2.7 
Interleukins 
Interleukin receptor 
antagonist 
Ilrn 1.0 15.8 3.6 -4.4 
Receptors 
Chemokine C-X-C motif 
receptor type 4 
Cxcr4 1.2 -8.2 -22.9 -2.8 
TNF Ligand Superfamily 
Lymphotoxin-β Ltb (also Tnfsf3) 1.0 3.1 1.2 -2.6 
CD40 ligand  Cd40l (also Tnfsf5) 1.0 2.4 -1.1 -2.5 
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3.4.2.3. Receptors 
Cxcr4 was the only receptor whose gene expression was affected by both LPS and Z-ajoene-LPS 
treatment. Interestingly, this receptor was also affected by allicin-LPS treatment (Table 3.3). LPS 
treatment resulted in an 8.2-fold downregulation of Cxcr4, and this downregulation was further 
decreased by Z-ajoene-LPS (Table 3.4).  
3.4.2.4. TNF ligand superfamily 
Lymphotoxin-β (LTB/TNFSF3) and the Cd40 ligand (CD40L/TNFSF5) are members of the TNF ligand 
superfamily. LPS treatment induced a 3.1-fold and 2.4-fold increase in Ltb/Tnfsf3 and Cd40l gene 
expression, respectively. Z-ajoene treatment, however, resulted in an approximately 2.5-fold 
downregulation of the LPS-induced expression of both ligands. Z-ajoene treatment therefore 
essentially negates LPS-induced upregulation of Ltb/Tnfsf3 and Cd40l/Tnfsf5. 
 Proteome Profiler Mouse Cytokine Array 
While studying mRNA expression is a useful way to detect rapid changes in gene expression, 
investigating protein expression provides a clearer and more detailed view of cellular activity in 
response to a stimulus 187. We therefore performed a Proteome ProfilerTM Mouse Cytokine Array (Cat. 
No. ARY006, R&D Systems) to obtain a more comprehensive indication of the effects of selected garlic 
OSCs on LPS-induced cytokine and chemokine expression. Murine RAW264.7 macrophages were pre-
treated with ½ IC50 concentrations of either allicin or Z-ajoene, followed by a second dose of the garlic 
OSC 24 h later plus 10 ng/ml LPS (Figure 3.2). Cell culture supernatants were then harvested 24 h after 
addition of the LPS and the garlic OSC. Cell culture supernatants for each treatment condition were 
incubated with nitrocellulose membranes pre-spotted with antibodies for 40 mouse cytokines and 
chemokines. Experiments were performed in duplicate. Detection of the cytokines and chemokines 
was determined using secondary antibodies conjugated to streptavidin-HRP and developed using a 
chemiluminescent substrate. Proteins were selected for further analysis if there was a strong antibody 
signal in one or more of the treatment conditions. Densitometric analysis was performed and the 
mean density (± SEM) of duplicate spots from two independent experiments (± SEM) was plotted 
(Figure 3.17).  Representative allicin and Z-ajoene experiments are displayed in Figure 3.16. 
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For easy referencing purposes, the number corresponding to the protein spots seen in Figure 3.16 and 
above each bar chart in Figure 3.17 is included in square brackets after the mention of each protein in 
the subsequent text.   
  
B 
A 
 Figure 3.16: Representative Proteome ProfilerTM Mouse Cytokine Arrays performed on cell culture 
supernatants harvested from murine RAW264.7 macrophages treated with LPS and/or a garlic OSC. A 
representative nitrocellulose blot is shown for the untreated, garlic OSC-treated, LPS-treated, and garlic OSC- LPS-
treated conditions. A. allicin experiment B. Z-ajoene experiment. Numbers in red indicate duplicate spots for 
proteins chosen for densitometric analysis based on a strong antibody signal in one or more of the treatment 
conditions from either allicin or Z-ajoene experiments.  
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Figure 3.17: The effect of selected garlic OSCs on the LPS-induced expression of 18 selected cytokines and 
chemokines in murine RAW264.7 macrophages and identified using the Proteome ProfilerTM Mouse Cytokine 
Array. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-ajoene, followed by a second dose after 
24 h in conjunction with 10 ng/ml LPS. Cell culture supernatants for protein expression analysis were harvested 
after 24 h of treatment with LPS and the garlic OSC. A. Allicin experiment, B. Z-ajoene experiment. Densitometric 
analysis was performed to obtain mean percentage expression (± SEM) for two independent experiments, 
shown relative to LPS-treated cells (set to 100%). One-way ANOVA significance testing followed by Tukey’s HSD 
test (*, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant) was performed.  Numbers above the charts 
correspond to the numbered spots in Figure 3.16.  
 
Of the 18 cytokines and chemokines analysed, 14 were upregulated and four were downregulated by 
LPS treatment (Figure 3.17 and summarised in Table 3.5). The four proteins downregulated by LPS 
treatment were soluble intercellular adhesion molecule-1 (ICAM1) [3), interferon-γ (IFNG) [4], CCL3 
[12] and CXCL12 [16]. Z-ajoene treatment further downregulated the expression of soluble ICAM1 
(p<0.05) [3], IFNG (decreasing trend) [4], CCL3 (p<0.001) [12] and CXCL12 (p<0.05) [16] (Figure 3.17 & 
Table 3.5).  
Interestingly, Z-ajoene treatment alone was also able to significantly downregulate the expression of 
all four proteins (p<0.001) compared to untreated cells. A decreasing trend in expression of soluble 
ICAM1 [3] and IFNG [4] was also seen upon allicin treatment alone and this response is comparable to 
the trend seen for the LPS-induced downregulation of expression for these proteins. Allicin treatment, 
unlike Z-ajoene treatment, did not have an additive effect on LPS-induced downregulation of 
expression of soluble ICAM1 [3] and IFNG [4], while there was a slight decreasing trend seen with 
allicin-treatment on LPS-induced downregulation of CXCL12 [16]. CCL3 [12] expression was elevated 
in allicin-treated cells and allicin treatment was able to buffer the downregulating effect of LPS-
treatment. None of these effects on CCL3 [12] protein expression, however, were statistically 
significant. 
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Of the 14 cytokines and chemokines upregulated by LPS-treatment, Z-ajoene treatment significantly 
downregulated the LPS-induced expression of 12 proteins, showed a downward trend for two proteins 
and an upward trend for one protein (Table 3.5 and Figure 3.17). Granulocyte macrophage colony 
stimulating factor (GMCSF) [2] was the only protein where Z-ajoene treatment showed an increasing 
trend in expression compared to LPS-treated cells. This result is questionable, however, because there 
was no increase in expression upon LPS treatment, in contrast to the allicin experiments. Consistent 
with the RT2 Profiler PCR Array, Z-ajoene significantly decreased the LPS-induced expression of IL1RN. 
Further, Z-ajoene treatment significantly decreased the expression of all eight chemokines selected 
for further analysis.  
Table 3.5: Summary of the effect of allicin or Z-ajoene treatment on percentage protein expression of selected 
LPS-induced cytokines and chemokines identified using the Proteome ProfilerTM Mouse Cytokine Array. This 
table summarises the results from Figure 3.17 showing the effect of LPS treatment and garlic OSC plus LPS 
treatment on cytokine and chemokine protein expression. The effect of LPS treatment on cells is shown as a red 
upward arrow for upregulation and a green downward arrow for downregulation. Statistically significant 
changes in LPS-induced protein expression following treatment with allicin or Z-ajoene are shown in red for 
upregulation and green for downregulation. 
Number  Cytokine/Inflammatory mediator Protein 
Symbol  
Up-/ 
downregulated 
by LPS 
% Protein Expression relative to 
LPS control 
Allicin-LPS Z-ajoene-LPS 
1 Granulocyte Colony-Stimulating 
Factor  
GCSF ↑ 121.7 ± 43.6 45 ±  3.3 
2 Granulocyte Macrophage Colony 
Stimulating Factor 
GMCSF ↑ 28.9 ± 7.7 196.1 ±  74.5 
3 Soluble Intercellular Adhesion 
Molecule-1 
ICAM1 ↓ 108.0 ± 50.8 31.9 ± 0.7 
4 Interferon-γ IFNG ↓ 109.0 ± 47.9 38.7 ± 3.5 
5 Interleukin-1α IL1A ↑ 61.0 ± 15.0 43.0 ± 0.9 
6 Interleukin-1 Receptor Antagonist IL1RN ↑ 53.6 ± 5.1 52.5 ± 16.2 
7 Interleukin-6 IL6 ↑ 14.6 ± 2.4 73.37 ± 15.5 
8 Interleukin-27 Il27 ↑ 25.1 ± 11.9 40.8 ± 14.8 
9 Chemokine C-X-C motif Ligand 10  CXCL10  ↑ 70.5 ± 19.8 45.0 ± 5.5 
10 Chemokine C-X-C motif Ligand 1 CXCL1  ↑ 122.5 ± 19.6 61.4 ± 2.8 
11 Chemokine C-C motif Ligand 2 CCL2  ↑ 95.0 ± 12.9 66.5 ±  1.6 
12 Chemokine C-C motif Ligand 3 CCL3  ↓ 190 ±  61.5 47.4 ± 1.4 
13 Chemokine C-C motif Ligand 4 CCL4  ↑ 269.1 ± 10.7 48.3 ±  1.7 
14 Chemokine C-X-C motif Ligand 2 CXCL2  ↑ 306.3 ± 21.2 43.8 ± 1.5 
15 Chemokine C-C motif Ligand 5 CCL5 (also 
RANTES) 
↑ 148.3 ± 42 48.1 ± 1.0 
16 Chemokine C-X-C motif Ligand 12 CXCL12 ↓ 56.6 ± 17.6 28.8 ± 3.4 
17 Tissue Inhibitor of 
Metalloprotease-1 
TIMP1 ↑ 58.2 ± 33.3 40.6 ±  10.4 
18 Tumour Necrosis Factor TNF  ↑ 123.9 ± 15.4 56.1 ± 1.9 
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Unlike Z-ajoene treatment, allicin treatment had a more variable effect on the LPS-induced 
upregulation of cytokine and chemokine protein expression (Figure 3.17 & Table 3.5). Allicin treatment 
significantly upregulated the LPS-induced expression of CCL4 (p<0.001) [13] and CXCL2 (p<0.001)[14], 
and showed an increasing trend in the expression of LPS-induced GCSF [1], CXCL1 [10], CCL5/RANTES 
[15] and TNF [18]. Conversely, allicin treatment significantly downregulated the LPS-induced increase 
in expression of GMCSF (p<0.003) [2], IL1RN (p<0.01) [6] and IL6 (p<0.001) [7]. Note that the 
downregulation of LPS-induced IL6 expression by allicin treatment is consistent with the ELISA data 
from Figure 3.3B for supernatant samples collected 24 h after addition of LPS and allicin. In addition, 
allicin treatment showed a trend towards abrogation of the LPS-induced increase in interleukin-1α 
(IL1A) [5], IL27 [8], CXCL10 [9] and tissue inhibitor of metalloproteinases-1 (TIMP1) [17].  
It is interesting to note that allicin treatment alone did not significantly affect the expression levels of 
any of the 18 cytokines and chemokines analysed, when compared to untreated cells. However, Z-
ajoene treatment alone resulted in the significant downregulation of expression of soluble ICAM1 [3], 
IFNG [4], IL1A [5], CXCL1 [10], CCL3 [12], CXCL12 [16] and TNF (p<0.01) [18] and showed a decreasing 
trend in expression for five of the other proteins whose expression is induced by LPS treatment. In 
addition, Z-ajoene treatment alone resulted in a significant increase in CCL4 [13]. 
Figure 3.18 summarises the effect of allicin and Z-ajoene treatment on LPS-induced expression of the 
18 cytokines and chemokines identified in the Proteome ProfilerTM Mouse Cytokine Array. While allicin 
treatment was found to be mildly up- or downregulating, Z-ajoene generally displayed stronger 
downregulatory effects on the expression of the selected LPS-induced inflammatory cytokines and 
chemokines.  
 
 
 
 
 
 
 
Figure 3.18: The effect of allicin and Z-ajoene treatment on the protein expression of 18 LPS-induced cytokines 
and chemokines selected for analysis from the Proteome ProfilerTM Mouse Cytokine Array (R&D Systems). A. 
Allicin experiment, B. Z-ajoene experiment. Experiments were performed in duplicate. 
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 The effect of selected garlic OSCs on LPS-induced STAT3 
phosphorylation 
The STAT3 transcription factor is an integral part of the inflammatory immune response, and has been 
shown to regulate the transcription of many genes which regulate said inflammatory response. Prior 
to STAT3 activation, cytokines and growth factors activate the Janus kinase/signal transducer and 
activator of transcription (JAK/STAT) signalling pathway resulting in the phosphorylation of STAT3 at 
Tyr70531. Phosphorylated-STAT3 (p-STAT3) can form homodimers and heterodimers (with STAT1) 
which facilitate its nuclear import. Once in the nucleus, p-STAT3 activates the transcription of many 
genes involved in inflammation, apoptosis and immune response signalling31. As treatment with allicin 
or Z-ajoene affects LPS-induced gene and protein expression of many STAT3 target genes including 
Il10/IL10 (Figure 3.7 & Table 3.3) and Il6/IL6 (Figure 3.5 & Table 3.3)(both activators of STAT3), we 
decided to investigate  whether allicin or Z-ajoene treatment affected the phosphorylation of STAT3 
at Tyr705. STAT3 target genes are discussed in more detail in Section 4.3. 
A time course experiment was performed to determine the effect of allicin and Z-ajoene treatment 
on LPS-induced STAT3 phosphorylation. Preliminary experiments showed that STAT3 was not 
phosphorylated in response to LPS treatment in RAW264.7 macrophages between 0 and 2 h (data not 
shown) and hence a time course measuring STAT3 phosphorylation after 0, 2, 4, 6, 8 and 24 h was 
performed. Cell lysates harvested after these timepoints were analysed by Western blot using both p-
STAT3 (Tyr705) and STAT3 antibodies, the latter served as a loading control (Figure 3.16). To control 
for the potential increase in protein expression of STAT3 upon LPS-treatment, GAPDH (Santa Cruz 
Biotechnology) was used as an additional loading control. Figure 3.17 shows the relative quantity of 
p-STAT3 after allicin and Z-ajoene treatment compared to the LPS-treated cells at the given timepoint. 
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Figure 3.19: A representative Western blot showing a time course experiment performed to determine the 
effect of allicin and Z-ajoene treatment on LPS-induced phosphorylation of STAT3 in murine RAW264.7 
macrophages. Cells were pre-treated with ½ IC50 concentrations of allicin or Z-ajoene, followed by a second dose 
after 24 h in conjunction with 10 ng/ml LPS. Whole cell lysates were harvested following the LPS/OSC treatment 
at timepoints 0, 2, 4, 6, 8 and 24 h and analysed by SDS-PAGE and Western blot. A. Allicin experiment, B. Z-
ajoene experiment. Nitrocellulose membranes were probed with an anti-p-STAT3 (Tyr705), STAT3 and GAPDH 
antibodies where STAT3 and GAPDH served as loading controls.  
 
Figure 3.19 shows that pre-treatment of cells with allicin or Z-ajoene does not result in any STAT3 
phosphorylation (24 h after treatment with the selected garlic OSC and 0 h after addition of LPS and 
the second dose of the garlic OSC). When quantified by densitometric analysis (Figure 3.6) allicin 
treatment and Z-ajoene treatment differentially affect the LPS-induced phosphorylation of STAT3. 
Allicin treatment causes an early peak in p-STAT3 levels after 6 h, while between 8 and 24 h the p-
STAT3 levels are very similar to that of the LPS-treated cells. Z-ajoene treatment, on the other hand, 
causes a 2.5-fold decrease in p-STAT3 levels between 6 and 24 h compared to the LPS treated cells. 
Allicin treatment was therefore found to induce a short, early peak in the LPS-induced phosphorylation 
of STAT3 after 6 h, while Z-ajoene was found to downregulate the levels of LPS-induced p-STAT3.  
B 
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Figure 3.20: A line graph showing the fold change in LPS-induced phosphorylation of STAT3 after allicin or Z-
ajoene treatment relative to the p-STAT3 levels in the LPS control. The dotted red line represents the LPS-
treated sample at the given timepoints. Densitometric analysis on p-STAT3 bands (of representative experiment 
in Figure 3.19) was performed to quantify protein concentration and were normalised to STAT3 loading control. 
Relative phosphorylation was then normalised to the LPS-control. 
 
 STAT3 alkylation by E/Z-ajoene 
In the previous section, we showed that the garlic OSCs allicin and Z-ajoene affect the phosphorylation 
of the transcription factor STAT3. A review of the literature indicates that STAT3 is susceptible to S-
glutathionylation, a post-translational modification where glutathione (GSH) is reversibly added to a 
cysteine-thiol of a protein under oxidative conditions161,188. Xie et al. (2009) showed that alkylation of 
STAT3 affects the phosphorylation, dimerization and transcriptional activity of STAT3161. Previous 
research in our laboratory led us to hypothesise that garlic OSCs may interact with proteins by 
undergoing thiol-disulfide exchange reactions with cysteine thiols of proteins (Figure 3.21). This thiol-
disulfide exchange (alkylation) reaction is analogous to S-glutathionylation. We thus hypothesised that 
garlic OSCs may alkylate STAT3 affecting protein function. 
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Figure 3.21: Schematic showing the reaction between dansylated-E/Z-ajoene and the cysteine nucleophile of 
a protein. The cysteine nucleophile reacts with the more electropositive sulfur of the E/Z-ajoene disulfide bond, 
resulting in the formation of a mixed disulfide product, consisting of the protein and the dansyl-tagged region 
of the E/Z-ajoene, and an anion leaving group.  
 
In order to determine whether garlic OSCs undergo a thiol-disulfide exchange reaction with STAT3, 
E/Z-ajoene, labelled with a dansyl-residue (Department of Chemistry, UCT), was incubated with 
recombinant human STAT3 protein and run on an SDS-PAGE gel either under non-reducing or reducing 
conditions. Under non-reducing conditions, it is hypothesised that a mixed-disulfide may form 
between STAT3 and the ajoene analogue via a thiol-disulfide exchange reaction to form an alkylated 
STAT3 protein product. If this reaction indeed occurs, it is then hypothesised that incubation with a 
reducing agent, i.e. DTT, should cleave this disulfide bond to release the free STAT3 protein. By probing 
the nitrocellulose membrane with an anti-STAT3 antibody and an anti-dansyl antibody, it may be 
possible to determine whether a mixed disulfide reaction between STAT3 and ajoene occurs. 
 
 
 
 
 
Figure 3.22: Western blot showing dansylation of recombinant human STAT3 via a thiol-disulfide exchange 
reaction with dansyl-tagged E/Z-ajoene. The nitrocellulose membrane was probed with an anti-dansyl 
antibody, stripped and re-probed with an anti-STAT3 antibody. The samples were run under reducing (100 mM 
DTT) or non-reducing (no DTT) conditions. 
Figure 3.22 shows that STAT3 is indeed reversibly alkylated by E/Z-ajoene. Co-localisation of the 
dansyl-signal and the STAT3-signal indicates that the thiol-disulfide reaction has occurred. Incubating 
the STAT3 dansyl-tagged E/Z-ajoene mixture with a reducing agent resulted in a significant decrease 
in the intensity of the dansyl-signal. This indicates that STAT3 is indeed reversibly alkylated by E/Z-
ajoene.  
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 Discussion 
Inflammation is known to play a key role in the pathogenesis and maintenance of a number of diseases 
including autoimmune disorders, diabetes and cancer28,189,190. Chronic inflammation has been 
described as an enabling characteristic of cancer as the pro-proliferative, pro-survival, pro-angiogenic 
mechanisms of wound healing are co-opted to facilitate tumourigenesis10,191–193. Significantly, the long 
term use of NSAIDs has been shown to have protective effects against cancer via their anti-
inflammatory activities74. Due to the high risk of adverse side-effects associated with the long-term 
use of NSAIDs, these drugs have limited therapeutic application79–81. A number of natural dietary anti-
inflammatory compounds that have NSAID-like activity, have been proposed as healthy alternatives 
to NSAIDs for the prevention of cancer82,194. The culinary plant, garlic has been shown to contain many 
natural bioactive compounds and is used to treat a variety of ailments. Historically, garlic was used as 
a prophylactic and therapeutic agent against infections, headaches, inflammation and tumours113,115. 
Modern research has shown garlic to have cancer preventative and therapeutic applications96–99. 
Significantly, a number of epidemiological studies suggests that regular dietary consumption of garlic 
(or related Allium vegetables) decreases the risk of gastric cancers104–106. Of the many bioactive 
compounds found in garlic, garlic OSCs have been most widely studied for their role as anti-cancer 
agents113. This anti-cancer activity may be mediated through modulation of immune system-regulated 
inflammatory responses85,130–132. While there are over 4000 published articles looking at the health 
benefits of garlic with respect to various diseases or conditions, differences in experimental design 
have made comparisons between studies challenging117. Many studies use garlic extracts or garlic oil 
with unspecified chemical composition and concentration. In addition, studies differ with respect to 
the cell type or experimental model used as well as the experimental time frame. There is therefore 
scope for experimental work focusing on the effect of individual pure garlic OSC treatment on 
stimulated inflammatory immune responses in a well-defined experimental system.  
 Establishment of a well-defined in vitro inflammatory model 
In this study, we established an in vitro inflammatory model to determine the effects of selected garlic 
OSC treatment on the LPS-stimulated inflammatory response in RAW264.7 murine macrophages. This 
model was chosen with the idea of ultimately determining the effects of garlic OSC gavage on induced 
gastrointestinal- and colorectal inflammation in BALB/c mice. The experimental work from this thesis 
serves as the basis for the in vitro proof-of-concept required for an ethics application for future in vivo 
experiments. 
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In our model, we used pure synthesised garlic OSCs (verified by 1H NMR spectroscopy) at sub-toxic (½ 
IC50) concentrations determined by MTT cell viability assays. IC50 values were determined for allicin, 
DADS, DATS, E-ajoene, and Z-ajoene (Table 3.1) after 24 h treatment. Based on preliminary 
inflammatory gene expression experiments, the garlic OSCs allicin and Z-ajoene were chosen for 
subsequent experiments due to their different immunomodulating effects on the gene expression of 
LPS-stimulated cytokines (Figure 3.3).  Further, we chose the comparatively low LPS concentration of 
10 ng/ml for stimulation experiments as we expected garlic OSCs to have subtle immunomodulating 
effects (Figure 3.1A).  
In line with the hypothesis that garlic OSCs, obtained from the regular dietary consumption of garlic, 
can aid in cancer prevention by counterbalancing the establishment of a chronic inflammatory 
microenvironment conducive to cancer, treatment conditions for RAW264.7 macrophages in the in 
vitro inflammatory model were chosen which best simulate regular dietary consumption. Cells were 
treated twice with ½ IC50 concentrations of either allicin and Z-ajoene, 24 h apart. The second dose of 
the garlic OSC was given in conjunction with 10 ng/ml LPS, which was representative of an infection.  
Preliminary gene and protein expression experiments were conducted, and 4 h and 8 h (gene 
expression), and 8 h and 24 h (protein expression) were chosen as the best timepoints post LPS 
stimulation to accommodate the gene and protein expression profiles of the cytokines tested (Figure 
3.1B). These gene and protein expression analyses provided the experimental conditions for 
subsequent gene and protein arrays with samples collected at 4 h- and 24 h-post treatment, 
respectively. 
While the greatest care was taken to establish and optimise a robust in vitro inflammatory model, 
there are a number of limitations to this model. Firstly, this model is a monoculture of immortalised 
macrophages taken out of the context of the tissue microenvironment. It is well-documented that 
inflammation relies on bidirectional communication between many different cell types (including 
numerous specialised innate and adaptive immune cells, fibroblasts and epithelial cells) and their 
environment191. Future work should make use of co-culture experiments with different cell types to 
better simulate the inflammatory microenvironment. One such study co-cultured murine peritoneal 
macrophages with B16 melanoma cells, and showed that allicin treatment increased the tumouricidal 
activities of these macrophages132. Secondly, LPS stimulation of macrophages is representative of the 
acute inflammatory response and not chronic inflammation which is the driving force of cancer 
development and progression. It is, however, difficult to study chronic inflammation in vitro, as 
macrophages are known to become tolerant and hence unresponsive to inflammatory stimuli when 
exposed for extended periods of time175,195. Thirdly, the concentrations of the garlic OSCs used in the 
in vitro experiments may not be biologically relevant to in vivo experiments. For example, unpublished 
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animal studies conducted in our laboratory where naïve BALB/c mice were fed garlic OSC gavage 
showed that allicin and Z-ajoene had a stronger immunomodulatory effects in proximal 
gastrointestinal tract organs such as the stomach and duodenum, where absorption of dietary 
material occurs, with little or no effect on the colon. In these experiments, different concentrations 
and secondary metabolites reach different parts of the gastrointestinal tract and may not necessarily 
reflect the concentrations used for the in vitro model presented in this thesis. 
While this model has its limitations, it provides the necessary groundwork and proof-of-concept 
required for an ethics application to study the effects of garlic OSC gavage on inflammation in a BALB/c 
mouse colitis-model.   
 Experiments investigating immune and inflammatory 
responses 
In order to determine the effect of allicin and Z-ajoene treatment on LPS-induced inflammation, 
inflammatory cytokines (Il1b/IL1B, Il6/IL6, Il12b/IL12B, Il10/IL10 and Tnf/TNF), enzymes (Cox2/COX2 
and Nos2) and the pro-apoptotic mediator Trail/TRAIL, all of which are associated with inflammation 
and inflammation-based cancer, were selected for initial gene and protein expression analyses. Based 
on these findings, gene and protein profiler arrays were conducted to obtain a broader indication of 
the effects of garlic OSC treatment on LPS-induced inflammation. It must be noted that as the 
expression data from the Proteome Profiler Array was performed in duplicate, we consider these 
results to be more reliable and statistically significant than those of the RT2 Profiler PCR Array which 
is representative of a single qPCR experiment.  
Major findings from the gene and protein expression analyses include the effect of allicin and Z-ajoene 
treatment on LPS-induced gene and protein expression of interleukins, chemokines, inflammatory 
enzymes and the TNF ligand superfamily.  
4.2.1. Allicin and Z-ajoene regulate interleukins to prevent inflammation 
In this study the pro-inflammatory interleukins Il1b/IL1B, Il6/IL6 and Il12b/IL12B (a subunit of the IL12 
and IL23 interleukin) and the anti-inflammatory interleukin Il10/IL10 were selected for gene and 
protein expression analysis in initial experiments. The pro-inflammatory interleukins have previously 
been shown to be upregulated during chronic inflammation and cancer, while IL10 can act as either 
an anti-inflammatory or immunosuppressive cytokine in these processes10,19,59,196.  
qPCR gene and ELISA protein expression data indicated that LPS-induced expression of Il1b/IL1B, 
Il6/IL6 and Il12b/IL12B was decreased by allicin and Z-ajoene treatment, whereas allicin generally had 
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a more pronounced immunomodulatory effect (Figures 3.4-3.6). Interestingly, Il6/IL6 gene expression 
was initially upregulated by allicin treatment after 4 h in both the qPCR (Figure 3.5A) and the RT2 
Profiler PCR Array (Table 3.3), but decreased after 8 h (Figure 3.5A). This downregulation was reflected 
at the protein level, where allicin treatment significantly decreased LPS-induced Il6/IL6 protein after 
24 h by both ELISA (Figure 3.5B) and the Proteome Profiler Array (Figure 3.17 and Table 3.5). The data 
for allicin immunomodulation of Il6/IL6 was thus reproducible across all experimental gene and 
protein expression analysis methods. Additionally, the RT2 Profiler PCR Array revealed that allicin also 
downregulated the gene expression of pro-inflammatory Il22 (a member of the IL10 family of 
cytokines) (Table 3.3), while the Proteome Profiler Array showed that both Z-ajoene and allicin 
treatment downregulated the protein expression of IL1A and IL27 (a member of the IL6 family of 
cytokines) (Figure 3.17 and Table 3.5). In addition, the LPS-induced expression of the receptor 
antagonist Il1rn/IL1RN, which is structurally related to IL1A and IL1B, was downregulated by Z-ajoene 
treatment at both the gene (Table 3.4) and protein level and by allicin treatment at the protein level 
(Figure 3.17 and Table 3.5). The expression of LPS-induced Il10/IL10, on the other hand, was 
significantly increased by allicin treatment at 4 h and 8 h (gene expression), and 8 h and 24 h (protein 
expression) (Figure 3.7A and B), and this was supported by the result from the RT2 Profiler PCR Array 
(Table 3.3). It must be noted that protein expression of IL10, IL1B and IL12 (full protein), included in 
the Proteome Profiler Array, was not detected for either the LPS-treated or the garlic OSC-LPS-treated 
samples, which suggests differences in sensitivity between the ELISAs versus the Proteome Profiler 
Array. 
In support of these findings, studies investigating the effect of garlic OSCs on LPS-stimulated 
RAW264.7 macrophages found that DATS decreased IL6 and IL12 (full protein) expression139; DAS 
decreased IL1B and IL6 expression140 and E/Z-ajoene decreased IL1B and IL6 expression143 (Table 1.1). 
In addition, LPS-stimulated CD4+ monocytes (isolated from human whole blood) treated with garlic 
extract showed a decrease in the expression of LPS-induced IL1A, IL2, IL6 and IL12 (full protein) 84. 
Reports on the effect of garlic OSC treatment on IL10 expression are contradictory; while DAS and 
DADS treated LPS-stimulated RAW264.7 macrophages showed a decrease in IL10 expression, allyl 
methyl sulfide (AMS) increased IL10 expression140. Another study also looking at LPS-stimulated 
RAW264.7 macrophages showed that DATS decreased IL10 expression139. Conversely, LPS-stimulated 
CD4+ monocytes treated with garlic extract were shown to have increased IL10 levels when treated 
with garlic extract84.  
In general, allicin and Z-ajoene downregulated the LPS-induced expression of pro-inflammatory 
cytokines IL1A, Il1b/IL1B, Il6/IL6, Il12b/Il12B, Il22 and IL27 while upregulating the anti-inflammatory 
cytokine Il10/IL10. As IL10 is known to play a dual role in cancer development (it can downregulate 
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inflammatory responses and promote tissue homeostasis and return to normal immune surveillance, 
or it can promote immunosuppression and thereby facilitate tumourigenesis and cancer 
progression55,59), future work should aim to distinguish between the anti-inflammatory and 
immunosuppressive functions of IL10, which are often context-dependent. As previously mentioned, 
LPS stimulation of macrophages simulates an acute inflammatory response and therefore the overall 
effect on LPS-induced interleukin expression by allicin and Z-ajoene treatment is anti-inflammatory.  
4.2.2. Allicin and Z-ajoene differentially modulate chemokine expression  
Chemokines, or chemoattractant cytokines, are low molecular weight proteins (7-15kDa) involved in 
the recruitment and activation of innate and adaptive immune cells to sites of injury or 
inflammation24. In addition to regulating leukocyte adhesion and migration, chemokines also regulate 
inflammation and wound healing processes including reactive oxygen species (ROS) release, 
angiogenesis and tissue remodelling21.  
Analysis of the RT2 Profiler PCR Array and the Proteome Profiler Array showed that allicin and Z-ajoene 
differentially modulated the expression of the chemokines selected for further analysis. A 4 h 
treatment with allicin generally had strong upregulating effects on the LPS-induced chemokine gene 
expression, while Z-ajoene showed a modest downregulatory effect on fewer chemokines (Table 3.3 
and 3.4). In contrast, and more importantly, the Proteome Profiler Array, performed on samples 
collected after 24 h, showed that Z-ajoene significantly decreased the LPS-induced expression of all 
eight chemokines that were affected by LPS treatment, while allicin significantly upregulated the LPS-
induced expression of only two of these chemokines (Figure 3.17 and Table 3.5). 
Z-ajoene was found to mediate the downregulation of the LPS-induced proteins CCL2 and CXCL1 
(Table 3.5) which is in agreement with the study conducted by You et al. (2013) which showed that 
treatment of LPS-stimulated RAW264.7 macrophages with DATS for 12 h resulted in a dose-dependent 
decrease in these same proteins139. Another study looking at the effects of allicin treatment in TNF-
stimulated colorectal adenocarcinoma cancer HT-29 and Caco-2 cells showed a dose-dependent 
decrease in protein expression of CXCL8 (also IL8), CXCL9 and CXCL10, after 24 h137. Similarly, in our 
study, allicin and Z-ajoene decreased the LPS-induced expression of CXCL10 (Table 3.5).  
Taken together, the gene expression data suggests that allicin upregulates the expression of many 
chemokines after 4 h while Z-ajoene has weaker downregulatory effects. More importantly, however, 
Z-ajoene exerts a strong downregulatory effect on LPS-induced protein expression of chemokines 
after 24 h, while allicin has mixed upregulatory- and downregulatory effects. This data suggests that 
allicin rapidly exerts its effects in the cells, while the effects of Z-ajoene treatment last for a longer 
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period of time. This is in line with the compounds’ reactivity, as allicin is a more reactive compound 
which readily interacts with proteins or other molecules120, while Z-ajoene is a more stable compound 
and has longer-lasting effects. The observed changes in expression over time add another layer of 
complexity to understanding the immunomodulatory effects of these garlic OSCs. Future experiments 
should investigate the effects of allicin treatment on protein expression at earlier timepoints to 
determine whether the strong pro-inflammatory effects of allicin treatment on LPS-induced gene 
expression are seen at a protein level.  
4.2.3. Differential effects on inflammatory enzymes 
COX2/PTGS2 and NOS2 are inflammatory enzymes which regulate the production of inflammatory 
prostaglandins and NO (an inflammatory signalling molecule), respectively. Significantly, NSAIDs and 
a number of naturally-occurring compounds with anti-inflammatory properties have been shown to 
have protective effects against cancer by either inhibiting COX2 enzyme activity or downregulating 
pro-inflammatory enzyme expression74,82. 
Surprisingly, gene and protein expression of Cox2/COX2 was found to be upregulated by both allicin 
and Z-ajoene treatment determined by qPCR and ELISA analysis, respectively (Figure 3.9 and Table 
3.2). Cox2 gene expression was also shown to be upregulated by allicin treatment in the RT2 Profiler 
PCR Array (Table 3.3). In contrast, three studies (summarised in Table 1.2) investigating the effect of 
garlic OSC treatment on LPS-stimulated macrophages showed a decrease in COX2 expression for 10 
μM DAS148, 100-200 μM DATS139 and 20 μM E/Z-ajoene143. These studies, however, used much higher 
treatment concentrations of these garlic OSCs (we report IC50 values for DATS of 4.59 ± 1.66 μM and 
E- and Z-ajoene between 2.71-4.39 μM after 24 h (Table 3.1) and higher LPS concentrations for shorter 
periods of time. In addition, all of these studies showed that treatment with the relevant garlic OSC 
downregulated PGE2 expression. In support of our findings, however, a study conducted by Dirsch and 
Vollmar (2001) showed that treatment of LPS (1 μg/ml)-stimulated RAW264.7 macrophages with 10 
μM of E/Z-ajoene for 2-8 h increased COX2 protein expression. The production of PGE2, however, was 
decreased by E/Z-ajoene treatment in a dose-dependent fashion, indicating that while COX2 
expression was increased, COX2 enzyme activity was inhibited147. In this way, the E/Z-ajoene mixture 
has NSAID-like properties147. In this thesis, COX2 enzyme activity was not measured due to time 
constraints. Similarities in experimental design between the Dirsch and Vollmar (2001) study and this 
thesis suggest that COX2 enzyme activity  may be similarly inhibited in our in vitro inflammatory 
model. Further experimentation is necessary to test this theory. 
With respect to LPS-induced Nos2 gene expression, modest increasing trends for allicin and decreasing 
trends for Z-ajoene were seen although these effects were not statistically significant (Figure 3.11). 
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The effects of allicin and Z-ajoene on LPS-induced NOS2 and NO protein expression, however, were 
not determined due to time limitations. Previous studies report that allicin146, DAS148, DADS148, DATS139 
and E/Z-ajoene143,146 decreased NOS2 expression and NO levels in LPS-stimulated RAW264.7 
macrophages. Again, the LPS and garlic OSC concentrations of allicin and E/Z-ajoene used for these 
studies was much higher than used in our research.  For example, Dirsch et al. (1998), , showed that 
treatment of LPS-stimulated (1μg/ml) RAW264.7 macrophages with 10 μM E/Z-ajoene or 50 μM allicin 
for 12 h significantly decreased NOS2 enzyme activity 146 . It thus appears that the sub-toxic (½ IC50) 
concentrations used in our study had only subtle effects on NOS2 expression.  
Taken together, both allicin and Z-ajoene increase the gene and protein expression of Cox2/COX2, but 
have no significant effect on Nos2 gene expression. Future work should investigate the effects of garlic 
OSC treatment on PGE2 and NO expression in order to determine whether these garlic OSCs modulate 
COX2 and NOS2 enzyme activity.  
4.2.4. Effects on TNF and TNF ligand superfamily cytokines 
The TNF ligand superfamily (TNFSF) consists of 19 structurally-related proteins which bind to TNF 
ligand superfamily receptors (also known as death receptors)197–199. These membrane-bound or 
soluble trimer ligands regulate immune functions including inflammation, cell growth, cell survival and 
cell death. Binding of soluble or membrane-bound TNFSF ligands can induce inflammatory signalling 
including activation of NF-κB pathways and/or caspase signalling which induces apoptosis. TNF (also 
known as TNFSF2), CD40L/TNFSF5 and lymphotoxin-α (LTA/TNFSF1) and –β (LTB/TNFSF3) generally 
promote survival and inflammatory signalling, while FASL/TNFSF6 and TRAIL/TNFSF10 stimulate 
caspase-mediated cell death197,198. In addition, CD40L/TNFSF5 and TNFSF14 have been shown to 
regulate immune responses by mediating communication between immune cells and non-immune 
cells197,198. To date, there are five clinically approved drugs which target TNF or LTA for the treatment 
of autoimmune and inflammatory disorders. In addition, a number of cancer therapeutic drugs 
targeting TNFSF ligands and receptors are in clinical trials (see Croft et al. (2013) for a comprehensive 
review)197.  
Significantly, a number of studies have shown that garlic OSCs activate caspase signalling and 
apoptosis in cancer cells124,125,127. In addition, DATS has also been shown to increase the expression of 
death receptors and enhance cancer-cell sensitivity to TRAIL-mediated apoptosis, suggesting that pro-
apoptotic activities of garlic OSCs can be mediated through TNFSF-family and death-receptor 
signalling124.   
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In this thesis the LPS-induced gene and protein expression of Tnf/TNF, a well-known pro-inflammatory 
cytokine, was shown to be upregulated by allicin treatment in qPCR gene expression analysis, as well 
as ELISA and Proteome Profiler Array protein expression analyses (Figure 3.8A and B, Table 3.2, Figure 
3.17 and Table 3.5). In contrast, Z-ajoene was found to have a modest downregulatory effect on LPS-
induced Tnf gene expression after 4 h (Figure 3.8C and Table 3.2), while a significant decrease in 
protein expression was seen after 24 h in the Proteome Profiler Array (Figure 3.17 and Table 3.5). In 
contrast, no significant change was seen in the ELISA analysis at the same timepoint (Figure 3.8D and 
Table 3.2). In general, however, allicin upregulated, while Z-ajoene downregulated TNF gene and 
protein expression. In support of these findings, Kang et al. (2001) found that allicin treatment 
increased the expression of TNF in thioglycollate-induced peritoneal macrophages132, while Lee et al. 
(2012) found that E/Z-ajoene decreased TNF expression in LPS-induced RAW264.7 macrophages143.  
Moreover, qPCR experiments showed that both allicin and Z-ajoene significantly increased the LPS-
induced gene expression of Trail/Tnfsf10 (Figure 3.10 and Table 3.2). However, when cell culture 
supernatants were analysed for soluble TRAIL/TNFSF10 protein, none was detected (data not shown). 
TRAIL/TNFSF10 belongs to the TNF ligand superfamily of type II transmembrane ligands, and can be 
cleaved by metalloproteases to release a soluble protein/ligand200. The absence of soluble 
TRAIL/TNFSF10 in cell culture supernatants could therefore be a result of no metalloprotease cleavage 
of transmembrane TRAIL/TNFSF10. Further analysis using protein lysates needs to be conducted to 
test this theory.   
The RT2 Profiler PCR array identified four additional TNFSF members whose expression is affected by 
either allicin or Z-ajoene treatment following stimulation with LPS. Significantly, the downregulatory 
effect of LPS treatment on Fasl/Tnfsf6 and Light/Tnfsf14 gene expression was further decreased in 
allicin-LPS treated cells (Table 3.3). It is also interesting to note that allicin treatment alone resulted in 
a large decrease in expression of Fasl/Tnfsf6, but an increase in Light/Tnfsf14 expression. In contrast, 
Z-ajoene treatment alone did not alter the endogenous expression levels of Ltb/Tnfsf3 or 
Cd40l/Tnfsf5, but did downregulate the LPS-induced increase in expression of these genes back to 
endogenous expression levels (Table 3.4).  
Taken together, allicin and Z-ajoene were shown to affect the gene expression levels of six TNFSF 
ligands as well as the protein expression of TNF/TNFSF2. Future work is needed to confirm the effect 
of these garlic OSCs on protein expression levels of these TNFSF ligands as well as the effect on 
associated signalling pathways. 
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 Garlic OSCs may affect STAT3 phosphorylation and activity 
through posttranslational modification of cysteine residues 
NF-κB and STAT3 are transcription factors which regulate diverse aspects of the immune 
response31,38,201. The dysregulation of these two transcription factors is associated with chronic 
inflammation and immunosuppression which can facilitate tumourigenesis and cancer progression30–
32. In addition, research has shown that these transcription factors co-operate to selectively transcribe 
pro-inflammatory and immunosuppressive genes that have binding sites for both transcription 
factors35.  
In this thesis, many of the cytokines, chemokines and growth factors whose LPS-induced expression 
was modulated by garlic OSC treatment are known to target NF-κB and/or STAT3 target genes such as 
Il1b, Il6, Il10, Nos2, Cox2/Ptgs2 and Cxcl10. While there are many reports showing that garlic OSC 
treatment affects NF-κB signalling and activity85,99,124,137,139,142, there is only one study investigating the 
effects of garlic OSC treatment on STAT3 signalling and activation150. That study showed that 20-40 
μM DATS decreased IL6-stimulated Tyr705 STAT3 phosphorylation and hence activation in LNCaP 
prostate cancer cells and downregulated levels of constitutively active Tyr705 phosphorylated STAT3 
in DU145 prostate cancer cells150. To date, however, no study has reported the effects of garlic OSC 
treatment of STAT3 Tyr705 phosphorylation in immune cells. 
To this end, we investigated the effect of allicin and Z-ajoene treatment on LPS-induced STAT3 Tyr705 
phosphorylation by Western blot in RAW264.7 murine macrophages. Western blot analysis showed 
that allicin treatment caused a spike in the LPS-induced STAT3 phosphorylation after 6 h, which 
returned to basal levels (i.e. LPS alone) after 8 h (Figure 3.19 and 3.20). Z-ajoene treatment, however, 
resulted in a sustained 2.5-fold decrease in LPS-induced STAT3 Tyr705 phosphorylation between 6 and 
24 h (Figure 3.19 and 3.20).  
In support of these findings, a number of gene targets that possess both NF-κB and STAT3 binding 
sites and are preferentially transcribed in the presence of both of these transcription factors were 
shown to be modulated by allicin or Z-ajoene treatment (Table 4.1). The increase (or increasing trend) 
in the LPS-induced gene expression of Cox2, Cxcl2, IL6, Nos2, Sele, Ccl5 and Cxcl10 after 4 h of 
treatment with allicin, corresponds with the observed peak in LPS-induced STAT3 phosphorylation 
seen for allicin treatment after 6 h. After 24 h, when LPS- and allicin-LPS-treated cells have similar 
levels of phosphorylated STAT3, allicin treatment had both up- and downregulatory effects on the LPS-
induced protein expression of the listed inflammatory mediators. In contrast, Z-ajoene treatment had 
little effect on gene expression after 4 h, when STAT3 phosphorylation levels were similar to that of 
LPS-only treated cells. However, the sustained downregulation in STAT3 phosphorylation by Z-ajoene 
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treatment was found to occur between 6 and 24 h (Figure 3.20) which correlates with the general 
decrease in protein expression of STAT3 and NF-κB gene targets listed in Table 4.1.  
Table 4.1: Summary of the effects of allicin or Z-ajoene treatment on the LPS-induced gene or protein 
expression of NF-κB and STAT3 target genes in RAW264.7 murine macrophages. Genes containing both NF-κB 
and STAT3 binding sites are often preferentially upregulated in immune and cancer cells in the tumour 
microenvironment over genes containing only NF-κB binding sites. Gene or protein upregulation is shown by red 
upward arrows, while downregulated gene or protein expression is shown as green downward arrows. Table 
adapted from supplementary Tables 3 and 4 from Lee et al. (2011)35. 
Gene Target 
Gene 
Symbol 
NF-κB 
Binding 
site 
STAT3 
Binding 
site 
STAT3-
dependent 
gene 
expression 
Effect of garlic OSCs on LPS-induced gene and/or 
protein expression 
Allicin Z-ajoene 
Gene 
expressio
n (4 h) 
Protein 
Expressio
n 
(24 h) 
Gene 
Expressio
n (4 h) 
Protein 
Expression 
(24 h) 
Chemokine C-C motif 
Ligand 2 
Ccl2 Yes Yes ↑ Not 
detected 
No change Not 
detected 
↓ 
Cyclooxygenase 2 Cox2/ 
Ptgs2 
Yes Yes ↑ ↑ ↑ ↑ ↑ 
Chemokine C-X-C motif 
Ligand 2 
Cxcl2 Yes Yes ↑ ↑ ↑ Not 
detected 
↓ 
Intercellular Adhesion 
Molecule 
Icam1 Yes Yes ↑ Not 
measured 
No change Not 
measured 
↓ 
Interleukin-1β Il1b Yes Yes ↑ No change ↓ ↓ ↓ 
Interleukin-6 Il6 Yes Yes ↑ ↑ ↓ No change ↓(trend) 
Nitric Oxide Synthase 2 Nos2 Yes Yes ↑ ↑ (trend) Not 
measured 
↓ (trend) Not 
measured 
E-selectin Sele Yes Yes ↑ ↑ Not 
measured 
Not 
detected 
Not 
measured 
Chemokine C-C motif 
Ligand 5 
Ccl5 Yes Not 
reported 
↓ ↑(trend) ↓ Not 
detected 
↓ 
Chemokine C-X-C motif 
Ligand 10 
Cxcl10 Yes Not 
reported 
↓ ↑ ↓ (trend) Not 
detected 
↓ 
Interferon-γ Ifng Yes Not 
reported 
↓ Not 
detected 
No change Not 
detected 
↓(trend) 
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Based on the decreased STAT3 phosphorylation and decreased gene and protein expression levels of 
many of the gene targets listed in Table 4.1, we hypothesised that Z-ajoene may downregulate LPS-
induced STAT3 phosphorylation by directly interacting with STAT3 cysteines via a thiol-disulfide 
exchange reaction analogous to S-glutathionylation. Significantly, Xie et al.(2009) showed that STAT3 
is susceptible to S-glutathionylation, and this is associated with decreased Tyr705 phosphorylation, 
loss of STAT3 nuclear accumulation and the impaired expression of STAT3 target genes161. In addition, 
the alkylating agent National Cancer Institute (NCI) compound NSC-368262 (C48) was shown to 
interact with Cys468 of STAT3188, while Stattic (an irreversible STAT3 inhibitor) alkylates STAT3 
cysteines 251, 259, 367 and 426202. In addition, a recent study by Sobotta et al. (2015) showed that 
STAT3 cysteines in the DNA-binding domain (DBD) and the trans-activating domain (TAD) are targets 
of perioxiredoxin-2-mediated oxidation, which results in the formation of mixed disulfide bridges 
between STAT3 oligomers and attenuates the transcriptional activity of STAT3203. Figure 4.1 shows the 
relative positions of the 14 cysteines in full length human STAT3. It is important to note that the STAT3 
amino acid sequence is highly conserved between Mus musculus and Homo sapiens, only differing in 
one amino acid (a Glu760 in the human sequence is substituted for Asp760 in the mouse sequence)204, 
allowing for direct comparison between human and mouse STAT3.  As shown in these papers, 
alkylation of cysteines in the TAD can affect STAT3 phosphorylation, dimerization and nuclear 
translocation, while alkylation of cysteines in the DBD can affect STAT3 DNA binding and hence 
transcriptional activity188,202. In addition, the modification of STAT3 by C48 and Stattic has been shown 
to induce apoptosis in tumour cells188,205,206.   
 
Figure 4.1: The relative position of the 14 cysteine residues with respect to the structural domains in full length 
human STAT3. NTD, N-terminal domain; CCD, coiled-coil domain; DBD, DNA-binding domain; LNK, linker 
domain; SH2, SH2-binding domain; TAD, trans-activating domain. Reproduced with permission from Sobotta et 
al. (2015)203. 
In this thesis we found that E/Z-ajoene does indeed reversibly alkylate STAT3 in vitro (Figure 3.22). 
This is the first report that a garlic OSC directly interacts with and modify STAT3. While we did not test 
whether E/Z-ajoene-mediated alkylation influences STAT3 transcriptional activity directly, the 
decrease in LPS-induced STAT3 phosphorylation (Figure 3.19B and 3.20), and the decreased 
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expression of LPS-induced STAT3 target genes (Table 4.1) by Z-ajoene treatment, suggests that STAT3 
activity is affected. We did not test whether STAT3 is alkylated by allicin, but the more pro-
inflammatory effects seen on LPS-induced gene expression of STAT3 targets after 4 h, and the short 
peak in STAT3 phosphorylation occurring at 6 h, suggests that allicin rather facilitates LPS-induced 
STAT3 phosphorylation and transcriptional activity at early timepoints. Therefore, if both allicin and Z-
ajoene alkylate STAT3, the cysteine targets are not likely to be the same. 
Future work should determine whether allicin alkylates STAT3 and if so, the STAT3 cysteine targets for 
allicin and Z-ajoene should be identified by proteomic analysis. In addition, E/Z-ajoene alkylation of 
STAT3 and the resulting effects on STAT3 activity must be confirmed in cell culture and in vivo. Possible 
experimental approaches include the use of immunofluorescence imaging-labelling to determine 
whether E/Z-ajoene affects STAT3 nuclear translocation, and the use of STAT3 reporter constructs to 
determine the effect of E/Z-ajoene alkylation of STAT3 on transcriptional activity. As STAT3 and NF-κB 
have been shown to directly interact and this interaction regulates the transcription profile in 
inflammation and cancer35, it would also be of interest to determine whether NF-κB is alkylated by 
garlic OSCs, especially because there are a number of reports in the literature which show that NF-κB 
subunits are targets of S-glutathionylation158,160. Further, if both STAT3 and NF-κB are targets of garlic 
OSC alkylation it would be interesting to ascertain whether alkylation of these transcription factors 
can modulate transcription factor interactions and transcriptional activity. 
 Potential garlic OSC-target proteins in inflammatory signalling 
pathways  
In this thesis we hypothesised that garlic OSCs reversibly alkylate redox-sensitive cysteine thiols in 
proteins, which are also targets of S-glutathionylation. We found that STAT3, a known target of S-
glutathionylation, can be reversibly alkylated by E/Z-ajoene. In addition, Western blot analysis of 
STAT3 phosphorylation and gene and protein expression analyses suggest that this alkylation may 
affect the LPS-induced expression of STAT3 target genes. There are, however, many signalling proteins 
and transcription factors involved in inflammatory signalling pathways that are known targets of S-
glutathionylation. Figure 4.2 summarises the literature reporting the effects of garlic OSC or garlic 
extract treatment on inflammatory signalling pathways (taken from Table 1.3). In order to identify 
potential garlic OSC targets, the Database of Cysteine S-glutathionylation (dbGSH) 
(http://csb.cse.yzu.edu.tw/dbGSH/index.php)207 was used to identify signalling proteins and 
transcription factors susceptible to S-glutathionylation (shown in blue in Figure 4.2). Based on Figure 
4.2, it is clear that garlic OSCs affect many aspects of inflammatory signalling pathways, and that many 
proteins involved in these pathways are targets of S-glutathionylation. We hypothesise that garlic 
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OSCs exert these effects by alkylating these S-glutathionylation target proteins. Future work should 
focus on determining whether these proteins are indeed garlic OSC targets and whether alkylation by 
garlic OSCs affects protein function and thereby inflammatory signalling.  
 
Figure 4.2: Visual representation of the effects of garlic OSC or garlic extract treatment on inflammatory 
signalling pathways and transcription factors based on the literature collated in Table 1.3. As redox sensitive 
cysteines are known to be targets of S-glutathionylation, The Database of Cysteine S-glutathionylation (dbGSH) 
(http://csb.cse.yzu.edu.tw/dbGSH/index.php) was used to identify signalling proteins depicted in Figure 1.5. 
Proteins susceptible to S-glutathionylation, and therefore likely targets of garlic OSCs, are shown in blue. The 
red arrows above the description of the transcription factor gene targets indicate the overall downregulatory 
effect of the garlic OSCs on these signalling pathways. Note that the NF-κB signalling pathway is representative 
of both canonical and non-canonical NF-κB signalling. Protein symbols can be found in the list of Abbreviations 
and Symbols.  
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Conclusion 
In this study we established a well-defined in vitro inflammatory model in cultured murine RAW264.7 
macrophage cells in order to measure the effects of the pure garlic OSCs allicin and Z-ajoene on the 
LPS-induced inflammatory response. We found that allicin had a short-lived pro-inflammatory-effect, 
initially upregulating LPS-induced Il6 gene expression, while IL6 protein was significantly 
downregulated by allicin treatment after 24 h. Allicin also upregulated the LPS-induced gene and 
protein expression of the anti-inflammatory cytokine IL10. Z-ajoene, on the other hand, was found to 
have longer-lasting anti-inflammatory effect on LPS-induced gene and protein expression as it 
downregulated the expression of Il1b/IL1B as well as eight chemokines affected by LPS treatment. 
Preliminary gene array experiments also showed that these garlic OSCs modulated the gene 
expression of a number of TNF ligand superfamily members, an observation that has not been 
previously reported in the literature.   
We also investigated the effect of allicin and Z-ajoene on the LPS-induced phosphorylation, and hence 
activation, of the transcription factor STAT3. While allicin facilitated and caused a spike in STAT3 
phosphorylation at 6 h, Z-ajoene was found to downregulate STAT3 phosphorylation between 6 and 
24 h. In addition, using a cell-free system, we showed that E/Z-ajoene reversibly alkylated recombinant 
STAT3 protein. This is the first report of a garlic OSC directly interacting with the STAT3 protein and 
coincides with the observed downregulation of LPS-induced STAT3 target genes by Z-ajoene. Future 
work will focus on whether this interaction occurs in vivo and if E/Z-ajoene-mediated alkylation affects 
STAT3 activity as suggested by the observed decrease in the LPS-induced expression of STAT3 target 
genes and STAT3 phosphorylation.  
Together, these observations suggest that the garlic OSCs allicin and Z-ajoene differentially modulate 
inflammatory gene and protein expression; where allicin has a short-lived pro-inflammatory effect and 
Z-ajoene has a longer-lasting anti-inflammatory effect. These effects may be a result of garlic OSC 
interactions with the transcription factor STAT3. Our findings therefore support the use of dietary 
garlic containing Z-ajoene and allicin as an immunomodulatory agent which may have implications in 
the prevention of inflammatory diseases. 
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Appendix A Reagent Recipes 
Lidocaine/EDTA  10 mM lidocaine HCl (Sigma-Aldrich) and 10 mM EDTA in 1x 
PBS, pH8 
 
MTT Reagent  5mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide, Cat. No. M2128, Sigma-
Aldrich) in 1x PBS, pH7.4 
 
Solubilisation Reagent    10 % w/v sodium dodecyl sulfate, 0.01M HCl 
 
3 % Agarose gel    3 % w/v agarose in 1x TAE buffer 
 
10x Tris-acetate-EDTA (TAE) Buffer 0.4M Tris, 0.04M acetate, 0.01M EDTA 
 
ELISA Wash Buffer 1   1x PBS (pH7.4), 0.5 % v/v Tween-20 
 
ELISA Wash Buffer 2   1x PBS (pH7.4), 0.1 % v/v Tween-20 
 
3 % SDS-PAGE Stacking Gel 0.05 % (w/v) ammonium persulfate; 0.1 % (w/v) SDS, 0.2 % 
(v/v) N,N,N’,N’-tetramethylethylenediamine; 3 % (v/v) 
Acrylamide/bis-acrylamide; 125 mM Tris, pH6.8 
 
10 % SDS-PAGE Resolving Gel 0.05 % (w/v) ammonium persulfate; 0.1 % (w/v) SDS; 0.1 % 
v/v) N,N,N’,N’-tetramethylethylenediamine; 10 % (v/v) 
Acrylamide/bis-acrylamide (Bio-Rad); 375 mM Tris, pH8.8 
 
10x SDS-PAGE Running Buffer  0.1 % (w/v) SDS; 25 mM Tris; 90 mM glycine 
 
10x SDS-PAGE Transfer Buffer 25 mM Tris; 90 mM glycine; 20 % (v/v) methanol (added 
immediately before use) 
Ponceau Stain  0.1 % (w/v) Ponceau-S Sodium Salt; 5 % (v/v) acetic acid 
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10x Phosphate-Buffered Saline (PBS) 1.37M NaCl; 14 mM KH2PO4; 27 mM KCl; 43 mM Na2HPO4 
 
10x Tris-Buffered Saline (TBS)  0.2M Tris, 5M NaCl, pH7.4 
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Appendix B Literature Review Supplementary Tables  
Supplementary Table B1: A summary of the literature reporting the effects of garlic OSC and garlic extract 
treatment on cell proliferation and apoptosis. All abbreviations and symbols used in this table can be found in the list 
of Abbreviations and Symbols. 
Functional 
Componen
t 
Concentration Experimental System Reported effect Ref 
E/Z-ajoene 5-40 μM Human promyeloleukemic 
cells 
Apoptosis induced by stimulated NF-κB 
activation and peroxide production.  
99 
Garlic 
extract 
10-1000 μg/ml Placenta and pre-eclampsic 
placenta explants  
Anti-inflammatory effect but no change in 
apoptotic rate. Increased soluble TRAIL at 
1000 μg/ml. 
86 
DATS 20-40 μM IL6-stimulated DU145 and 
LNCaP prostate cancer cells 
Inhibition of STAT3 phosphorylation 
resulted in apoptosis. 
150 
Z-ajoene In vitro: 1-80 μM 
In vivo: 
2-8 mg/kg/day x 
12 days  
In vitro: Cancer cell lines; 
MCF-7, HL60, HeLa, Bel-
7402, HCT, BGC-823 and 
normal marsupial kidney 
(PtK2) cells 
In vivo: Kunming mice 
implanted with 
hepatocarcinoma 22 & 
sarcoma 180 cells 
In vitro: Increased cytotoxicity seen in 
cancer cells as opposed to normal cells. 
Induced microtubule network disassembly 
associated with G2/M cell cycle arrest.  
In vivo: Inhibited tumour growth . 
208 
DAS, DADS, 
DATS 
1-100 μM Human colon cancer HCT-1 
and DLD-1 cells 
DATS oxidised β-tubulin cysteines by mixed 
disulfide bond formation affecting β-tubulin 
function causing G2/M cell cycle arrest, 
increased caspase 3 activity and apoptosis. 
127 
Allicin 1-20 μM Human gastric carcinoma 
cells 
Increase in mitochondrial Bax and 
Cytochrome C release. Caspase-
independent apoptosis. 
209 
Allicin 1-100 μM SiHa and Hela human 
cervical cancer cells, 
murine fibrosarcoma cells (L-
929) and human colon 
cancer cells (SW480) 
Inhibition of cancer cell growth. Induced 
formation of apoptosis bodies, DNA 
fragmentation and activation of caspase-3, -
8 and -9.  
125 
DATS In vitro: 0-40 
μM/L 
In vivo: 40 mg/kg 
x 5 days per week 
In vitro: PC-3 and LNCaP 
human prostate cancer cells 
In vivo: Orthotopically 
implanted PC-3 cells in nude 
BALB/c mice 
 
Enhanced apoptosis-inducing potential of 
TRAIL. In vitro: Increased expression of 
death receptors and pro-apoptotic BCL2 
proteins. Inhibited expression of anti-
apoptotic BCL2 proteins. Inhibited cell 
proliferation and induced apoptosis by 
inducing caspase-3 and -9. 
In vivo: Inhibited tumour cell proliferation, 
angiogenesis and metastasis and induced 
apoptosis. 
124 
Allicin 1-100 ng/ml B16 melanoma cells & 
thioglycolate-induced 
murine peritoneal 
macrophages 
Increased tumouricidal activity of 
macrophages against B16 melanoma cells. 
132 
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Supplementary Table B2: A summary of the literature reporting the effects of garlic OSC and garlic extract 
treatment on antioxidant enzymes. All abbreviations and symbols used in this table can be found in the list of 
Abbreviations and Symbols. 
Functional 
Componen
t 
Concentration Experimental System Reported effect Ref 
E/Z-ajoene 5-40 μM 
Human promyeloleukemic 
cells 
Apoptosis induced by increased peroxide 
production and NF-κB activation. 
99 
AGE, S-allyl 
cysteine 
0.1-5g/L, 0.1-20 
mmol/L 
Oxidative-LDL induced injury 
of epithelial cells 
Prevention of membrane damage, lipid 
peroxidation and cell viability via prevention 
of GSH depletion. 
210 
DADS 100mg/kg 
Ethanol-induced gastric 
ulceration in Sprague-
Dawley rats 
Increased GR, GPX and CAT enzyme activity. 149 
DAS 15 μM 
TNF- or histamine-
stimulated A7r5 aortic 
smooth rat muscle cells 
Decreased ROS and ROS-induced signalling 
by activating the antioxidant NRF2 
transcription factor and increasing the 
expression antioxidant enzymes. 
142 
DAS, DADS, 
DATS 
100 μM/kg/day x 
14 days 
CCl4-induced liver injury in 
rats 
DATS reduced Liver injury by suppressing 
LDH and AST enzyme activity. DADS and 
DATS increased antioxidant enzyme activity 
of GST and QR. 
211 
DATS 100-200 μM 
LPS-stimulated RAW264.7 
macrophages 
Stimulated expression of HO1& NQO1. 139 
AGE 100-200mg/kg 
Indomethacin-induced 
gastric inflammation in male 
albino rats 
Increased GSH levels and SOD and CAT 
enzyme activity. 
212 
DAS 
150mg/kg x 6 
days 
Gentamicin-induced 
nephrotoxicity in Wistar rats 
Prevented gentamicin-induced decrease in 
antioxidant enzymes SOD, GPx, CAT, NQO1, 
GST and GR via activation of NRF2. 
Prevented LPS-induced lipid peroxidation 
and kidney damage.  
95 
Garlic 
powder, 
DADS 
5% garlic 
powder- or 3.4 
mmol/kg DADS-
supplemented 
diet x 14 days 
Male Wistar rats 
Increased levels and activity of CYP1A2. 
Increased activity of GST and UDP and 
decreased activity of CYP2E1. 
213 
Garlic 
Powder 
0-5% garlic 
powder-
supplemented 
diet x 8 weeks 
Diethylnitrosamine (DEN)-
stimulated hepatocellular 
carcinoma in  male Sprague-
Dawley rats 
Decreased activity expression levels of 
CYP2E1. Decreased GST foci (a marker for 
DEN-induced lesions).  
214 
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Appendix C MIQE Guidelines Checklist and qPCR 
Optimisation and Quality Control 
Supplementary Table C1: A checklist for the Minimum Information for Publication of Quantitative Real-Time 
PCR Experiments (MIQE) guidelines168. The listed items are designated as either E, essential or D, desirable. 
ITEM TO CHECK IMPORTANCE CHECKLIST COMMENTS 
EXPERIMENTAL DESIGN       
Definition of experimental and 
control groups 
E YES Section 2.5, Table 2.1 
Number within each group E YES Section 2.5 
Assay carried out by core lab or 
investigator's lab? 
D YES Core lab 
Acknowledgement of authors' 
contributions  
D YES  All experiments performed by 
author 
SAMPLE     
Description E YES Section 2.5 
     Volume/mass of sample processed D YES  4 x 105 cells plated and cultured 
for 52 h 
    Microdissection or macrodissection E N/A  Not tissue (N/A) 
Processing procedure E N/A   
     If frozen - how and how quickly? E N/A   
     If fixed - with what, how quickly? E N/A   
Sample storage conditions and 
duration  
E YES RNA samples stored at -80ᵒC 
NUCLEIC ACID EXTRACTION     
Procedure and/or instrumentation E YES Section 2.7.1 
     Name of kit and details of any 
modifications 
E YES GeneJETTM RNA Purification kit 
(Thermo Scientific) 
     Source of additional reagents used  D YES Section 2.7.1 
Details of DNase or RNase treatment E YES Section 2.7.2 
Contamination assessment (DNA or 
RNA) 
E YES RT-negative control  
Nucleic acid quantification  E YES Section 2.7.1-2.7.3 
     Instrument and method E YES Section 2.7.1 
     Purity (A260/A280)  D YES 2.7.3 
     Yield D YES Section 2.7.1-2.7.3 
RNA integrity method/instrument E YES Section 2.7.4 
    RIN/RQI or Cq of 3' and 5' 
transcripts  
E YES Section 2.7.4 
    Electrophoresis traces D NO   
 Inhibition testing (Cq dilutions, spike 
or other)  
E YES  Serial dilution  
REVERSE TRANSCRIPTION     
Complete reaction conditions E YES Section 2.7.5 
     Amount of RNA and reaction 
volume 
E YES Section 2.7.5 
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    Priming oligonucleotide (if using 
GSP) and concentration 
E NO Section 2.7.5 
     Reverse transcriptase and 
concentration 
E YES Section 2.7.5 
     Temperature and time E YES Section 2.7.5 
     Manufacturer of reagents and 
catalogue numbers 
D YES Section 2.7.5 
Cqs with and without RT D YES RT negative control  
Storage conditions of cDNA D YES Section 2.7.5 
qPCR TARGET INFORMATION     
If multiplex, efficiency and LOD of 
each assay. 
E N/A  Not multiplex 
Sequence accession number E YES Table 2.2 
Location of amplicon D YES Supplementary Table C2, 
Appendix C 
     Amplicon length E YES Table 2.2 
     In silico specificity screen (BLAST, 
etc.) 
E YES  NCBI BLAST, Supplementary 
Table C2, Appendix C 
     Pseudogenes, retropseudogenes 
or other homologs? 
D NO   
          Sequence alignment D YES  Supplementary Table C2, 
Appendix 
     Secondary structure analysis of 
amplicon 
D YES Maximum Tm of secondary 
structures, Supplementary Table 
C2, Appendix C 
Location of each primer by exon or 
intron (if applicable) 
E YES Supplementary Table C2, 
Appendix C 
     What splice variants are targeted? E Y Supplementary Table C2, 
Appendix C 
qPCR OLIGONUCLEOTIDES     
Primer sequences E YES Table 2.2 
RTPrimerDB Identification Number  D YES Table 2.2 
Probe sequences D N/A No probes used  
Location and identity of any 
modifications 
E N/A  No modifications 
Manufacturer of oligonucleotides D YES Section 2.7.6.1 
Purification method D YES Direct precipitation with butanol  
qPCR PROTOCOL     
Complete reaction conditions E YES Table 2.3, Section 2.7.6.3 
  Reaction volume and amount of 
cDNA/DNA 
E YES Section 2.7.6.3 
  Primer, (probe), Mg++ and dNTP 
concentrations 
E YES Section 2.7.6.3 
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  Polymerase identity and 
concentration  
E YES SensiMixTM SYBR®-No-ROX Kit 
(BioLine), hot-start DNA 
polymerase 
  Buffer/kit identity and manufacturer  E YES SensiMixTM SYBR®-No-ROX Kit 
(BioLine) 
  Exact chemical constitution of the 
buffer 
D NO Information not provided by kit 
  Additives (SYBR Green I, DMSO, etc.) E YES No additives were used 
Manufacturer of plates/tubes and 
catalogue number 
D YES  White LightCycler® 480 Multi well 
Plate 384 (Cat. No. 04 729 749 
001, Roche) & 96 (Cat. No. 04 729 
692 001, Roche) & Hard-Shell® 96-
Well PCR Plates (Cat. No.  
HSP9655, Bio-Rad Laboratories, 
Inc) 
Complete thermocycling parameters E YES Table 2.3, Section 2.7.6.3 
Reaction setup (manual/robotic) D YES Manual  
Manufacturer of qPCR instrument E YES Roche LightCycler® 480II 
qPCR VALIDATION     
Evidence of optimisation (from 
gradients)  
D YES  Optimised for specificity based on 
annealing temperature gradients, 
Supplementary Figure 3C, 
Appendix C 
Specificity (gel, sequence,  melt, or 
digest) 
E YES Supplementary Figure 3A and B, 
Appendix C 
For SYBR Green I, Cq of the NTC E YES NTC is >5 cycles from 
experimental samples  
Standard curves with slope and y-
intercept 
E YES Performed, amplification 
efficiency reported Supplementary 
Table C2 
PCR efficiency calculated from slope E YES Supplementary Table C2 
Confidence interval for PCR efficiency 
or standard error 
D NO  
     r2 of standard curve E NO Performed but not reported 
Linear dynamic range E NO Performed but not reported 
     Cq variation at lower limit E NO   
     Confidence intervals throughout 
range 
D NO   
Evidence for limit of detection  E NO   
If multiplex, efficiency and LOD of 
each assay. 
E N/A   
DATA ANALYSIS     
qPCR analysis program (source, 
version) 
E YES Biogazelle qbase+ version 2.6.1 
     Cq method determination E YES Target and run specific 
amplification efficiency standards 
curves were determined using 
qBase plus software 
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     Outlier identification and 
disposition 
E YES Cq value cut-off 0.5 difference 
between samples 
Results of NTCs  E YES NTC is >5 cycles from 
experimental samples 
Justification of number and choice of 
reference genes 
E YES Section 2.7.6.6 
Description of normalisation method E YES Section 2.7.6.6 
Number and concordance of 
biological replicates 
D YES 3 biological repeats with 2 
technical repeats performed for 
each sample  
Number and stage (RT or qPCR) of 
technical replicates 
E YES 2 qPCR technical repeats 
Repeatability (intra-assay variation) E NO   
Reproducibility (inter-assay variation, 
%CV) 
D NO   
Power analysis D NO   
Statistical methods for result 
significance 
E YES Section 2.12, 1-way ANOVA, 
Tukey’s HSD test 
Software (source, version) E YES GraphPad Prism 5.00 (GraphPad 
Software, 
http://www.graphpad.com) 
Cq or raw data submission using 
RDML 
D NO   
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Supplementary Table C2: Primer oligonucleotide design supplementary information to Table 2.2. Primer amplification efficiency was determined by qBase plus software 
(Biogazelle) using a standard curve obtained from a serial dilution of pooled cDNA.   In silico analysis of primer melting temperature (Tm); the maximum Tm of the amplicon 
secondary structure and the Gibbs Free energy (Delta G kcal/mol) for the homo- and heterodimers was obtained using the OligoAnalyzer 3.1 software (Integrated DNA 
Technologies, Inc). The spontaneity of the oligonucleotide binding to its perfect complement was always -30 kcal/mol more spontaneous than any other structure. Analysis 
of primer exon location and amplicon position on the coding sequence was determined using the RTPrimerDB In silico analysis tool. In silico NCBI Primer BLASTs were 
performed to verify primer targets and transcript variants. 
Gene 
Symbol 
Primer 
amplifi-
cation 
efficiency 
Exon
/s 
Primer 
Tm 
Max Tm 
Amplicon 
secondary 
structure 
Amplico
n 
position 
on 
coding 
sequenc
e 
Primer 
Blast 
Results 
Transcript 
variants 
recognised 
Perfect 
Comple-
ment Max 
kcal/mol 
Most 
spontaneous 
homodimer 
kcal/mol 
Difference: 
Perfect 
complement 
- homodimer 
Perfect 
complement 
Max 
kcal/mol 
Most 
spontaneous 
heterodimer 
kcal/mol 
Difference: 
Perfect 
complement – 
heterodimer 
kcal/mol 
Actb 100.5 3 67.1 50.1 692-830 NM_007
393.3 
 -39.29 -3.61 -36 -40 -4.67 -35.33 
3 66.9 -40 -9.28 -31 
B2m 199.5 2 67.7 53.3 338-403 NM_009
735.3 
 -38.63 -3.53 -35 -38.63 -4.89 -33.74 
2 & 
3 
65.6 -37.52 -6.76 -31 
Gapdh 102.2 4 68.7 48.3 756-905 NM_001
289726.1 
Transcript 
variant 1 
-42.41 -5.02 -37 -42.41 -4.87 -37.54 
5 67.6 NM_008
084.3 
-41.05 -5.24 -36 
Ptgs2/ 
Cox2 
106.6 5 67.4 38.8 663 - 716 NM_011
198.3 
 -39.45 -3.14 -36 -39.52 -4.74 -34.78 
5 67.7 -39.52 -4.67 -35 
Il1b 99.1 3 66.5 Too long 
for analysis 
248 - 597 XM_006
498795.1 
Transcript 
variant X1 
-36.85 -3.14 -34 -38.89 -6.21 -32.68 
5 65.3 NM_008
361.3 
-38.89 -9.28 -30 
Il6 106.3 2 67.9 40.6 139 - 280 NM_031
168.1 
 -42.05 -4.64 -37 -42.05 -5.24 -36.81 
3 65.8 -41.38 -7.05 -34 
Il10 102.9 3 67.4 48.1 308 - 500 NM_010
548.2 
 -42.03 -3.9 -38 -42.03 -5.05 -36.98 
4 71.3 -40.64 -3.14 -38 
Il12b 107.5 Purchased from Qiagen Cat. No. 330001 PPM03020E 
Nos2 107..8 16 67.6 50.5 2174 - 
2269 
NM_010
927.3 
 -40.52 -10.24 -30 -41.1 -5.23 -35.87 
17 64.8 XM_006
532440.1 
-41.1 -3.61 -37 
Tnf 106.2 3 64.8 49.9 408 - 522 NM_013
693.3 
Transcript 
variant 1 
-41.04 -6.76 -34 -41.04 -6.21 -34.83 
4 65.9 -37.52 -6.21 -31 
91.6 2 65 51 296 - 475  -36.73 -3.55 -33 -38.44 -3.55 -34.89 
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Tnfsf10/ 
Trail 
4 64.7 NM_009
425.2 
-38.44 -4.62 -34 
99 
 
   
Actb B2m Gapdh 
   
   
Ptgs2/Cox2 Il1b Il6 
   
   
Il10 Il12b Nos2 
   
  
 
Tnf Tnfsf10  
Supplementary Figure C1: Confirmation of primer oligonucleotide specificity determined by qPCR melt-curve 
analysis. Melt curve analysis was performed after every qPCR run using default settings on the Roche LightCycler 
480II thermal cycler. A single peak is indicative of a single amplicon product. All gene symbols are listed in the 
Abbreviations and Symbols section.  
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Supplementary Figure C2: Confirmation of primer oligonucleotide specificity analysed by agarose gel 
electrophoresis. In order to verify primer oligonucleotide specificity, qPCR samples and 5 μl O’GeneRuler 50bp 
DNA Ladder (Thermo Scientific) were loaded onto a 3% agarose gel and subjected to gel electrophoresis in 1x 
TBE for 2 h at 100 V to separate products by size. The expected amplicon sizes listed correspond with the band 
size. As these samples were used for qPCR analysis and subjected to 45 thermal cycles and melt curve analysis, 
we expect some product degradation. All gene symbols are listed in the Abbreviations and Symbols section. 
 
 
 
 
 
 
 
 
 
Supplementary Figure C3: Optimisation of qPCR annealing temperature. A temperature gradient qPCR was 
performed using the CFX96 Touch™ Real-Time PCR System (Bio-Rad Laboratories, Inc) gradient PCR thermal 
cycler, with the following reaction conditions; 95ᵒC for 10 min, 45 cycles of (95ᵒC for 30 s, gradient annealing 
temperature (58-65ᵒC) for 30 s, 72ᵒC for 90 s (extension and fluorescence acquisition)), followed by melt curve 
analysis. The mean Cq value was determined by averaging the Cq values determined for all target genes 
including; Actb, B2m, Gapdh, Il1b, Il6, Il10, Tnf, Trail/Tnfsf10, Cox2/Ptgs2 and Nos2. The optimal annealing 
temperature is defined as the temperature that yields the lowest average Cq value, which is 64ᵒC (highlighted 
by the red arrow).  
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